

MECHANISM OF RESISTANCE TO FUMONISIN B₁-INDUCED CYTOTOXICITY

by

NEELESH SHARMA

(Under the Direction of Raghbir P. Sharma)

ABSTRACT

Fumonisin B₁ (FB₁) is a mycotoxin produced by *Fusarium verticillioides* present on corn worldwide. Fumonisin B₁ inhibits ceramide synthase and induces expression of cytokines in liver. Fumonisin B₁ induces apoptosis in some cells whereas other cells are resistant to its apoptotic effects. We hypothesized that sphingolipid metabolism and interaction of different cytokines may be important in rendering some cells resistant to fumonisin B₁ induced apoptosis.

We found that despite the accumulation of sphinganine, human embryonic kidney (HEK-293) cells are resistant to fumonisin B₁ toxicity and DL-*threo*-dihydrosphingosine, the sphingosine kinase inhibitor (SKI), considerably increased the sensitivity of HEK-293 cells to fumonisin B₁. Results indicated that HEK-293 cells are resistant to fumonisin B₁ due to rapid conversion of sphingosine to sphingosine-1-phosphate, which imparts survival properties.

Cellular interactions in fumonisin B₁ induced toxicity were investigated using co-cultures of murine macrophages (J774A.1) and nonparenchymatous liver epithelial cells (NMuLi). Treatment of the co-cultures with fumonisin B₁ produced cytotoxicity whereas either J774A.1 or NMuLi cultures alone showed no response to the mycotoxin. Expression of cytokines was increased in co-cultures but not in individual cultures. Results indicated that macrophages and

liver epithelial cells interact in response to fumonisin B₁ and potentiate the cytokines expression, which may have implications in making hepatocytes responsive to cytotoxicity of fumonisin B₁.

Fumonisin B₁ induced apoptosis and activated c-Jun NH₂-terminal kinase (JNK) in primary culture of liver cells. JNK inhibitor (SP600125) and anti-TNF α reduced the apoptosis induced by fumonisin B₁. The role of JNK signaling in fumonisin B₁ induced apoptosis is downstream of TNF α production, as fumonisin B₁ mediated activation of JNK was reduced by the presence of anti TNF α in the medium, whereas presence of JNK inhibitor did not change the fumonisin B₁ induced TNF α expression.

To determine the role of T cells in fumonisin B₁-induced apoptosis in mice liver, we depleted T cells in wild-type mice by injecting monoclonal antibodies directed against Thy-1.2 surface antigens of mature T cells. Results obtained in this study indicated that T cell activation followed by production of proinflammatory cytokines is an important mechanism for fumonisin B₁-induced hepatotoxicity in mice.

INDEX WORDS: Fumonisin B₁, Resistance, Hepatotoxicity, Tumor necrosis factor α , Sphingosine kinase, c-Jun NH₂-terminal kinase, T cell depletion,

MECHANISM OF RESISTANCE TO FUMONISIN B₁-INDUCED CYTOTOXICITY

by

NEELESH SHARMA

M.D., G.S.V.M. MEDICAL COLLEGE, KANPUR, INDIA, 2001

A Dissertation Submitted to The Graduate Faculty of The University of Georgia in Partial
Fulfillment of the Requirements for the Degree

DOCTOR OF PHILOSOPHY

ATHENS, GEORGIA

2005

© 2005

NEELESH SHARMA

All Rights Reserved

MECHANISM OF RESISTANCE TO FUMONISIN B₁-INDUCED CYTOTOXICITY

by

NEELESH SHARMA

Major Professor: Raghbir P. Sharma

Committee: Ronald T. Riley
Cham E. Dallas

Electronic Version Approved:

Maureen Grasso
Dean of the Graduate School
The University of Georgia
August 2005

DEDICATION

To

My Parents

Dr. S. B. Sharma and Mrs. Kusum Sharma,

My Brothers

Manish and Sheelesh Sharma

ACKNOWLEDGEMENTS

I would like to thank God for giving me the opportunity to explore his creation and appreciate its artistry, truthfulness, and originality. I would like to thank my major professor Dr. Sharma for introducing me to amazing world of fumonisin and sphingolipids; I am honored to have been his student. I have learned the very basic lesson of hard work, discipline and attention to detail from him. I thank him for his professional and financial support and, as importantly, for his great mentorship.

I would like to acknowledge the support I received from Mrs. Sharma, who cared for me no less than my own mother and in whom I could always find all the strength needed for this challenging endeavor.

I was fortunate to have a remarkable committee that shaped my education and research: Dr. Cham E. Dallas and Dr. Ronald T. Riley. Each of them was always willing to answer any questions I had and taught me a great deal through classes or seminars. My thanks extend to Dr. Murray, who is an excellent scientist and a great mentor.

Thanks to all the members of the Sharma lab that have come and gone over my time here, for their companionship. Special thanks to Shashank for his conversations about anything, and for his friendship throughout my stay in Athens.

I would also like to thank my parents and brothers for their sacrifice and support over the years. I would never have accomplished so much had it not been for them.

TABLE OF CONTENTS

	Page
ACKNOWLEDGEMENTS.....	v
LIST OF TABLES.....	vii
LIST OF FIGURES.....	viii
CHAPTER	
1 INTRODUCTION.....	1
2 LITERATURE REVIEW.....	13
3 SPHINGOSINE KINASE ACTIVITY CONFERS RESISTANCE TO APOPTOSIS BY FUMONISIN B ₁ IN HUMAN EMBRYONIC KIDNEY (HEK-293) CELLS.....	51
4 AUGMENTED FUMONISIN B ₁ TOXICITY IN CO-CULTURES: EVIDENCE FOR CROSSTALK BETWEEN MACROPHAGES AND NONPARANCHYMATOUS LIVER EPITHELIAL CELLS INVOLVING PROINFLAMMATORY CYTOKINES	81
5 TUMOR NECROSIS FACTOR α -MEDIATED ACTIVATION OF C-JUN NH ₂ TERMINAL KINASE AS A MECHANISM FOR FUMONISIN B ₁ -INDUCED APOPTOSIS IN MURINE PRIMARY HEPATOCYTES.....	116
6 AMELIORATION OF FUMONISIN B ₁ HEPATOTOXICITY IN MICE BY DEPLETION OF T CELLS WITH ANTI-THY1.2.....	149
7 SUMMARY AND CONCLUSIONS.....	177

LIST OF TABLES

Page

TABLE 6.1: CHANGES IN BODY AND ORGAN WEIGHTS AFTER FUMONISIN B₁
(FB₁) TREATMENT IN MICE170

LIST OF FIGURES

	Page
FIGURE 2.1: STRUCTURES OF SPHINGANINE, SPHINGOSINE AND FUMONISIN B ₁	15
FIGURE 2.2: SPHINGOLIPID METABOLISM.....	20
FIGURE 3.1: VIABILITY OF HEK-293 CELLS AFTER FUMONISIN B ₁ AND SKI TREATMENT.....	74
FIGURE 3.2: INDUCTION OF APOPTOSIS IN HEK-293 CELLS TREATED WITH FUMONISIN B ₁ AND SKI	75
FIGURE 3.3: DOCUMENTATION OF APOPTOSIS BY ANNEXIN V AND HOECHST 33258 STAINING.....	76
FIGURE 3.4: FUMONISIN B ₁ (FB ₁) AND SKI INDUCED ACCUMULATION OF FREE SPHINGOID BASES, SPHINGANINE AND SPHINGOSINE.....	77
FIGURE 3.5: INDUCTION OF APOPTOSIS IN HEK-293 CELLS TREATED WITH FUMONISIN B ₁ , SKI AND SPHINGOSINE.....	78
FIGURE 3.6: INDUCTION OF APOPTOSIS IN HEK-293 CELLS TREATED WITH FUMONISIN B ₁ , SKI AND SPHINGANINE.....	79

FIGURE 3.7: PREVENTION OF FUMONISIN B ₁ AND SKI-INDUCED APOPTOSIS BY SPHINGOSINE-1-PHOSPHATE.....	80
FIGURE 4.1: DETERMINATION OF CELL DEATH IN INDIVIDUAL CULTURES AND CO-CULTURE (J774A.1 AND NMuLi) AFTER FUMONISIN B ₁ TREATMENT.....	104
FIGURE 4.2: DOCUMENTATION OF CELL DEATH BY ANNEXIN V, HOECHST 33258 AND PROPIDIUM IODIDE STAINING.....	106
FIGURE 4.3: FUMONISIN B ₁ (FB ₁)-INDUCED ACCUMULATION OF FREE SPHINGOID BASES IN INDIVIDUAL CULTURES AND CO-CULTURE (J774A.1 AND NMuLi).....	108
FIGURE 4.4: EFFECT OF FUMONISIN B ₁ ON EXPRESSIONS OF TNF α , IFN γ AND IL-12 IN INDIVIDUAL AND CO-CULTURES.....	109
FIGURE 4.5: INHIBITION OF CYTOTOXICITY BY ANTI-TNF α AND ANTI-IFN γ ANTIBODIES.....	111
FIGURE 4.6: EFFECT OF TRANSFER OF PRECONDITIONED SUPERNATANT FROM J774A.1 CELLS TO NMuLi CELLS (A) AND NMuLi CELLS TO J774A.1 CELLS (B).....	112
FIGURE 4.7: EFFECT OF TRANSFER OF CONDITIONED SUPERNATANT FROM FUMONISIN B ₁ TREATED CO-CULTURE TO INDIVIDUAL CULTURES.....	130

FIGURE 4.8: TREATMENT OF J774A.1 OR NMuLi CELLS WITH RECOMBINANT TNF α , OR IFN γ	114
FIGURE 4.9: EFFECT OF REPLACING FUMONISIN B ₁ TREATED MEDIA WITH FRESH MEDIA (WITHOUT FUMONISIN B ₁).....	115
FIGURE 5.1: FUMONISIN B ₁ INDUCED APOPTOSIS IN PRIMARY CULTURE OF LIVER CELLS.....	140
FIGURE 5.2: STAINING OF APOPTOTIC CELLS BY ANNEXIN V IN PRIMARY CULTURE OF LIVER CELLS.....	141
FIGURE 5.3: CULTURE OF PRIMARY LIVER CELLS STAINED BY FLUORESCENCE-CONJUGATED ANTIBODY AGAINST MICE THY 1.2 ANTIGEN ON THE SURFACE OF MATURE T CELLS.....	142
FIGURE 5.4: CONCENTRATIONS OF FREE SPHINGANINE AND SPHINGOSINE AFTER EXPOSURE OF HEPATOCYTES TO FUMONISIN B ₁	143
FIGURE 5.5: INHIBITION OF FUMONISIN B ₁ MEDIATED APOPTOSIS BY JNK INHIBITOR (SP600125).....	144
FIGURE 5.6: EFFECT OF FUMONISIN B ₁ TREATMENT ON PHOSPHORYLATION OF JNK AND EXPRESSION OF TOTAL JNK.....	145
FIGURE 5.7: EFFECT OF ANTI-TNF α AND ANTI-IFN γ ON FUMONISIN B ₁ MEDIATED APOPTOSIS.....	146
FIGURE 5.8: EFFECT OF FUMONISIN B ₁ TREATMENT ON PHOSPHORYLATION OF JNK AND EXPRESSION OF TOTAL JNK IN THE PRESENCE OF NEUTRALIZING ANTIBODIES FOR TNF α	147

FIGURE 5.9: EFFECT OF JNK INHIBITOR (JNKI) ON FUMONISIN B ₁ INDUCED EXPRESSION OF TNF α	148
FIGURE 6.1: ACTIVITIES OF ALANINE AMINOTRANSFERASE AND ASPARTATE AMINOTRANSFERASE IN PLASMA OF WT, TCD AND NUDE MICE AFTER TREATMENT WITH FUMONISIN B ₁	171
FIGURE 6.2: ENUMERATION OF APOPTOTIC CELLS IN LIVER BY TUNEL ASSAY.....	172
FIGURE 6.3: IMMUNOHISTOCHEMICAL STAINING OF MOUSE LIVER SECTION WITH ANTI THY 1.2 ANTIBODY AND PERIPHERAL WBC COUNT AFTER TREATMENT WITH FUMONISIN B ₁	173
FIGURE 6.4: EFFECTS OF FUMONISIN B ₁ ON ACCUMULATION OF FREE SPHINGOID BASES, SPHINGANINE AND SPHINGOSINE.....	174
FIGURE 6.5: FUMONISIN B ₁ INDUCED ALTERATION IN GENE EXPRESSION OF TUMOR NECROSIS FACTOR (TNF) α , LYMPHOTOXIN β , INTERFERON (IFN) γ AND INTERLEUKIN-2 IN LIVER.....	175
FIGURE 6.6: FUMONISIN B ₁ INDUCED ALTERATION IN GENE EXPRESSION OF INTERLEUKIN-1 α , INTERLEUKIN-1 β , INTERLEUKIN-6, AND INTERLEUKIN-1 RECEPTOR ANTAGONIST IN LIVER.....	176

CHAPTER 1
INTRODUCTION

Fumonisin B₁ is a toxic and carcinogenic mycotoxin produced by *Fusarium verticillioides* and related species, commonly found on corn (Riley *et al.*, 1993). Fumonisin B₁ is the most abundant fumonisin and occurs naturally in contaminated foods and feeds. The toxicity of fumonisin B₁ has been described in a number of farm and laboratory animals and depends on different factors such as animal species, gender, age, dose and route of administration (Diaz and Boermans, 1994). It has been established as a cause of equine leukoencephalomalacia and porcine pulmonary edema. Fumonisin B₁ has been shown to be hepatotoxic and nephrotoxic in mice and rats (Voss *et al.*, 2001). It was hepatocarcinogenic in male BD IX rats (Gelderblom *et al.*, 2001) and a nephrocarcinogen in male F344/N rats, whereas it was hepatocarcinogenic in only female B6C3F1 mice (Howard *et al.*, 2001). In the Transkei region of South Africa where incidence of esophageal cancer is high, an association between fumonisin B₁ consumption and esophageal cancer was reported (Sydenham *et al.*, 1990).

Fumonisin B₁ is structurally similar to sphingoid bases and causes inhibition of ceramide synthase (sphinganine or sphingosine *N*-acyltransferase) leading to accumulation of free sphingoid bases, sphingoid base metabolites, and depletion of more complex sphingolipids (Riley *et al.*, 1996, Wang *et al.*, 1991). Physiological consequences possible after ceramide synthase inhibition include apoptosis caused by accumulation of free sphingoid bases (sphinganine and sphingosine), increased proliferation caused by increased sphingosine-1-phosphate, or/and decreased ceramide and altered lipid raft function due to disruption of complex sphingolipids synthesis/transport (Merrill *et al.*, 2001). Studies in pig renal epithelial cells (LLC-PK₁) human keratinocytes (Tolleson *et al.*, 1999) and human colonic cells (HT29) (Schmelz *et al.*, 1998) have shown that fumonisin B₁-induced apoptosis, necrosis, and

inhibition of proliferation are sphinganine dependent. There is a close association between increased apoptosis in liver and kidney and the disruption of sphingolipid metabolism (Tsunoda *et al.*, 1998). A previous study demonstrated that fumonisin B₁ induced cell cycle arrest in the G1 phase in African green monkey kidney cells (CV-1) but CV-1 cells transformed by the simian virus 40 (SV40) large T antigen (COS-7) were unaffected by the same levels of fumonisin B₁ (Wang *et al.*, 1996; Ciacci-Zanella *et al.*, 1998). Wang *et al.* (1991) and Schmelz *et al.* (1998) showed that concentrations of fumonisin B₁ as low as 1 μM caused an almost complete inhibition of ceramide formation by primary hepatocytes, while much higher (>75 μM) concentrations of fumonisin B₁ did not induce cytotoxicity. In sensitive cell lines, different studies have reported different doses (HT29: 10 μM, LLC-PK1: 35 μM, CV-1: 5 μM) to be cytotoxic in 24 to 72 hr treatment. It remains to be understood why increased levels of sphinganine do not cause toxicity in some cells and why high dose of fumonisin B₁ and long incubation periods are required in sensitive cells in which sphinganine levels rise significantly within hours of as low as 1 μM fumonisin treatment.

Levels of free sphingoid bases decrease consistently in fumonisin B₁-treated cells between 48 and 72 h indicating the induction of sphingoid base metabolism (Yoo *et al.*, 1996). Catabolism of sphingoid bases requires two independent and sequential steps. The first step involves phosphorylation of sphingoid bases to their 1-phosphate derivative and is mediated by sphingosine kinase (Keenan *et al.*, 1969). Second step involves cleavage of the resulting product by sphingosine-1-phosphate lyase into ethanolamine phosphate and corresponding aldehyde (Van Veldhoven *et al.*, 1991). Due to relative low levels of sphingosine-1-phosphate in cells, it is evident that phosphorylation of sphingosine by sphingosine kinase is the rate-

limiting step in this process. Sphingosine kinase in human tissues is widely expressed with highest levels in adult lung, spleen, kidney, heart, and brain (Melendez *et al.*, 2000). Activation of sphingosine kinase and formation of sphingosine-1-phosphate are linked to cell growth and survival (Spiegel *et al.*, 2002; Spiegel *et al.*, 2002). Diverse external stimuli, particularly growth and survival factors stimulate sphingosine kinase and intracellularly generated sphingosine-1-phosphate has been implicated in their mitogenic and anti-apoptotic effects (Xia *et al.*, 2002; Pitson *et al.*, 2000).

In our preliminary experiments, we found that human embryonic kidney (HEK-293) cells were resistant to cytotoxic effects of up to 50 μM fumonisin B₁ whereas porcine kidney (LLC-PK₁) cells show significant toxic response with 10 μM fumonisin B₁ (Yoo *et al.*, 1992). We hypothesized that the HEK-293 cells are resistant to apoptotic effects of fumonisin B₁ due to rapid conversion of accumulate sphinganine or sphingosine to their respective phosphates by sphingosine kinase and the antiapoptotic and proliferative role of the 1-phosphate derivatives.

Fumonisin B₁ treatment caused an increased expression of tumor necrosis factor α (TNF α), interferon γ (IFN γ) and interleukin (IL)-12, in liver, where cells involved in TNF α production were identified as Kupffer cells (Bhandari *et al.*, 2002). Increase of proinflammatory cytokines from immune cells has been implicated in fumonisin B₁-induced hepatotoxicity. Depletion of Kupffer cells by gadolinium chloride attenuated fumonisin B₁ induced hepatotoxicity (He *et al.*, 2005). Deletion of tumor necrosis factor receptors 1 and 2 and interferon γ genes reduced fumonisin B₁-induced hepatotoxicity in mice (Sharma *et al.*, 2001, 2003).

The role of inflammatory cytokines in the initiation and development of liver toxicity has been well documented. Liver associated immune cells such as lymphocytes, Kupffer cells and their cytokine products; especially $\text{TNF}\alpha$ and $\text{IFN}\gamma$ are involved in liver injury during alcoholic hepatitis (Batey and Wang, 2002). $\text{TNF}\alpha$ and $\text{IL-1}\alpha$ are responsible for certain pathological manifestation of acetaminophen-induced hepatotoxicity in mice (Blazka *et al.*, 1995). $\text{IFN}\gamma$ and $\text{TNF}\alpha$ released from T lymphocytes and macrophages, respectively, are involved in concanavalin A (Con A)-induced hepatitis and in liver toxicity in response to repeated challenges of lipopolysaccharide (Wolf *et al.*, 2001).

Interaction of different types of cells in liver may amplify the cytokine production in response to fumonisin B₁ as reported by Bhandari *et al.* (2002) after treatment of mice with fumonisin B₁. In various models of acute liver injury a positive amplification loop involving $\text{TNF}\alpha$, $\text{IFN}\gamma$ and IL-12 has been implied and involves Kupffer cells (liver macrophages) hepatic lymphocytes and nonparenchymatous liver epithelial cells (NPECs). A remarkable crosstalk between macrophages and T cells involving $\text{TNF}\alpha$ and $\text{IFN}\gamma$ has been suggested using *in vitro* co-culture experiments (Gantner *et al.*, 1996). Interactions of this kind have been reported in several co-culture experiments involving alveolar macrophages and type II pneumocytes (Tao *et al.*, 2002) or microglia and neurons (Hemmer *et al.*, 2001). We hypothesized that interaction of macrophages and non-parenchymatous epithelial cells of liver may amplify the cytokine production in co-culture and make them more susceptible to fumonisin B₁ induced cytotoxicity.

Reports on the effects of fumonisin B₁ on the immune system are conflicting. Fumonisin- B₁ was found to be both immunosuppressive and immunostimulatory in BALB/c

mice, depending on the dose administered and induced an antigenic response (Martinova and Merrill, 1995). Fumonisin B₁ was shown to alter the expression of the CD3 receptor, which is integral to T lymphocyte activation. Recently Taranu *et al.* (2005) reported that ingestion of fumonisin B₁ alters the Th1/Th2 balance leading to reduced vaccinal antibody response in pigs.

Despite many reports confirming the role of proinflammatory cytokines in fumonisin B₁ induced liver damage, little is known about the contribution of T cells in this regard. We hypothesized that fumonisin B₁ hepatotoxicity in mice will be compromised by depletion of T cells.

The objective of the research under this dissertation is to test the overall hypothesis that pathways of sphingolipid metabolism and lack of cytokine interactions are responsible for observed differences to apoptotic effects of fumonisin B₁ in resistant cultured cells. The following specific aims were attempted to achieve this objective.

- 1. Evaluate the role of sphingosine kinase, the enzyme that converts sphingoid bases to their respective phosphates, in rendering some cells resistant to fumonisin B₁-induced apoptosis.**
- 2. Investigate the effect of interaction of macrophages (J774A.1) and nonparanchymatous liver epithelial cells (NMuLi) in a co-culture on fumonisin B₁-induced apoptosis**
- 3. Evaluate the role of TNF α and mitogen activated protein kinases in fumonisin B₁-induced apoptosis in murine primary hepatocytes**
- 4. Examine the fumonisin B₁-induced hepatotoxicity in mice depleted of T cells.**

REFERENCES

- Batey, R. G. and Wang, J. (2002). Molecular pathogenesis of T lymphocyte-induced liver injury in alcoholic hepatitis. *Front Biosci.* **7**, d1662-d1675.
- Bhandari, N., Brown, C. C., and Sharma, R. P. (2002). Fumonisin B₁-induced localized activation of cytokine network in mouse liver. *Food Chem. Toxicol.* **40**, 1483-1491.
- Blazka, M. E., Wilmer, J. L., Holladay, S. D., Wilson, R. E., and Luster, M. I. (1995). Role of proinflammatory cytokines in acetaminophen hepatotoxicity. *Toxicol. Appl. Pharmacol.* **133**, 43-52.
- Ciacci-Zanella, J. R., Merrill, A. H., Jr., Wang, E., and Jones, C. (1998). Characterization of cell-cycle arrest by fumonisin B₁ in CV-1 cells. *Food Chem. Toxicol.* **36**, 791-804.
- Diaz, G. J. and Boermans, H. J. (1994). Fumonisin toxicosis in domestic animals: a review. *Vet. Hum. Toxicol.* **36**, 548-555.
- Gantner, F., Leist, M., Kusters, S., Vogt, K., Volk, H. D., and Tiegs, G. (1996). T cell stimulus-induced crosstalk between lymphocytes and liver macrophages results in augmented cytokine release. *Exp. Cell Res.* **229**, 137-146.
- Gelderblom, W. C., Abel, S., Smuts, C. M., Marnewick, J., Marasas, W. F., Lemmer, E. R., and Ramljak, D. (2001). Fumonisin-induced hepatocarcinogenesis: mechanisms related to cancer initiation and promotion. *Environ. Health Perspect.* **109 Suppl 2**, 291-300.

- Haschek, W. M., Gumprecht, L. A., Smith, G., Tumbleson, M. E., and Constable, P. D. (2001). Fumonisin toxicosis in swine: An overview of porcine pulmonary edema and current perspectives. *Environmental Health Perspectives* **109**, 251-257.
- He, Q., Kim, J., and Sharma, R. P. (2005). Fumonisin B₁ hepatotoxicity in mice is attenuated by depletion of Kupffer cells by gadolinium chloride. *Toxicology* **207**, 137-147.
- Hemmer, K., Fransen, L., Vanderstichele, H., Vanmechelen, E., and Heuschling, P. (2001). An in vitro model for the study of microglia-induced neurodegeneration: involvement of nitric oxide and tumor necrosis factor-alpha. *Neurochem.Int.* **38**, 557-565.
- Howard, P. C., Eppley, R. M., Stack, M. E., Warbritton, A., Voss, K. A., Lorentzen, R. J., Kovach, R. M., and Bucci, T. J. (2001). Fumonisin B₁ carcinogenicity in a two-year feeding study using F344 rats and B6C3F(1) mice. *Environmental Health Perspectives* **109**, 277-282.
- Keenan, R. W. and Haegelin, B. (1969). The enzymatic phosphorylation of sphinganine. *Biochem.Biophys.Res.Commun.* **37**, 888-894.
- Martinova, E. A. and Merrill, A. H., Jr. (1995). Fumonisin B₁ alters sphingolipid metabolism and immune function in BALB/c mice: immunological responses to fumonisin B₁. *Mycopathologia* **130**, 163-170.

- Melendez, A. J., Carlos-Dias, E., Gosink, M., Allen, J. M., and Takacs, L. (2000). Human sphingosine kinase: molecular cloning, functional characterization and tissue distribution. *Gene* **251**, 19-26.
- Merrill, A. H., Jr., Sullards, M. C., Wang, E., Voss, K. A., and Riley, R. T. (2001). Sphingolipid metabolism: roles in signal transduction and disruption by fumonisins. *Environ. Health Perspect.* **109 Suppl 2**, 283-289.
- Pitson, S. M., Moretti, P. A., Zebol, J. R., Xia, P., Gamble, J. R., Vadas, M. A., D'Andrea, R. J., and Wattenberg, B. W. (2000). Expression of a catalytically inactive sphingosine kinase mutant blocks agonist-induced sphingosine kinase activation. A dominant-negative sphingosine kinase. *J. Biol. Chem.* **275**, 33945-33950.
- Riley, R. T., Norred, W. P., and Bacon, C. W. (1993). Fungal Toxins in Foods - Recent Concerns. *Annual Review of Nutrition* **13**, 167-189.
- Riley, R. T., Wang, E., Schroeder, J. J., Smith, E. R., Plattner, R. D., Abbas, H., Yoo, H. S., and Merrill, A. H., Jr. (1996). Evidence for disruption of sphingolipid metabolism as a contributing factor in the toxicity and carcinogenicity of fumonisins. *Nat. Toxins* **4**, 3-15.
- Schmelz, E. M., Dombrink-Kurtzman, M. A., Roberts, P. C., Kozutsumi, Y., Kawasaki, T., and Merrill, A. H., Jr. (1998). Induction of apoptosis by fumonisin B₁ in HT29 cells is mediated by the accumulation of endogenous free sphingoid bases. *Toxicol. Appl. Pharmacol.* **148**, 252-260.

- Sharma, R. P., Bhandari, N., He, Q., Riley, R. T., and Voss, K. A. (2001). Decreased fumonisin hepatotoxicity in mice with a targeted deletion of tumor necrosis factor receptor 1. *Toxicology* **159**, 69-79.
- Sharma, R. P., He, Q., and Johnson, V. J. (2003). Deletion of IFN-gamma reduces fumonisin-induced hepatotoxicity in mice via alterations in inflammatory cytokines and apoptotic factors. *J.Interferon Cytokine Res.* **23**, 13-23.
- Spiegel, S. and Milstien, S. (2002). Sphingosine 1-phosphate, a key cell signaling molecule. *J.Biol.Chem.* **277**, 25851-25854.
- Spiegel, S. and Kolesnick, R. (2002). Sphingosine 1-phosphate as a therapeutic agent. *Leukemia* **16**, 1596-1602.
- Tao, F. and Kobzik, L. (2002). Lung macrophage-epithelial cell interactions amplify particle-mediated cytokine release. *Am.J.Respir.Cell Mol.Biol.* **26**, 499-505.
- Taranu, I., Marin, D. E., Bouhet, S., Pascale, F., Bailly, J. D., Miller, J. D., Pinton, P., and Oswald, I. P. (2005). Mycotoxin fumonisin B₁ alters the cytokine profile and decreases the vaccinal antibody titer in pigs. *Toxicol.Sci.* **84**, 301-307.
- Tolleson, W. H., Dooley, K. L., Sheldon, W. G., Thurman, J. D., Bucci, T. J., and Howard, P. C. (1996). The mycotoxin fumonisin induces apoptosis in cultured human cells and in livers and kidneys of rats. *Adv.Exp.Med.Biol.* **392**, 237-250.

- Tolleson, W. H., Couch, L. H., Melchior, W. B., Jr., Jenkins, G. R., Muskhelishvili, M., Muskhelishvili, L., McGarrity, L. J., Domon, O., Morris, S. M., and Howard, P. C. (1999). Fumonisin B₁ induces apoptosis in cultured human keratinocytes through sphinganine accumulation and ceramide depletion. *Int.J.Oncol.* **14**, 833-843.
- Tsunoda, M., Sharma, R. P., and Riley, R. T. (1998). Early fumonisin B₁ toxicity in relation to disrupted sphingolipid metabolism in male BALB/c mice. *J.Biochem.Mol.Toxicol.* **12**, 281-289.
- Van Veldhoven, P. P. and Mannaerts, G. P. (1991). Subcellular localization and membrane topology of sphingosine-1-phosphate lyase in rat liver. *J.Biol.Chem.* **266**, 12502-12507.
- Voss, K. A., Riley, R. T., Norred, W. P., Bacon, C. W., Meredith, F. I., Howard, P. C., Plattner, R. D., Collins, T. F., Hansen, D. K., and Porter, J. K. (2001). An overview of rodent toxicities: liver and kidney effects of fumonisins and *Fusarium moniliforme*. *Environ.Health Perspect.* **109 Suppl 2**, 259-266.
- Wang, E., Norred, W. P., Bacon, C. W., Riley, R. T., and Merrill, A. H., Jr. (1991). Inhibition of sphingolipid biosynthesis by fumonisins. Implications for diseases associated with *Fusarium moniliforme*. *J.Biol.Chem.* **266**, 14486-14490.
- Wang, W., Jones, C., Ciacci-Zanella, J., Holt, T., Gilchrist, D. G., and Dickman, M. B. (1996). Fumonisin and *Alternaria alternata* lycopersici toxins: sphinganine analog mycotoxins induce apoptosis in monkey kidney cells. *Proc.Natl.Acad.Sci.U.S.A* **93** , 3461-3465.

- Wolf, D., Hallmann, R., Sass, G., Sixt, M., Kusters, S., Fregien, B., Trautwein, C., and Tiegs, G. (2001). TNF-alpha-induced expression of adhesion molecules in the liver is under the control of TNFR1--relevance for concanavalin A-induced hepatitis. *J.Immunol.* **166**, 1300-1307.
- Xia, P., Wang, L., Moretti, P. A., Albanese, N., Chai, F., Pitson, S. M., D'Andrea, R. J., Gamble, J. R., and Vadas, M. A. (2002). Sphingosine kinase interacts with TRAF2 and dissects tumor necrosis factor-alpha signaling. *J.Biol.Chem.* **277**, 7996-8003.
- Yoo, H. S., Norred, W. P., Wang, E., Merrill, A. H., Jr., and Riley, R. T. (1992). Fumonisin inhibition of de novo sphingolipid biosynthesis and cytotoxicity are correlated in LLC-PK1 cells. *Toxicol.Appl.Pharmacol.* **114**, 9-15.
- Yoo, H. S., Norred, W. P., Showker, J., and Riley, R. T. (1996). Elevated sphingoid bases and complex sphingolipid depletion as contributing factors in fumonisin-induced cytotoxicity. *Toxicol.Appl.Pharmacol.* **138**, 211-218.

CHAPTER 2
LITERATURE REVIEW

Fumonisin B₁: A fusarium mycotoxin


Fumonisin B₁ is an environmental toxin produced by the molds *Fusarium moniliforme* (*F. verticillioides*), *F. proliferatum*, and other *Fusarium* species that grow on maize in the field or during storage. These mycotoxins have been found as contaminants worldwide, mainly in corn. There are many other toxins produced by the same fungus but only fumonisin B₁ has been implicated in fusarium induced toxicities. More than ten types of fumonisins have been isolated and characterized. Of the identified fumonisins produced by the fungus *F. verticillioides*, B₁, B₂, and B₃ are the most abundant in contaminated food and feed. Fumonisin B₁ is the most common, comprising approximately 75 percent of the total fumonisin and is believed to be the most toxic.

Structure of fumonisin B₁

Fumonisin B₁ is a water-soluble polar molecule comprised of a long-chain hydroxylated hydrocarbon backbone (Blackwell et al., 1996). Similar to sphingolipids, it is also formed by condensation of long chain fatty acid and amino acid serine. The structure of FB₁ consists of a 20-carbon backbone; an amine group at C₂; three hydroxyl groups at C₃, C₅, and C₁₀; two methyl groups at C₁₂ and C₁₆; and two tricarballic acid monoester groups at C₁₄ and C₁₅ (Fig 2.1). Fumonisin B₁ is a water soluble and polar compound due to the presence of amine and carboxylic groups. Fumonisin B₁ has a remarkable structural similarity to sphinganine and sphingosine, the long-chain sphingoid base backbone of sphingolipids (Fig. 2.1).

Species and gender specificity of fumonisin B₁

Fumonisin B₁ is known to cause equine leukoencephalomalacia (ELEM) (Kellerman et al. 1990, Marasas et al. 1988, Marasas 2001). Exposure of swine to FB₁ containing diet results in



specific porcine pulmonary edema (PPE) along with commonly observed general hepatotoxicity (Casteel et al., 1993). The animals fed feed with higher levels of FB₁ die of pulmonary edema and those exposed to lower levels exhibit subacute hepatotoxicosis. Pure FB₁ was shown to cause porcine pulmonary edema (PPE) by intravenous injection (Colvin and Harrison 1992). Due to abnormal climate conditions during the fall of 1989 and spring of 1990, widespread, large-scale outbreaks of ELEM and PPE occurred in the United States. Many horses and pigs died from ingesting fumonisin-contaminated corn (Osweiler *et al.* 1992, Ross *et al.* 1991a, b, 1992). Fumonisin B₁ is cardiovascular toxin, which is assumed to responsible for the PPE (Haschek *et al.* 2001, Smith *et al.* 1999). Liver injury has been observed in all animals tested so far, and kidney is also affected by fumonisins in most animals (Riley *et al.* 1994, Sharma *et al.* 1997, Voss *et al.* 1995, 1998, 2001). Fumonisin B₁ is immunotoxic in female mice

(Johnson and Sharma 2001), and rats (Theumer *et al.* 2002). It has been suggested that the observed adverse effects of FB₁ toxicity are the result of general immunosuppression (Chatterrje *et al.*, 1995; Martinova *et al.*, 1995). In poultry reduced body weight gain, hepatic necrosis, biliary hyperplasia, diarrhea and thymic cortical atrophy was shown, as in the case of one day-old broiler chickens fed FB₁ in doses from 0 to 400 mg/kg (Brown *et al.*, 1992). Ducklings exposed to *Fusarium* isolates, showed high mortality, loss in weight, low body fat and swollen and reddened livers (Dutton, 1996) and in quail severe paralysis was observed (Grimes *et al.*, 1993).

Toxicity of fumonisin B₁ manifests in various types of diseases in different affected species, although liver is thought to be a target organ in all animals regardless of other co-existing symptoms. High levels of FB₁ in human food have been correlated with increased incidence of neural tube defects (NTD) in parts of Texas, USA (Hendricks 1999). In mouse embryo cultures, FB₁ has been shown to produce embryotoxicity and NTD (Sadler *et al.* 2002). It has been documented or plausibly suggested that high incidences of NTD occur in some regions of the world (Guatemala, South Africa, and China) where substantial consumption of fumonisins (Marasas *et al.* 2004).

Carcinogenic potential of fumonisin B₁

Treatment with FB₁ in rats causes acute and chronic liver toxicity, bile duct proliferation, fibrosis further developing into cirrhosis, cholangiogenesis and hepatocellular carcinoma and/or cholangiocarcinoma (Gelderblom *et al.*, 1988; Voss *et al.*, 1993). Although, the findings regarding the FB₁-related tumor genesis in humans are speculative, FB₁ has been associated with the high incidences of esophageal cancer, first diagnosed by Burrell in 1957

and endemically re-occurring in Transkei, South Africa (Dutton, 1996) and later reported in China (Li et al, 1980). A different form of tumor, primary liver cancer, was also linked to FB₁ consumption in Haimen province, China. Carcinogenic properties of FB₁ observed in rodents are not associated with its direct genotoxicity. As a potent promoter of apoptosis, FB₁ causes further regeneration that is characterized by increased cell proliferation in affected tissues. Consequently, the constant elevation of DNA replication in exposed tissues has the potential for increasing the likelihood of cancer induction (Riley et al., 2001). Considering the available evidence the International Agency for Research on Cancer has declared toxins of *Fusarium verticillioides* as potential human carcinogens graded as class 2B (Vainio et al., 1993).

In vitro studies on the toxicity of Fumonisin B₁ in different cell lines

Different cell lines respond differently to fumonisin B₁ treatment. Diverse cellular responses credited to fumonisin B₁ exposure include apoptosis, proliferation and cell cycle arrest. FB₁ induces apoptosis in various cell lines such as HT29 cells (human colonic cell line) (Schmelz et al., 1998), and porcine renal epithelial (LLC-PK1) cells (Yoo et al., 1992), while Murine or Human leukemia cells (U937) do not undergo apoptosis, when treated with fumonisin B₁ (Ciacci-Zanella et al., 1998; Bose et al., 1995). Primary rat hepatocytes and liver slices (Norred et al., 1996) are quite resistant to fumonisin B₁-induced apoptosis.

FB₁ induced cell cycle arrest in the G₁ phase in African green monkey kidney cells (CV-1) but CV-1 cells transformed by the simian virus 40 (SV40) large T antigen (COS-7) are unaffected by the same levels of fumonisin B₁ (Wang et al., 1996). Hepatocyte mitotic activity, oval cell proliferation and formation of regenerative nodules were demonstrated in

rats fed with fumonisin B₁ containing diet (Lemmer et al., 1999). Taken together these studies indicate that some cells are responsive to fumonisin B₁ induced apoptosis while some are resistant and the ability of fumonisin B₁ to induce apoptosis may select for cells resistant to apoptosis, providing a way to induce cancer.

Fumonisin B₁ and sphingolipid biosynthesis:

Structural similarity of fumonisin B₁ to one of the intermediates in the *de novo* pathway of sphingolipid biosynthesis implicated the possibility of FB₁-related interference with sphingolipid metabolism. Indeed, it has been shown that FB₁ is a potent and specific inhibitor of ceramide synthase (sphinganine and sphingosine-N-acyl transferase), a key enzyme in sphingolipid synthesis (Wang et al., 1991; Merrill et al., 1993). Sphingolipids are integral part of all eukaryotic cell membranes, providing the highly resistant protective layer on the outer side of the lipid membrane. Their crucial role in signal transduction pathways, modulating cell growth, differentiation and death is known and expanding (Merrill, 2002). Their *de novo* synthesis proceeds in a number of steps modifying the core-structure (sphinganine) into further intermediates (i.e. ceramide) and more complex final products such as sphingomyelin and gangliosides, which are vital components of the brain white matter (Riboni et al., 1997).

The events resulting in the deregulation of sphingolipid metabolism include inhibition of dihydroceramide synthesis, an increase in free sphinganine, a decrease in reacylation of sphingosine derived from complex sphingolipid turnover (and consequent increase), an increase in sphingoid base degradation products (i.e. sphingosine (sphinganine) 1-phosphate, ethanolamine phosphate and fatty acid aldehydes). The elevation in the levels of sphinganine

and sphingosine in tissue and serum has been established as an accepted biomarker of exposure to FB₁ (Solfrizzo et al., 2004)

Initially, the ceramide levels do not decrease after FB₁-related inhibition of ceramide synthase, which may be due to the breakdown of sphingomyelin caused by TNF α -dependent activation of sphingomyelinase, resulting in compensatory ceramide synthesis but later there is depletion of complex sphingolipids (Tsunoda et al., 1998). The FB₁-induced disruption of sphingolipid metabolism usually precedes and is tightly correlated with the occurrence and severity of the *in vivo* toxicity (Voss et al., 1996).

Role of cytokines in fumonisin B₁ toxicity:

Fumonisin B₁ treatment caused an increased expression of TNF α , interferon (IFN) γ , and interleukine (IL) 12 in liver without any change in kidney or spleen, suggesting the localized site of their production (Bhandari et al., 2002). Cells involved in TNF α production following fumonisin B₁ treatment were identified as Kupffer cells in liver (Bhandari et al., 2002). Macrophages derived from animals treated with fumonisin B₁ also produce higher amounts of TNF α in response to lipopolysaccharide activation (Dugyala et al., 1998). TNF α was also induced in macrophages directly treated with fumonisin B₁ and pretreatment of mice with anti TNF α antibodies prevented acute hematological effects of fumonisin B₁ (Dugyala et al., 1998). There is considerable evidence that TNF α and interferon γ signaling pathways play an important role in fumonisin B₁ induced toxicity *in vitro* (in sensitive cells) and *in vivo*. Deletion of tumor necrosis factor receptors 1 and 2 and interferon γ genes reduced fumonisin B₁-induced hepatotoxicity in mice (Sharma et al., 2001, 2003).




Figure. 2.2 Scheme depicting the bioactive intermediates of sphingolipid biosynthesis. Dihydroceramide and ceramide biosynthesis takes place at the cytosolic surface of the ER. In the membrane recycling/salvage pathway, sphingosine produced from sphingolipids in the lysosome is phosphorylated by sphingosine kinase in the cytosol to S1P and dephosphorylated in the ER by SPP-1, where it is reutilized for synthesis of ceramide. Inhibition of ceramide synthase by FB₁ results in accumulation of sphingoid bases and disruption of complex sphingolipid metabolism. Abbreviations: SPHK- Sphingosine Kinase, SPP1- Sphingosine-1-phosphate phosphatase, Endo-Endosomes, SPT- Serine Palmitoyl Transferrase, PM- Plasma membrane, ER- Endoplasmic Reticulum, SPH- Sphingosine, S1P- Sphingosine-1-Phosphate, DHS- Dihydrosphingosine, SM- Sphigomylin, GSL- Glycosphingolipids. GlcCer- GlycosylCeramide, Pal-CoA- Palmityl Coenzyme A.

However, fumonisin B₁ hepatotoxicity was enhanced by deletion of *TNF α* gene or unchanged in mice lacking both TNF α receptors, which suggests that TNF α has paradoxical role in fumonisin B₁ toxicity (Sharma et al., 2002). FB₁ alters expression of a wide array of cytokines and mediators of apoptotic pathway. Fumonisin B₁ increased expression of mediators of apoptosis such as caspase 8 in the liver, which are involved in the TNF α signaling pathway and oncogenic transcription factors such as b-Myc, c-Myc and Max, in the kidney (Bhandari et al., 2002).

Crosstalk between macrophage and other cell types

In normal liver, close proximity of different cells such as hepatocytes, Kupffer cells, T cells and other nonparenchymal cells provide an excellent microenvironment for physiological interactions between these cells (Kmiec, 2001). It has been increasingly recognized that both under normal and pathological conditions, substances released from neighboring nonparenchymal cells regulate many hepatocyte and Kupffer cell functions. Kupffer cells are the most abundant macrophage population in the body and when activated by various toxins produce proinflammatory cytokines which have been implicated in liver damage.

In various models of acute liver injury by concavalin A (Con A) or *Pseudomonas* exotoxin A (PEA), where T cells seem to be responsible for liver damage it has been shown that absence of Kupffer cells restricts the area of necrosis (Schumann et al., 1998). A remarkable cross talk between macrophages and T cells involving TNF α and IFN γ has been suggested in other in vitro co culture experiments.

It was shown that TNF α and IL-12 produced by the Kupffer cells in liver can act on NK cells or Th 1 cells to produce IFN γ (Gantner et al., 1996). IFN γ can then further activate the Kupffer cells to produce more TNF α , and IL-12 eventually producing more IFN γ from the Th1 cells, thus generating a positive feedback loop between the two cells. These two cytokines, TNF α and IFN γ have synergistic effects in producing liver damage (Ozmen et al., 1994). Similar crosstalk between macrophages and cell types other than the T cells is also important. Interactions of this kind have been reported in several *in vitro* co culture experiments involving alveolar macrophages and type II pneumocytes (epithelial cells) (Tao et al., 2002) or microglia and neurons (Hemmer et al., 2001), where cytokine production was augmented due to induction of cross-talk between cells in response to toxins.

Liver nonparenchymal epithelial cells (NPECs)

Liver lobule is formed by parenchymal cells i.e. hepatocytes and nonparenchymal cells. Among nonparenchymal cells there are small epithelial cells that are phenotypically distinct from either hepatocytes or biliary epithelial cells and seem to have stem cell like potential to differentiate into hepatocytes and biliary epithelial cells (Grisham, 1995). Role of these cells in regenerative response following loss of cells through apoptosis or necrosis has been extensively studied (Thorgeirsson, 1996). Recent studies on liver regeneration have demonstrated that apart from hepatocytes, multipotential NPEC system also generates differentiated lineages needed for liver regeneration under situations where hepatocytes are unable to respond or are functionally compromised (Thorgeirsson, 1996). Rats treated with 2-acetylaminofluorene (2-AAF) for 2 weeks have mitotically inhibited hepatocytes, under these

conditions powerful activation of the NPECs and their differentiation to hepatocytes has been established (Evarts et al., 1987)

Cytokines and liver regeneration

According to widely accepted multi step model of liver regeneration, cells require priming by cytokines such as TNF α and IL-6 which make them responsive to growth factors (Michalopoulos et al., 1997). Administration of anti TNF α antibodies inhibits liver regeneration (Akerman et al., 1992) and mice lacking TNFR-1 receptors show reduced DNA replication after partial hepatectomy (Yamada et al., 1997). TNF injected in to rats at relatively high doses induces cell replication, which occurs first in NPECs followed by hepatocytes (Fausto, 2000).

Sphingosine kinase (SK):

Catabolism of sphingosine requires two independent and sequential steps. In cell free system dihydrosphingosine is cleaved to ethanolamine phosphate and palmitaldehyde (Keenan et al., 1969). First step involves phosphorylation of hydroxyl group on the first carbon of sphingosine and is mediated by Sphingosine Kinase. Sphingosine-1-phosphate lyase cleaves the product into ethanolamine phosphate and corresponding aldehyde. Due to relative inabundance of sphingosine-1-phosphate in cells, phosphorylation by sphingosine kinase is the rate-limiting step in this process.

Sphingosine kinase is highly conserved enzyme found in organisms as diverse as plants, yeast, worms, flies and mammals. Two distinct isoforms of SK, designated SK1 and SK2, have been cloned (Kohama et al., 1998; Liu et al., 2000). Although highly similar in amino

acid sequence and possessing five conserved catalytic domains related to that of the diacylglycerol kinase family (Pitson et al., 2000), SK2 diverges in its amino terminus and central region. These two isozymes have different kinetic properties and also differ in developmental expression (Liu et al., 2002), implying that they may have distinct physiological functions. Human sphingosine kinase is widely expressed with highest levels in adult liver, kidney, heart, and skeletal muscles. About 70% of sphingosine kinase activity was found in cytosol and only about 30% was membrane associated (Nava et al, 2000).

Recent studies suggest that SK1 and formation of sphingosine-1-phosphate (S1P) are linked to cell growth and survival (Spiegel and Milstien 2002). Diverse external stimuli, particularly growth and survival factors stimulate SK1 and intracellularly generated S1P has been implicated in their mitogenic and anti-apoptotic effects. TNF α stimulates SK1 leading to activation of extracellular signal-regulated kinase (ERK) (Pitson et al., 2000) and of NF- κ B, critical for prevention of apoptosis (Xia et al., 2002). Similar to platelet-derived growth factor (PDGF) (Olivera et al., 1999), the potent angiogenic factor vascular endothelial growth factor (VEGF) can also stimulate SK1, producing S1P, which mediates VEGF-induced activation of Ras and consequently, ERK signaling and cell growth (Shu et al., 2002). Indeed, Ras transformation requires SK1 activation (Xia et al., 2000).

Moreover, expression of SK1 enhanced proliferation and growth in soft agar, promoted the G1-S transition, protected cells from apoptosis (Olivera et al., 1999; Edsall et al., 2001), and induced tumor formation in mice (Xia et al., 2000). Inhibition of this enzyme activity markedly inhibits cell growth or induces apoptosis (Meyer zu et al., 1998).

Sphingosine-1-phosphate lyase (S1P lyase):

S1P lyase is pyridoxal 5 phosphate dependent enzyme with a conserved pyridoxal dependent decarboxylase domain. Once formed S1P is rapidly degraded by S1P lyase to hexadecenal and phosphoethanolamine (Stoffel et al, 1973). Hence intracellular S1P levels are determined by the balance of Sphingosine kinase mediated synthesis and its degradation by S1P lyase and S1P phosphohydrolase (Kihara et al, 2003). S1P lyase is thought to play central role in keeping intracellular S1P or dihydroS1P levels low.

Inhibition of *Caenorhabditis elegans* S1P Lyase expression by RNA interference causes accumulation of phosphorylated and unphosphorylated long-chain bases and leads to poor feeding, delayed growth, reproductive abnormalities, and intestinal damage (Mendel et al., 2003). Disruption of S1P Lyase gene induced differentiation to primitive endoderm in mouse F9 embryonal carcinoma cells, which suggests role of S1P regulation by S1P lyase in differentiation (Kihara et al, 2003).

Sphingosine-1-phosphate lyase is ubiquitously distributed, being present in yeast, protozoa, and mammals. One notable exception is platelets from man, rabbit and pig (Yatomi et al, 1996). Highest activity was found in microsomal fractions with some activity in mitochondrial and nuclear fractions. Lyase is an integral membrane protein, the catalytic sites or essential domains of which face the cytosol in the cell, which implies that substrate does not have to cross the membrane and reaction products are released into the cytoplasm (Van Veldhoven et al., 1991).

Primary breakdown products of phosphorylated sphingoid bases are actively metabolized *in vivo*. Ethanolamine phosphate is incorporated in phosphatidylethanolamine and subsequently can be transferred to phosphatidylcholine and sphingomyelin. The other fragment, fatty aldehyde is oxidized to fatty acid. After activation, the acyl-CoA is either degraded via β -oxidation or esterified in glycerolipids (Van Veldhoven 2000).

Sphingosine-1-phosphate phosphohydrolase (SPP):

Besides cleavage, dephosphorylation of sphingosine-1-phosphate might be another attenuation mechanism. The importance of dephosphorylation is perhaps illustrated by the severe toxicity of sphingosine-1-phosphate, which cannot be dephosphorylated but is still cleaved by the lyase. S1P being an important mediator of signal transduction is tightly regulated through its synthesis catalyzed by sphingosine kinase and degradation by S1P lyase and Phosphohydrolase. Recently two different kinds of enzymes SPP-1 (Le Stunff et al., 2002) and SPP-2 (Ogawa et al, 2003) with sphingosine phosphate phosphohydrolase (SPP) activity have been characterized in human embryonic kidney (HEK) 293 cells. Both SPPs reside predominantly in ER, thus it is likely that SPP is one of the enzymes for the regulation of sphingoid bases and ceramide levels as ER also contains the other enzymes of ceramide biosynthesis and sphingolipid metabolism.

Dihydro-S1P is also a substrate for SPP forming dihydrosphingosine, which is then converted by a fumonisin B₁ sensitive ceramide synthase to dihydroceramide. Stunff et al. (2002) have shown that when S1P or dihydro S1P are added to SPP transfected cells, S1P is dephosphorylated to sphingosine which forms ceramide and induces apoptosis whereas dihydro

S1P also forms dihydroceramide but it does not accumulate due to its more efficient use for sphingomyelin or glycosphingolipid biosynthesis.

Sphingoid bases and apoptosis:

Intensive investigation in past decade has confirmed the role of sphingolipid metabolites, ceramide, sphingosine and sphingosine-1-phosphate in controlling apoptosis. There is considerable debate about which is primary inducer of apoptosis, ceramide or sphingosine (Cuvillier et al., 2000). Uptake and distribution within the cell of exogenously added sphingolipids is complex, direct correlation between effects of exogenous sphingolipids and increase in endogenous levels cannot be made.

Ceramide and sphingosine are interconvertible sphingolipid metabolites, ceramide synthase can form ceramide from sphingosine and ceramide can be degraded to sphingosine by ceramidase. Ceramide generated from sphingomyelin by activation of sphingomyelinase has been implicated in apoptosis induced by diverse apoptotic stimuli, such as TNF α or Fas ligand (Kolesnick and Kronke 1998). In addition, administration of exogenous ceramide analogs can mimic apoptotic cell death. However many have challenged this direct role of ceramide based on the observations that ceramide increase in many such situations is followed by increase in sphingosine levels which is proapoptotic and is itself capable of inducing apoptosis when added exogenously to many cell types (Ohta et al., 1994; Hung et al., 1999).

Recent data suggest that ceramide and sphingosine could signal mitochondrial apoptosis by inhibiting the protein kinase Akt, responsible for Bad phosphorylation, hence leading to inhibition of anti-apoptotic protein Bcl-2 by Bad (Chang et al, 2001). Although some believe that due to its lysosomotropic properties sphingosine may work by relocating lysosomal

hydrolases to cytosol and this partial leakage may lead to early events of apoptosis (Kagedal et al, 2001), little is known overall about potential function of sphingosine in mitochondria and how it signals apoptosis.

Sphingosine-1-phosphate (S1P): Regulation of proliferation and survival:

S1P is a lysophospholipid derived from phosphorylation of sphingosine by-sphingosine kinases. As a specific ligand for a family of five G protein coupled receptors (S1P1-5) (Chun et al, 2002), which are ubiquitously expressed and couple to various G proteins (Goetzl and An 1998), S1P regulates a wide variety of important cellular processes, including cytoskeletal rearrangements and cell movements (Graeler et al, 2002), angiogenesis and vascular maturation (Garcia et al, 2001), and heart development (Kupperman et al, 2000). An important function for S1P in lymphocytes and immune responses emerged from studies with the immunosuppressive drug FTY720, a sphingosine analogue, which is phosphorylated by SK1 (Brinkmann et al, 2002). Although there is no doubt that S1P acts extracellularly, several studies suggest that this important bioactive lipid, like its precursors sphingosine and ceramide (N-acyl sphingosine), may also have intracellular functions important for calcium homeostasis (Meyer zu et al., 1998), cell growth (Olivera et al., 1999), and suppression of apoptosis (Cuvillier et al., 1996). Because intracellular targets of S1P have not yet been identified, its intracellular function is still a matter of debate (Hla et al, 2001).

There are many reports which suggest relationship between S1P production and early innate inflammatory activation, many external stimuli are capable of activating sphingosine kinase, including TNF α and IL1- β and PDGF. It is interesting to note that both the precursors for S1P (sphingomyelin) and some of the receptors for S1P (S1P1) colocalize in the same

plasma membrane microdomain, the caveolae (Rosen and Liao 2003). Mitogenic response of S1P have shown to be unrelated to it's binding with cell surface receptor as microinjection of SPP in cell causes increased DNA synthesis with out binding to surface receptors (Lee et al, 1998).

The ceramide/S1P rheostat

While ceramide acts as mediator of stress response, causing cell cycle arrest and /or apoptosis (Hannun et al, 1996) S1P counteracts these effects (Cuvillier et al, 1996). Thus, it has been suggested that the balance between cellular concentration of ceramide and S1P determines physiological fate of cell. Deletion of long chain sphingoid base phosphate phosphatase in *Saccharomyces* leads to accumulation of phosphorylated long chain sphingoid bases and reduced ceramide levels and concomitant enhancement of survival upon severe heat shock (Mandala et al, 1998). Therefore in addition to it's role as a ligand for Edg-1 (endothelial differentiation gene) receptor, the cellular level of S1P is important for cell proliferation and survival.

Mitogen activated protein kinases (MAPKs) in cell survival and apoptosis

MAPKs are one of the Ser/Thr protein kinases, which are responsible for transmitting extracellular signals in to the nucleus (Robinson et al., 1997; Schaeffer et al., 1999). Five different types of MAPKs have been identified, which include extracellular signal-related kinase (ERK1/2), c-Jun NH₂ terminal kinase (JNK) and p38MAPK, ERK3 and ERK5 (Schaeffer et al., 1999). Cellular effects downstream to MAPK signaling are diverse and include cell growth, cell differentiation and cell death (Robinson et al., 1997).

ERK is activated by a variety of growth factors, insulin and oxidative stress and leads to a wide array of cellular responses (Bergmann et al., 1998). ERK pathway can transmit both anti-apoptotic and pro-apoptotic signals, probably depending on the nature of the extra cellular stimuli (Bergmann et al., 1998).

Deactivation of p38 MAPK has been shown to lead to both anti-apoptotic and pro-apoptotic responses. Nerve growth factor induced dephosphorylation of p38 prevents Bcl-2 phosphorylation and apoptotic response in lymphoblastoid CESS B cell line (Rosini et al., 2004), whereas, anticancer desipeptide, FR901228, induced apoptosis of ras-transformed 10T1/2 cells through suppression of p38 pathway (Fecteau et al., 2002).

JNK is a member of the mitogen-activated protein (MAP) kinase family and is activated by a variety of extracellular stimuli through JNK kinases and multiple MAP kinase kinase kinases (Chang et al., 2001). Activated JNK, phosphorylates and activates c-Jun, a component of the transcription factor AP-1 and many other targets as well (Chang et al., 2001). The role of JNK activation in mediating the TNF receptor signaling is uncertain, ranging from being protective, irrelevant or pro-apoptotic, which depends on the stimuli and cell types (Liu, 2003). However, there is strong evidence indicating that JNK activation could increase TNF α -induced apoptosis in hepatocytes (Liu et al., 2002; Schwabe et al., 2004). JNK-mediated apoptosis in hepatocytes was shown to involve mitochondrial permeability transition, release of cytochrome c and activation of caspase-3, -8 and -7, suggesting that JNK acts upstream of the mitochondria (Liu et al., 2002). A recent report provided strong evidence that JNK activation in TNF α signaling involves release of Smac/DIABLO from the mitochondria, but not cytochrome c (Deng et al., 2003). The released Smac/DIABLO then disrupts the TRAF2-

ciAP1 complex, relieving the inhibition imposed by TRAF2-ciAP1 on caspase 8 activation and induction of apoptosis (Deng et al., 2003). TRAF2 also mediates the activation of the JNK pathway, as shown by JNK inhibition by TRAF2 Δ and in TRAF2 (-/-) mice (Natoli et al., 1997).

Increases in hepatocellular oxidation stress such as those that occur with hepatic overexpression of cytochrome *P*-450 isoforms promoted TNF α mediated apoptosis in hepatocytes through increased activity of c-Jun NH₂-terminal kinase (Liu et al., 2002)

There are only few reports indicating the role of MAPKs in fumonisin B₁ induced toxicity in mammalian cells (Pinelli et al., 1999; Rentz et al., 2005; Wattenberg et al., 1996). A differential activation of JNK but not of ERK or p38 was reported in LLC-PK1 cells by fumonisin B₁ (Johnson et al., 2003). Recently, a decrease in ERK has been reported in LLC-PK1 cells at 24 h (Rentz et al., 2005). In our other studies, we have noticed the induction of both total and phosphorylated JNK in livers of fumonisin B₁-treated mice (unpublished data).

REFERENCES

- Abbas, A. K., Murphy, K. M., and Sher, A. (1996). Functional diversity of helper T lymphocytes. *Nature* **383**, 787-793.
- Akerman, P., Cote, P., Yang, S. Q., McClain, C., Nelson, S., Bagby, G. J., and Diehl, A. M. (1992). Antibodies to tumor necrosis factor-alpha inhibit liver regeneration after partial hepatectomy. *Am.J.Physiol* **263**, G579-G585.
- Bergmann, A., Agapite, J., McCall, K., and Steller, H. (1998). The Drosophila gene hid is a direct molecular target of Ras-dependent survival signaling. *Cell* **95**, 331-341.
- Bhandari, N., Brown, C. C., and Sharma, R. P. (2002). Fumonisin B₁-induced localized activation of cytokine network in mouse liver. *Food Chem.Toxicol.* **40**, 1483-1491.
- Bhandari, N. and Sharma, R. P. (2002). Fumonisin B₁-induced alterations in cytokine expression and apoptosis signaling genes in mouse liver and kidney after an acute exposure. *Toxicology* **172**, 81-92.
- Blackwell, B. A., Edwards, O. E., Fruchier, A., ApSimon, J. W., and Miller, J. D. (1996). NMR structural studies of fumonisin B₁ and related compounds from *Fusarium moniliforme*. *Adv.Exp.Med.Biol.* **392**, 75-91.
- Bondy, G. S., Suzuki, C. A., Fernie, S. M., Armstrong, C. L., Hierlihy, S. L., Savard, M. E., and Barker, M. G. (1997). Toxicity of fumonisin B₁ to B6C3F1 mice: a 14-day gavage study. *Food Chem.Toxicol.* **35**, 981-989.

- Bose, R., Verheij, M., Haimovitz-Friedman, A., Scotto, K., Fuks, Z., and Kolesnick, R. (1995). Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals. *Cell* **82**, 405-414.
- Brinkmann, V., Davis, M. D., Heise, C. E., Albert, R., Cottens, S., Hof, R., Bruns, C., Prieschl, E., Baumruker, T., Hiestand, P., Foster, C. A., Zollinger, M., and Lynch, K. R. (2002). The immune modulator FTY720 targets sphingosine 1-phosphate receptors. *J.Biol.Chem.* **277**, 21453-21457.
- Brown, T. P., Rottinghaus, G. E., and Williams, M. E. (1992). Fumonisin mycotoxicosis in broilers: performance and pathology. *Avian Dis.* **36**, 450-454.
- Carlson, D. B., Williams, D. E., Spitsbergen, J. M., Ross, P. F., Bacon, C. W., Meredith, F. I., and Riley, R. T. (2001). Fumonisin B₁ promotes aflatoxin B₁ and N-methyl-N'-nitro-nitrosoguanidine-initiated liver tumors in rainbow trout. *Toxicol.Appl.Pharmacol.* **172**, 29-36.
- Casteel, S. W., Turk, J. R., Cowart, R. P., and Rottinghaus, G. E. (1993). Chronic toxicity of fumonisin in weanling pigs. *J.Vet.Diagn.Invest* **5**, 413-417.
- Chang, H. C., Tsai, L. H., Chuang, L. Y., and Hung, W. C. (2001). Role of AKT kinase in sphingosine-induced apoptosis in human hepatoma cells. *J.Cell Physiol* **188**, 188-193.
- Chang, L. and Karin, M. (2001). Mammalian MAP kinase signalling cascades. *Nature* **410**, 37-40.

- Chatterjee, D., Mukherjee, S. K., and Dey, A. (1995). Nuclear disintegration in chicken peritoneal macrophages exposed to fumonisin B₁ from Indian maize. *Lett. Appl. Microbiol.* **20**, 184-185.
- Chun, J., Goetzl, E. J., Hla, T., Igarashi, Y., Lynch, K. R., Moolenaar, W., Pyne, S., and Tigyi, G. (2002). International Union of Pharmacology. XXXIV. Lysophospholipid receptor nomenclature. *Pharmacol. Rev.* **54**, 265-269.
- Ciacchi-Zanella, J. R., Merrill, A. H., Jr., Wang, E., and Jones, C. (1998). Characterization of cell-cycle arrest by fumonisin B₁ in CV-1 cells. *Food Chem. Toxicol.* **36**, 791-804.
- Colvin, B. M. and Harrison, L. R. (1992). Fumonisin-induced pulmonary edema and hydrothorax in swine. *Mycopathologia* **117**, 79-82.
- Cuvillier, O., Pirianov, G., Kleuser, B., Vanek, P. G., Coso, O. A., Gutkind, S., and Spiegel, S. (1996). Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. *Nature* **381**, 800-803.
- Cuvillier, O., Edsall, L., and Spiegel, S. (2000). Involvement of sphingosine in mitochondria-dependent Fas-induced apoptosis of type II Jurkat T cells. *J. Biol. Chem.* **275**, 15691-15700.
- Deng, Y., Ren, X., Yang, L., Lin, Y., and Wu, X. (2003). A JNK-dependent pathway is required for TNF α -induced apoptosis. *Cell* **115**, 61-70.

- Dombrink-Kurtzman, M. A., Gomez-Flores, R., and Weber, R. J. (2000). Activation of rat splenic macrophage and lymphocyte functions by fumonisin B₁. *Immunopharmacology* **49**, 401-409.
- Dresden, O. C., Pittman, N. G., Enongene, E. N., Bacon, C. W., Riley, R. T., and Voss, K. A. (2002). Host resistance to *Trypanosoma cruzi* infection is enhanced in mice fed *Fusarium verticillioides* (= *F. moniliforme*) culture material containing fumonisins. *Food Chem. Toxicol.* **40**, 1789-1798.
- Dugyala, R. R., Sharma, R. P., Tsunoda, M., and Riley, R. T. (1998). Tumor necrosis factor-alpha as a contributor in fumonisin B₁ toxicity. *J.Pharmacol.Exp.Ther.* **285**, 317-324.
- Dutton, M. F. (1996). Fumonisins, mycotoxins of increasing importance: their nature and their effects. *Pharmacol.Ther.* **70**, 137-161.
- Edsall, L. C., Cuvillier, O., Twitty, S., Spiegel, S., and Milstien, S. (2001). Sphingosine kinase expression regulates apoptosis and caspase activation in PC12 cells. *J.Neurochem.* **76**, 1573-1584.
- Evarts, R. P., Nagy, P., Marsden, E., and Thorgeirsson, S. S. (1987). A precursor-product relationship exists between oval cells and hepatocytes in rat liver. *Carcinogenesis* **8**, 1737-1740.
- Fausto, N. (2000). Liver regeneration. *J.Hepatol.* **32**, 19-31.

- Fecteau, K. A., Mei, J., and Wang, H. C. (2002). Differential modulation of signaling pathways and apoptosis of ras-transformed 10T1/2 cells by the depsipeptide FR901228. *J.Pharmacol.Exp.Ther.* **300**, 890-899.
- Gantner, F., Leist, M., Kusters, S., Vogt, K., Volk, H. D., and Tiegs, G. (1996). T cell stimulus-induced crosstalk between lymphocytes and liver macrophages results in augmented cytokine release. *Exp.Cell Res.* **229**, 137-146.
- Garcia, J. G., Liu, F., Verin, A. D., Birukova, A., Dechert, M. A., Gerthoffer, W. T., Bamberg, J. R., and English, D. (2001). Sphingosine 1-phosphate promotes endothelial cell barrier integrity by Edg-dependent cytoskeletal rearrangement. *J.Clin.Invest* **108**, 689-701.
- Gelderblom, W. C., Jaskiewicz, K., Marasas, W. F., Thiel, P. G., Horak, R. M., Vlegaar, R., and Kriek, N. P. (1988). Fumonisin--novel mycotoxins with cancer-promoting activity produced by *Fusarium moniliforme*. *Appl.Environ.Microbiol.* **54**, 1806-1811.
- Goetzl, E. J. and An, S. (1998). Diversity of cellular receptors and functions for the lysophospholipid growth factors lysophosphatidic acid and sphingosine 1-phosphate. *FASEB J.* **12**, 1589-1598.
- Graeler, M., Shankar, G., and Goetzl, E. J. (2002). Cutting edge: suppression of T cell chemotaxis by sphingosine 1-phosphate. *J.Immunol.* **169**, 4084-4087.
- Grimes, J. L., Eleazer, T. H., and Hill, J. E. (1993). Paralysis of undetermined origin in bobwhite quail. *Avian Dis.* **37**, 582-584.

- Grisham, J. W. (1995). Hepatic epithelial stem-like cells. *Verh.Dtsch.Ges.Pathol.* **79**, 47-54.
- Haschek, W. M., Gumprecht, L. A., Smith, G., Tumbleson, M. E., and Constable, P. D. (2001). Fumonisin toxicosis in swine: an overview of porcine pulmonary edema and current perspectives. *Environ.Health Perspect.* **109 Suppl 2**, 251-257.
- Hemmer, K., Fransen, L., Vanderstichele, H., Vanmechelen, E., and Heuschling, P. (2001). An in vitro model for the study of microglia-induced neurodegeneration: involvement of nitric oxide and tumor necrosis factor-alpha. *Neurochem.Int.* **38**, 557-565.
- Hendricks, K. (1999). Fumonisin and neural tube defects in South Texas. *Epidemiology* **10**, 198-200.
- Hla, T., Lee, M. J., Ancellin, N., Paik, J. H., and Kluk, M. J. (2001). Lysophospholipids--receptor revelations. *Science* **294**, 1875-1878.
- Hung, W. C., Chang, H. C., and Chuang, L. Y. (1999). Activation of caspase-3-like proteases in apoptosis induced by sphingosine and other long-chain bases in Hep3B hepatoma cells. *Biochem.J.* **338 (Pt 1)**, 161-166.
- Johnson, V. J. and Sharma, R. P. (2001). Gender-dependent immunosuppression following subacute exposure to fumonisin B₁. *Int.Immunopharmacol.* **1**, 2023-2034.
- Johnson, V. J., He, Q., Kim, S. H., Kanti, A., and Sharma, R. P. (2003). Increased susceptibility of renal epithelial cells to TNFalpha-induced apoptosis following treatment with fumonisin B₁. *Chem.Biol.Interact.* **145**, 297-309.

- Kagedal, K., Zhao, M., Svensson, I., and Brunk, U. T. (2001). Sphingosine-induced apoptosis is dependent on lysosomal proteases. *Biochem.J.* **359**, 335-343.
- Keenan, R. W. and Haegelin, B. (1969). The enzymatic phosphorylation of sphinganine. *Biochem.Biophys.Res.Comm.* **37**, 888-894.
- Kellerman, T. S., Marasas, W. F., Thiel, P. G., Gelderblom, W. C., Cawood, M., and Coetzer, J. A. (1990). Leukoencephalomalacia in two horses induced by oral dosing of fumonisin B₁. *Onderstepoort J.Vet.Res.* **57**, 269-275.
- Kihara, A., Ikeda, M., Kariya, Y., Lee, E. Y., Lee, Y. M., and Igarashi, Y. (2003). Sphingosine-1-phosphate lyase is involved in the differentiation of F9 embryonal carcinoma cells to primitive endoderm. *J.Biol.Chem.* **278**, 14578-14585.
- Kmiec, Z. (2001). Cooperation of liver cells in health and disease. *Adv.Anat.Embryol.Cell Biol.* **161**, III-151.
- Kohama, T., Olivera, A., Edsall, L., Nagiec, M. M., Dickson, R., and Spiegel, S. (1998). Molecular cloning and functional characterization of murine sphingosine kinase. *J.Biol.Chem.* **273**, 23722-23728.
- Kolesnick, R. N. and Kronke, M. (1998). Regulation of ceramide production and apoptosis. *Annu.Rev.Physiol* **60**, 643-665.

- Kupperman, E., An, S., Osborne, N., Waldron, S., and Stainier, D. Y. (2000). A sphingosine-1-phosphate receptor regulates cell migration during vertebrate heart development. *Nature* **406**, 192-195.
- Le Stunff, H., Galve-Roperh, I., Peterson, C., Milstien, S., and Spiegel, S. (2002). Sphingosine-1-phosphate phosphohydrolase in regulation of sphingolipid metabolism and apoptosis. *J. Cell Biol.* **158**, 1039-1049.
- Lee, M. J., Van Brocklyn, J. R., Thangada, S., Liu, C. H., Hand, A. R., Menzeleev, R., Spiegel, S., and Hla, T. (1998). Sphingosine-1-phosphate as a ligand for the G protein-coupled receptor EDG-1. *Science* **279**, 1552-1555.
- Lemmer, E. R., de la Motte, H. P., Omori, N., Omori, M., Shephard, E. G., Gelderblom, W. C., Cruse, J. P., Barnard, R. A., Marasas, W. F., Kirsch, R. E., and Thorgeirsson, S. S. (1999). Histopathology and gene expression changes in rat liver during feeding of fumonisin B₁, a carcinogenic mycotoxin produced by *Fusarium moniliforme*. *Carcinogenesis* **20**, 817-824.
- Li, M. H., Li, P., and Li, P. J. (1980). Recent progress in research on esophageal cancer in China. *Adv. Cancer Res.* **33**, 173-249.
- Liu, H., Sugiura, M., Nava, V. E., Edsall, L. C., Kono, K., Poulton, S., Milstien, S., Kohama, T., and Spiegel, S. (2000). Molecular cloning and functional characterization of a novel mammalian sphingosine kinase type 2 isoform. *J. Biol. Chem.* **275**, 19513-19520.

- Liu, H., Chakravarty, D., Maceyka, M., Milstien, S., and Spiegel, S. (2002). Sphingosine kinases: a novel family of lipid kinases. *Prog.Nucleic Acid Res.Mol.Biol.* **71**, 493-511.
- Liu, H., Lo, C. R., and Czaja, M. J. (2002). NF-kappaB inhibition sensitizes hepatocytes to TNF-induced apoptosis through a sustained activation of JNK and c-Jun. *Hepatology* **35**, 772-778.
- Liu, H., Jones, B. E., Bradham, C., and Czaja, M. J. (2002). Increased cytochrome P-450 2E1 expression sensitizes hepatocytes to c-Jun-mediated cell death from TNF-alpha. *Am.J.Physiol Gastrointest.Liver Physiol* **282**, G257-G266.
- Liu, Z. G. (2003). Adding facets to TNF signaling. The JNK angle. *Mol.Cell* **12**, 795-796.
- Mandala, S. M., Thornton, R., Tu, Z., Kurtz, M. B., Nickels, J., Broach, J., Menzeleev, R., and Spiegel, S. (1998). Sphingoid base 1-phosphate phosphatase: a key regulator of sphingolipid metabolism and stress response. *Proc.Natl.Acad.Sci.U.S.A* **95**, 150-155.
- Marasas, W. F., Kellerman, T. S., Gelderblom, W. C., Coetzer, J. A., Thiel, P. G., and van der Lugt, J. J. (1988). Leukoencephalomalacia in a horse induced by fumonisin B₁ isolated from *Fusarium moniliforme*. *Onderstepoort J.Vet.Res.* **55**, 197-203.
- Marasas, W. F. (2001). Discovery and occurrence of the fumonisins: a historical perspective. *Environ.Health Perspect.* **109 Suppl 2**, 239-243.
- Marasas, W. F., Riley, R. T., Hendricks, K. A., Stevens, V. L., Sadler, T. W., Gelineau-van Waes, J., Missmer, S. A., Cabrera, J., Torres, O., Gelderblom, W. C., Allegood, J.,

Martinez, C., Maddox, J., Miller, J. D., Starr, L., Sullards, M. C., Roman, A. V., Voss, K. A., Wang, E., and Merrill, A. H., Jr. (2004). Fumonisin disrupt sphingolipid metabolism, folate transport, and neural tube development in embryo culture and in vivo: a potential risk factor for human neural tube defects among populations consuming fumonisin-contaminated maize. *J.Nutr.* **134**, 711-716.

Martinova, E. A. and Merrill, A. H., Jr. (1995). Fumonisin B₁ alters sphingolipid metabolism and immune function in BALB/c mice: immunological responses to fumonisin B₁. *Mycopathologia* **130**, 163-170.

Mendel, J., Heinecke, K., Fyrst, H., and Saba, J. D. (2003). Sphingosine phosphate lyase expression is essential for normal development in *Caenorhabditis elegans*. *J.Biol.Chem.* **278**, 22341-22349.

Merrill, A. H., Jr., van Echten, G., Wang, E., and Sandhoff, K. (1993). Fumonisin B₁ inhibits sphingosine (sphinganine) N-acyltransferase and de novo sphingolipid biosynthesis in cultured neurons in situ. *J.Biol.Chem.* **268**, 27299-27306.

Merrill, A. H., Jr. (2002). De novo sphingolipid biosynthesis: a necessary, but dangerous, pathway. *J.Biol.Chem.* **277**, 25843-25846.

Meyer zu, H. D., Lass, H., Alemany, R., Laser, K. T., Neumann, E., Zhang, C., Schmidt, M., Rauen, U., Jakobs, K. H., and van Koppen, C. J. (1998). Sphingosine kinase-mediated Ca²⁺ signalling by G-protein-coupled receptors. *EMBO J.* **17**, 2830-2837.

Michalopoulos, G. K. and DeFrances, M. C. (1997). Liver regeneration. *Science* **276**, 60-66.

Nava, V. E., Lacana, E., Poulton, S., Liu, H., Sugiura, M., Kono, K., Milstien, S., Kohama, T., and Spiegel, S. (2000). Functional characterization of human sphingosine kinase-1. *FEBS Lett.* **473**, 81-84.

Norred, W. P., Voss, K. A., Riley, R. T., and Plattner, R. D. (1996). Fumonisin toxicity and metabolism studies at the USDA. Fumonisin toxicity and metabolism. *Adv.Exp.Med.Biol.* **392**, 225-236.

Norred, W. P., Voss, K. A., Riley, R. T., and Plattner, R. D. (1996). Fumonisin toxicity and metabolism studies at the USDA. Fumonisin toxicity and metabolism. *Adv.Exp.Med.Biol.* **392**, 225-236.

Ogawa, C., Kihara, A., Gokoh, M., and Igarashi, Y. (2003). Identification and characterization of a novel human sphingosine-1-phosphate phosphohydrolase, hSPP2. *J.Biol.Chem.* **278**, 1268-1272.

Ohta, H., Yatomi, Y., Sweeney, E. A., Hakomori, S., and Igarashi, Y. (1994). A possible role of sphingosine in induction of apoptosis by tumor necrosis factor-alpha in human neutrophils. *FEBS Lett.* **355**, 267-270.

Olivera, A., Kohama, T., Edsall, L., Nava, V., Cuvillier, O., Poulton, S., and Spiegel, S. (1999). Sphingosine kinase expression increases intracellular sphingosine-1-phosphate and promotes cell growth and survival. *J.Cell Biol.* **147**, 545-558.

- Oswailer, G. D., Ross, P. F., Wilson, T. M., Nelson, P. E., Witte, S. T., Carson, T. L., Rice, L. G., and Nelson, H. A. (1992). Characterization of an epizootic of pulmonary edema in swine associated with fumonisin in corn screenings. *J. Vet. Diagn. Invest* **4**, 53-59.
- Ozmen, L., Pericin, M., Hakimi, J., Chizzonite, R. A., Wysocka, M., Trinchieri, G., Gately, M., and Garotta, G. (1994). Interleukin 12, interferon gamma, and tumor necrosis factor alpha are the key cytokines of the generalized Shwartzman reaction. *J. Exp. Med.* **180**, 907-915.
- Pascale, M., Visconti, A., and Chelkowski, J. (2002). Ear rot susceptibility and mycotoxin contamination of maize hybrids inoculated with *Fusarium* species under field conditions. *European Journal of Plant Pathology* **108**, 645-651.
- Pinelli, E., Poux, N., Garren, L., Pipy, B., Castegnaro, M., Miller, D. J., and Pfohl-Leszkowicz, A. (1999). Activation of mitogen-activated protein kinase by fumonisin B₁ stimulates cPLA(2) phosphorylation, the arachidonic acid cascade and cAMP production. *Carcinogenesis* **20**, 1683-1688.
- Pitson, S. M., Moretti, P. A., Zebol, J. R., Xia, P., Gamble, J. R., Vadas, M. A., D'Andrea, R. J., and Wattenberg, B. W. (2000). Expression of a catalytically inactive sphingosine kinase mutant blocks agonist-induced sphingosine kinase activation. A dominant-negative sphingosine kinase. *J. Biol. Chem.* **275**, 33945-33950.

- Rentz, S. S., Showker, J. L., Meredith, F. I., and Riley, R. T. (2005). Inhibition of sphingolipid biosynthesis decreases phosphorylated ERK2 in LLC-PK1 cells. *Food Chem. Toxicol.* **43**, 123-131.
- Riboni, L., Viani, P., Bassi, R., Prinetti, A., and Tettamanti, G. (1997). The role of sphingolipids in the process of signal transduction. *Prog. Lipid Res.* **36**, 153-195.
- Riley, R. T., Norred, W. P., and Bacon, C. W. (1993). Fungal Toxins in Foods - Recent Concerns. *Annual Review of Nutrition* **13**, 167-189.
- Riley, R. T., Hinton, D. M., Chamberlain, W. J., Bacon, C. W., Wang, E., Merrill, A. H., Jr., and Voss, K. A. (1994). Dietary fumonisin B₁ induces disruption of sphingolipid metabolism in Sprague-Dawley rats: a new mechanism of nephrotoxicity. *J. Nutr.* **124**, 594-603.
- Riley, R. T., Enongene, E., Voss, K. A., Norred, W. P., Meredith, F. I., Sharma, R. P., Spitsbergen, J., Williams, D. E., Carlson, D. B., and Merrill, A. H., Jr. (2001). Sphingolipid perturbations as mechanisms for fumonisin carcinogenesis. *Environ. Health Perspect.* **109 Suppl 2**, 301-308.
- Robinson, M. J. and Cobb, M. H. (1997). Mitogen-activated protein kinase pathways. *Curr. Opin. Cell Biol.* **9**, 180-186.
- Rosen, H. and Liao, J. (2003). Sphingosine 1-phosphate pathway therapeutics: a lipid ligand-receptor paradigm. *Curr. Opin. Chem. Biol.* **7**, 461-468.

- Rosini, P., De Chiara, G., Bonini, P., Lucibello, M., Marcocci, M. E., Garaci, E., Cozzolino, F., and Torcia, M. (2004). Nerve growth factor-dependent survival of CESS B cell line is mediated by increased expression and decreased degradation of MAPK phosphatase 1. *J. Biol. Chem.* **279**, 14016-14023.
- Ross, P. F., Rice, L. G., Plattner, R. D., Osweiler, G. D., Wilson, T. M., Owens, D. L., Nelson, H. A., and Richard, J. L. (1991). Concentrations of fumonisin B₁ in feeds associated with animal health problems. *Mycopathologia* **114**, 129-135.
- Ross, P. F., Rice, L. G., Reagor, J. C., Osweiler, G. D., Wilson, T. M., Nelson, H. A., Owens, D. L., Plattner, R. D., Harlin, K. A., Richard, J. L., and . (1991). Fumonisin B₁ concentrations in feeds from 45 confirmed equine leukoencephalomalacia cases. *J. Vet. Diagn. Invest* **3**, 238-241.
- Ross, P. F., Rice, L. G., Osweiler, G. D., Nelson, P. E., Richard, J. L., and Wilson, T. M. (1992). A review and update of animal toxicoses associated with fumonisin-contaminated feeds and production of fumonisins by *Fusarium* isolates. *Mycopathologia* **117**, 109-114.
- Sadler, T. W., Merrill, A. H., Stevens, V. L., Sullards, M. C., Wang, E., and Wang, P. (2002). Prevention of fumonisin B₁-induced neural tube defects by folic acid. *Teratology* **66**, 169-176.
- Schaeffer, H. J. and Weber, M. J. (1999). Mitogen-activated protein kinases: specific messages from ubiquitous messengers. *Mol. Cell Biol.* **19**, 2435-2444.

- Schmelz, E. M., Dombink-Kurtzman, M. A., Roberts, P. C., Kozutsumi, Y., Kawasaki, T., and Merrill, A. H., Jr. (1998). Induction of apoptosis by fumonisin B₁ in HT29 cells is mediated by the accumulation of endogenous free sphingoid bases. *Toxicol.Appl.Pharmacol.* **148**, 252-260.
- Schumann, J., Angermuller, S., Bang, R., Lohoff, M., and Tiegs, G. (1998). Acute hepatotoxicity of *Pseudomonas aeruginosa* exotoxin A in mice depends on T cells and TNF. *J.Immunol.* **161**, 5745-5754.
- Schwabe, R. F., Uchinami, H., Qian, T., Bennett, B. L., Lemasters, J. J., and Brenner, D. A. (2004). Differential requirement for c-Jun NH₂-terminal kinase in TNF α - and Fas-mediated apoptosis in hepatocytes. *FASEB J.* **18**, 720-722.
- Sharma, R. P., Dugyala, R. R., and Voss, K. A. (1997). Demonstration of in-situ apoptosis in mouse liver and kidney after short-term repeated exposure to fumonisin B₁. *J.Comp Pathol.* **117**, 371-381.
- Sharma, R. P., Bhandari, N., He, Q., Riley, R. T., and Voss, K. A. (2001). Decreased fumonisin hepatotoxicity in mice with a targeted deletion of tumor necrosis factor receptor 1. *Toxicology* **159**, 69-79.
- Sharma, R. P., He, Q., Meredith, F. I., Riley, R. T., and Voss, K. A. (2002). Paradoxical role of tumor necrosis factor alpha in fumonisin-induced hepatotoxicity in mice. *Toxicology* **180**, 221-232.

- Sharma, R. P., He, Q., and Johnson, V. J. (2003). Deletion of IFN-gamma reduces fumonisin-induced hepatotoxicity in mice via alterations in inflammatory cytokines and apoptotic factors. *J. Interferon Cytokine Res.* **23**, 13-23.
- Shu, X., Wu, W., Mosteller, R. D., and Broek, D. (2002). Sphingosine kinase mediates vascular endothelial growth factor-induced activation of ras and mitogen-activated protein kinases. *Mol. Cell Biol.* **22**, 7758-7768.
- Smith, G. W., Constable, P. D., Tumbleson, M. E., Rottinghaus, G. E., and Haschek, W. M. (1999). Sequence of cardiovascular changes leading to pulmonary edema in swine fed culture material containing fumonisin. *Am. J. Vet. Res.* **60**, 1292-1300.
- Solfrizzo, M., Chulze, S. N., Mallmann, C., Visconti, A., De Girolamo, A., Rojo, F., and Torres, A. (2004). Comparison of urinary sphingolipids in human populations with high and low maize consumption as a possible biomarker of fumonisin dietary exposure. *Food Addit. Contam* **21**, 1090-1095.
- Spiegel, S. and Milstien, S. (2002). Sphingosine 1-phosphate, a key cell signaling molecule. *J. Biol. Chem.* **277**, 25851-25854.
- Stoffel, W. and Grol, M. (1974). Chemistry and biochemistry of 1-desoxysphinganine 1-phosphonate (dihydrosphingosine-1-phosphonate). *Chem. Phys. Lipids* **13**, 372-388.
- Tao, F. and Kobzik, L. (2002). Lung macrophage-epithelial cell interactions amplify particle-mediated cytokine release. *Am. J. Respir. Cell Mol. Biol.* **26**, 499-505.

- Taranu, I., Marin, D. E., Bouhet, S., Pascale, F., Bailly, J. D., Miller, J. D., Pinton, P., and Oswald, I. P. (2005). Mycotoxin Fumonisin B₁ Alters the Cytokine Profile and Decreases the Vaccinal Antibody Titer in Pigs. *Toxicol.Sci.* **84**, 301-307.
- Theumer, M. G., Lopez, A. G., Masih, D. T., Chulze, S. N., and Rubinstein, H. R. (2002). Immunobiological effects of fumonisin B₁ in experimental subchronic mycotoxicoses in rats. *Clin.Diagn.Lab Immunol.* **9**, 149-155.
- Thorgeirsson, S. S. (1996). Hepatic stem cells in liver regeneration. *FASEB J.* **10**, 1249-1256.
- Tsunoda, M., Sharma, R. P., and Riley, R. T. (1998). Early fumonisin B₁ toxicity in relation to disrupted sphingolipid metabolism in male BALB/c mice. *J.Biochem.Mol.Toxicol.* **12**, 281-289.
- Vainio, H., Heseltine, E., and Wilbourn, J. (1993). Report on an IARC working group meeting on some naturally occurring substances. *Int.J.Cancer* **53**, 535-537.
- Van Veldhoven, P. P. and Mannaerts, G. P. (1991). Subcellular localization and membrane topology of sphingosine-1-phosphate lyase in rat liver. *J.Biol.Chem.* **266**, 12502-12507.
- Van Veldhoven, P. P. (2000). Sphingosine-1-phosphate lyase. *Methods Enzymol.* **311**, 244-254.
- Voss, K. A., Chamberlain, W. J., Bacon, C. W., and Norred, W. P. (1993). A preliminary investigation on renal and hepatic toxicity in rats fed purified fumonisin B₁. *Nat.Toxins* **1**, 222-228.

- Voss, K. A., Chamberlain, W. J., Bacon, C. W., Herbert, R. A., Walters, D. B., and Norred, W. P. (1995). Subchronic feeding study of the mycotoxin fumonisin B₁ in B6C3F1 mice and Fischer 344 rats. *Fundam.Appl.Toxicol.* **24**, 102-110.
- Voss, K. A., Riley, R. T., Bacon, C. W., Chamberlain, W. J., and Norred, W. P. (1996). Subchronic toxic effects of *Fusarium moniliforme* and fumonisin B₁ in rats and mice. *Nat.Toxins* **4**, 16-23.
- Voss, K. A., Plattner, R. D., Riley, R. T., Meredith, F. I., and Norred, W. P. (1998). In vivo effects of fumonisin B₁-producing and fumonisin B₁-nonproducing *Fusarium moniliforme* isolates are similar: fumonisins B₂ and B₃ cause hepato- and nephrotoxicity in rats. *Mycopathologia* **141**, 45-58.
- Voss, K. A., Riley, R. T., Norred, W. P., Bacon, C. W., Meredith, F. I., Howard, P. C., Plattner, R. D., Collins, T. F., Hansen, D. K., and Porter, J. K. (2001). An overview of rodent toxicities: liver and kidney effects of fumonisins and *Fusarium moniliforme*. *Environ.Health Perspect.* **109 Suppl 2**, 259-266.
- Wang, E., Norred, W. P., Bacon, C. W., Riley, R. T., and Merrill, A. H., Jr. (1991). Inhibition of sphingolipid biosynthesis by fumonisins. Implications for diseases associated with *Fusarium moniliforme*. *J.Biol.Chem.* **266**, 14486-14490.
- Wang, W., Jones, C., Ciacci-Zanella, J., Holt, T., Gilchrist, D. G., and Dickman, M. B. (1996). Fumonisins and *Alternaria alternata* lycopersici toxins: sphinganine analog mycotoxins induce apoptosis in monkey kidney cells. *Proc.Natl.Acad.Sci.U.S.A* **93** , 3461-3465.

- Wattenberg, E. V., Badria, F. A., and Shier, W. T. (1996). Activation of mitogen-activated protein kinase by the carcinogenic mycotoxin fumonisin B₁. *Biochem.Biophys.Res. Commun.* **227**, 622-627.
- Xia, P., Gamble, J. R., Wang, L., Pitson, S. M., Moretti, P. A., Wattenberg, B. W., D'Andrea, R. J., and Vadas, M. A. (2000). An oncogenic role of sphingosine kinase. *Curr.Biol.* **10**, 1527-1530.
- Xia, P., Wang, L., Moretti, P. A., Albanese, N., Chai, F., Pitson, S. M., D'Andrea, R. J., Gamble, J. R., and Vadas, M. A. (2002). Sphingosine kinase interacts with TRAF2 and dissects tumor necrosis factor-alpha signaling. *J.Biol.Chem.* **277**, 7996-8003.
- Yamada, Y., Kirillova, I., Peschon, J. J., and Fausto, N. (1997). Initiation of liver growth by tumor necrosis factor: deficient liver regeneration in mice lacking type I tumor necrosis factor receptor. *Proc.Natl.Acad.Sci.U.S.A* **94**, 1441-1446.
- Yatomi, Y., Ruan, F., Megidish, T., Toyokuni, T., Hakomori, S., and Igarashi, Y. (1996). N,N-dimethylsphingosine inhibition of sphingosine kinase and sphingosine 1-phosphate activity in human platelets. *Biochemistry* **35**, 626-633.
- Yoo, H. S., Norred, W. P., Wang, E., Merrill, A. H., Jr., and Riley, R. T. (1992). Fumonisin inhibition of de novo sphingolipid biosynthesis and cytotoxicity are correlated in LLC-PK1 cells. *Toxicol.Appl.Pharmacol.* **114**, 9-15.

CHAPTER 3

**SPHINGOSINE KINASE ACTIVITY CONFERS RESISTANCE TO APOPTOSIS BY
FUMONISIN B₁ IN HUMAN EMBRYONIC KIDNEY (HEK-293) CELLS¹**

¹Sharma N., He Q., and Sharma R.P. 2004. *Chemico-Biological Interactions*.

30;151(1):33-42. Reprinted here with permission of the publisher.

Abstract

Fumonisin B₁ induces cytotoxicity in sensitive cells by inhibiting ceramide synthase due to its structural similarity to the long-chain backbones of sphingolipids. The resulting accumulation of sphingoid bases has been established as a mechanism for fumonisin B₁ cytotoxicity. We found that despite the accumulation of sphinganine, human embryonic kidney (HEK-293) cells are resistant to fumonisin B₁ toxicity; 25 μM fumonisin B₁ exposure for 48 h did not increase apoptosis in these cells while it did so in sensitive porcine kidney epithelial (LLC-PK₁) cells. In this study DL-*threo*-dihydrosphingosine, the sphingosine kinase inhibitor (SKI), considerably increased the sensitivity of HEK-293 cells to fumonisin B₁. Treatment of these cells with 25 μM fumonisin B₁ and 2.5 μM SKI increased apoptosis. Sphingoid bases, sphinganine or sphingosine, added to cell cultures induced apoptosis by themselves and their effects were potentiated by SKI or fumonisin B₁. Addition of physiological amounts of sphingosine-1-phosphate prevented the toxic effects induced by SKI inhibition and fumonisin B₁. Results indicated that HEK-293 cells are resistant to fumonisin B₁ due to rapid formation of sphingosine-1-phosphate that imparts survival properties. Taken together these findings suggest that sphingoid base metabolism by sphingosine kinase may be a critical event in rendering the HEK-293 cells relatively resistant to fumonisin B₁-induced apoptosis.

Key words: Fumonisin B₁; Sphingosine-1-phosphate; Human embryonic kidney cells; Sphingosine kinase

1. Introduction

Fumonisin B₁ is a structurally related toxic and carcinogenic mycotoxin produced by *Fusarium verticillioides*, a common fungal contaminant of maize. Fumonisin B₁ is the most abundant fumonisin and occurs naturally in contaminated foods and feeds [1]. Fumonisin B₁ toxicity is specific to tissue and also depends on species and gender of the treated animal. Fumonisin B₁ causes equine leukoencephalomalacia and porcine pulmonary edema [2, 3]. In vivo studies demonstrated that fumonisin B₁ induced apoptosis in kidney and liver of rodents [4-6]. It was hepatocarcinogenic in male BD IX rats [7] and a nephrocarcinogen in male F344/N rats, whereas it was hepatocarcinogenic in only female B6C3F1 mice [8, 9]. An association between human esophageal cancer and fumonisin B₁ in areas highly contaminated with these mycotoxins was reported [10].

Fumonisin B₁ is structurally related to sphingoid bases and cause inhibition of ceramide synthase (sphinganine- or sphingosine-*N*-acyltransferase) leading to accumulation of corresponding free sphingoid bases, sphingoid base metabolites, and depletion of more complex sphingolipids [11, 12]. Physiological consequences possible after ceramide synthase inhibition include apoptosis caused by accumulation of free sphingoid bases (sphinganine and sphingosine), increased proliferation caused by increased sphingosine-1-phosphate, or/and decreased ceramide and altered lipid raft function due to disruption of complex sphingolipids synthesis/transport [12].

It has been shown that fumonisin B₁-induced apoptosis, necrosis, and inhibition of proliferation in pig renal epithelial (LLC-PK₁) cells [13], human colonic cells HT29 [14] and human keratinocytes [15] depend on sphingoid base accumulation. However, other studies

demonstrated that neoplastic African green monkey kidney cells (COS-7) [16] and primary hepatocytes [17] were resistant to the toxic effects of fumonisin B₁ despite sphinganine accumulation.

Ceramide and sphingosine are interconvertible sphingolipid messengers; intensive investigations in past decade have confirmed the role of ceramide and sphingosine in inducing apoptosis. However, there is considerable debate whether the ceramide or sphingosine is the primary inducer of apoptosis, it [18]. In fumonisin B₁ sensitive cells the same final pathway may mediate apoptosis by which sphingoid bases affect apoptosis; accumulation of sphingoid bases directly correlates with their cytotoxicity [19]. In HL-60 cells [20, 21] and Hep3B hepatoma cells [22] fumonisin B₁ did not affect the apoptosis directly induced by sphingosine or sphinganine indicating that these sphingoid bases could independently produce apoptosis without getting converted to ceramide.

Recent data suggest that sphingoid bases could signal mitochondrial apoptosis by inhibiting the protein kinase Akt, responsible for Bad phosphorylation and hence leading to inhibition of anti-apoptotic protein Bcl-2 by Bad [23, 24,25]. Events leading to apoptosis in fumonisin B₁ treated cells have not been characterized, although a role for Bax has been suggested based on the observation that Bcl-2 can protect p53^{-/-} cells from fumonisin B₁-induced apoptosis [26].

Levels of free sphingoid bases decrease consistently in fumonisin B₁-treated cells between 48 and 72 h indicating the induction of sphingoid base metabolism [19]. Catabolism of sphingoid bases requires two independent and sequential steps. The first step involves phosphorylation of sphingoid bases to their 1-phosphate derivative and is mediated by

sphingosine kinase [27]. Second step involves cleavage of the resulting product by sphingosine-1-phosphate lyase into ethanolamine phosphate and corresponding aldehyde [17]. Due to relative low levels of sphingosine-1-phosphate in cells, it is evident that phosphorylation of sphingosine by sphingosine kinase is the rate-limiting step in this process.

Sphingosine kinase in human tissues is widely expressed with highest levels in adult lung, spleen, kidney, heart, and brain [28]. Activation of sphingosine kinase and formation of sphingosine-1-phosphate are linked to cell growth and survival [29-31]. Diverse external stimuli, particularly growth and survival factors stimulate sphingosine kinase and intracellularly generated sphingosine-1-phosphate has been implicated in their mitogenic and anti-apoptotic effects [32, 33].

In our preliminary experiments, we found that human embryonic kidney (HEK-293) cells were resistant to cytotoxic effects of up to 50 μM fumonisin B₁ whereas porcine kidney (LLC-PK₁) cells show significant toxic response with 10 μM fumonisin B₁ [13, 19]. We hypothesized that the HEK-293 cells are resistant to apoptotic effects of fumonisin B₁ due to rapid conversion of accumulate sphinganine or sphingosine to their respective phosphates by sphingosine kinase and the antiapoptotic and proliferative role of the 1-phosphate derivatives. In the present study we tested above hypothesis by employing specific inhibitor of sphingosine kinase, the enzyme that converts sphingoid bases to their respective phosphates. DL-*threo*-dihydrosphingosine was employed as sphingosine kinase inhibitor (SKI).

2. Materials and Methods

2.1. Materials

Fumonisin B₁ (purity>95%) was obtained from Programme on Mycotoxin and Experimental Carcinogenesis (Tygerberg, South Africa). Human Embryonic Kidney cells (HEK-293) were obtained from American type culture collection (CRL-1573, ATCC, Manassas, VA). Dulbecco's Modified Eagle's Medium was purchased from Gibco (Carlsbad, CA). Sphingolipids and DL-*threo*-dihydrosphingosine were procured from Biomol (Plymouth Meeting PA). Annexin V and propidium iodide were purchased from Molecular Probes (Eugene, OR). All other reagents were obtained from Sigma (St. Louis, MO) and were of tissue culture grade.

2.2. Preparations of fumonisin B₁ and sphingolipid stock solutions

Fumonisin B₁ was dissolved in phosphate-buffered saline (PBS) at 1 mM, and then diluted into growth medium and added to cultures to achieve proper final concentrations. Relatively high concentration of fumonisin B₁ was used as the HEK-293 cells are not responsive to it up to 50 μM concentration. Control cultures were treated with similar dilutions of the vehicle but without fumonisin B₁. Free sphinganine, free sphingosine, and DL-*threo*-dihydrosphingosine were first dissolved in ethanol to a concentration of 50 mM and then were prepared in 1.0 ml of 1.5 mM fatty acid-free bovine serum albumin (BSA) to get a concentration of 1 mM as previously described [19]. An equal volume of absolute ethanol was added into BSA and processed as above as a BSA vehicle control.

2.3. Cell Culture and treatment

HEK-293 cells were grown in Dulbecco's Modified Eagle's Medium containing 100 units/ml penicillin and 10% non-heat-inactivated fetal bovine serum (Atlanta Biologics, Atlanta, GA) in 5% CO₂ at 37 °C. Cells were grown in 75 cm² culture flasks and sub cultured when the cells reached 70–80% confluence. For all experiments cells were seeded in the CD 293 chemically defined media (Gibco, Carlsbad, CA), which was devoid of any active biolipids, containing 0.5% fetal bovine serum, 2 mM glutamine and 5 µg/ml insulin (Sigma, St. Louis, MO). Cells were seeded 18 h before treatment with fumonisin B₁, sphingosine, sphinganine or SKI in their 2nd or 3rd passages. Concentrations of each chemical and time points for the treatments were optimized in preliminary trials.

2.4 Hoechst 33258 and propidium iodide staining

Apoptotic changes in the nuclear chromatin of cells were evaluated by staining with the DNA binding fluorochrome Hoechst 33258 (bis-benzimide). Cell death was also analysed using propidium iodide (PI), a membrane impermeable dye, which binds to DNA by intercalating between the bases with little or no sequence preference. At the end of treatment, supernatant was removed and 50 µl of 30% glycerol/PBS solution of Hoechst 33258 (8 µg/ml) or PI (1 µg/ml) was added. The plates were read at 346/460 nm or 535/617 nm (excitation/emission) for Hoechst 33258 or PI fluorescence, respectively, using a Spectramax Gemini fluorescent plate reader (Molecular Devices, Irvine, CA).

2.5. Mitochondrial function assay

3[4,5-dimethyl thiazolyl-2]2,5-diphenyl tetrazolium bromide (MTT) was employed to observe cell viability. Cells were seeded at 3×10^4 cells/well in 96-well plates and treated with the indicated concentration of treatments in total volume of 200 μ l. Cells were incubated with addition of 20 μ l MTT (5 mg/ml) 4 h before the end of treatment. At the end of treatment, 120 μ l of media containing MTT was taken out from each well and 100 μ l of 0.02 N HCl-isopropanol (warm) was added to dissolve formazan crystals. The absorbance of each well was measured using a scanning spectrophotometer (Bio-Tek Instrument, INC, Winooski, VT, USA).

2.6. Determination of intracellular free sphingoid bases

At the end of 48 h treatment with fumonisin B₁, the medium was aspirated, and cells were washed once with ice-cold PBS and then scraped into 1 ml ice-cold PBS. An aliquot (0.1 ml) of cell suspension in PBS was transferred to another tube, spun at 2,000g, 4°C for 5 min. The cells were lysed and stored at -85°C until analysis of total protein by Bradford reagent (Bio-Rad Laboratories, Hercules, CA) using a 96-well plate according to the manufacturer's protocol. Free sphingoid bases were extracted from the remainder of cells by using the modified method described previously [34]. The relative amounts of free sphinganine and sphingosine in base-treated cell extracts were determined by high performance liquid chromatography (HPLC) as described earlier. Sphingoid bases were quantified based on the recovery of a C₂₀ sphinganine internal standard. The limit of detection for C₂₀ was 26.8 fmol/assay (equivalent to 1 fmol/ g protein).

2.7. Statistical analysis of data

Each experiment was repeated three times with reproducible results consistently. The results expressed as mean \pm standard error of combined results from three independent experiments with each performed in triplicates. Differences among treatments were analyzed statistically by one-way analysis of variance (ANOVA) followed by Duncan's multiple range test. The level of $p \leq 0.05$ was considered significant for all comparisons.

3. Results

3.1. Fumonisin B₁ and SKI decreased the viability of HEK-293 cells when used together

HEK-293 cells are resistant to cytotoxic effects of fumonisin B₁ considering that even 50 μ M fumonisin B₁ for 72 h could not increase significant LDH release from these cells. (Data not shown). Fumonisin B₁ at 25 μ M and SKI at 2.5 μ M alone had no effect on viability of HEK-293 cells. Cell viability decreased significantly in HEK-293 cell culture, when treated together with 25 μ M fumonisin B₁ and 2.5 μ M SKI for 72 h. (Fig.3 1), determined by MTT assay.

3.2. Induction of apoptosis in HEK-293 cells treated with fumonisin B₁ and SKI

Exposure to 25 μ M fumonisin B₁ alone for 48 h did not induce apoptosis in HEK-293 cells, however treatment with 25 μ M fumonisin B₁ and 2.5 μ M SKI together for 48 h resulted in increased apoptosis, measured by the fluorescence of Hoechst 33258 (Fig. 3.2).

Cell death in HEK-293 culture was a combination of apoptosis and necrosis. Cells treated with fumonisin B₁ and SKI together had ~ 20% apoptotic cells and ~ 8% necrotic cells, while in control wells less than 1% cells were undergoing either apoptosis or necrosis. Necrotic cell death was confirmed by nuclear staining with membrane impermeant dye propidium iodide, which is taken up only by necrotic cells as their cell membrane is damaged. To confirm apoptosis, cells were stained with annexin V and Hoechst 33258 dye. Early apoptotic cells stain with Annexin V and Hoechst 33258, which can bind to exposed phosphatidyl serine and fragmented nuclear chromatin respectively but exclude PI as their cell membrane is still intact. Cells treated with fumonisin B₁ and SKI together had significantly greater number of cells stained with, annexin V and Hoechst 33258 compared to control and SKI alone (Fig. 3.3a). Visual inspection under Olympus IX71 inverted fluorescence microscope (Olympus America, Melville, NY) confirmed the presence of increased number of cells exhibiting bright green staining of Annexin V on cell surface and blue staining of Hoechst 33258 on nucleus indicating apoptotic cells.

Overlay of Annexin V, Hoechst 33258 and PI staining in fumonisin B₁ and SKI treated cells showed predominance of apoptotic cells stained with only Annexin V and Hoechst 33258 and presence of some necrotic cells which were stained by all three dyes (PI, Annexin V and Hoechst 33258) (Fig. 3.3b).

3.3. Increased accumulation of intracellular sphingoid bases in cells treated with fumonisin B₁ and SKI

HEK-293 cells were treated with 25 μ M fumonisin B₁ and 2.5 μ M SKI for 48 h. Treatment of cells together with SKI and fumonisin B₁ caused higher elevation of intracellular level of sphinganine compared to fumonisin B₁ treatment alone. Fumonisin B₁ alone did not increase intracellular level of sphingosine, whereas exposure of cells to fumonisin B₁ and SKI together caused significantly higher accumulation of sphingosine (Fig. 3.4)

3.4. *Fumonisin B₁ and SKI induced apoptosis was further increased by sphingoid bases*

Sphingoid bases are known to induce apoptosis. We treated HEK-293 cells with 5 μ M sphinganine or 5 μ M sphingosine alone or in the presence of 25 μ M fumonisin B₁ and 2.5 μ M SKI for 48 h. Apoptosis was measured by recording the fluorescence of Hoechst 33258 at 346/460 nm. Sphingosine when added to cell cultures induced apoptosis by itself. Fumonisin B₁ and sphingosine treated cells had more apoptotic cells compared to fumonisin B₁ treatment alone. Sphingosine increased the apoptosis induced by the combined treatment of fumonisin B₁ and SKI (Fig. 3.5). Sphinganine treatment followed the similar trend and had the synergistic effects with SKI and fumonisin B₁ to induce apoptosis except that at 5 μ M concentration sphinganine itself could not induce apoptosis (Fig. 3.6).

3.5. *Sphingosine-1-phosphate prevented the apoptosis induced by fumonisin B₁ and SKI*

HEK-293 cells were treated with 25 μ M fumonisin B₁, 2.5 μ M SKI and 1, 5 and 10 nM concentrations of sphingosine-1-phosphate for 48 h (Fig. 3.7). Sphingosine-1-phosphate significantly reduced the apoptosis induced by fumonisin B₁ and SKI. Apoptosis was measured

by Hoechst 33258 fluorescence at 346/460 nm. A similar trend was shown when sphinganine-1-phosphate (1-100 nM) was used instead of sphingosine-1-phosphate; however, the protection was not statistically significant (data not shown). Direct addition of either sphingosine-1-phosphate or sphinganine-1-phosphate in concentrations greater than 100 nM was cytotoxic in this cell line.

4. Discussion

We found that HEK-293 cells are resistant to fumonisin B₁-induced apoptosis. Results in the current study showed that inhibition of sphingosine kinase enzyme that converts sphingoid bases to their respective 1-phosphates makes HEK-293 cells sensitive to fumonisin B₁-induced apoptosis. In HEK-293 cells the rapid formation of sphingoid base-1-phosphate is the putative mechanism of protection from fumonisin B₁ toxicity. In most cell lines fumonisin B₁ blocks de novo ceramide biosynthesis and causes accumulation of free sphingoid bases but only selected cell lines are sensitive to toxic effects of fumonisin B₁ while others are resistant [16, 17]. Accumulation of sphingoid bases has been established as a mechanism for fumonisin B₁ induced apoptosis in various types of cells.

For fumonisin B₁ the IC₅₀ for inhibition of ceramide synthase is 0.1 μM in primary hepatocytes and doses as low as 1 μM caused almost complete inhibition of this enzyme leading to accumulation of sphingoid bases as quickly as in 3 h [11]. Elevation of sphinganine level by almost 20-fold in 24 h treatment with fumonisin B₁ is a common finding with most of

the cell lines. Sphingoid bases are toxic to cells [18] and are responsible for fumonisin B₁ cytotoxicity [13]. Inhibition of fumonisin B₁ cytotoxicity by myriocin (inhibits serine palmitoyltransferase activity) correlated well with this conclusion [14]. Since level of sphingosine depends on the rate of turnover of the complex sphingolipids it either does not change or increases little after fumonisin B₁ treatment [11].

It has been a question as why increased levels of sphinganine do not cause toxicity in some cells. Even though sphinganine levels rise significantly within hours with as low as 1 μ M fumonisin B₁ treatment in sensitive and insensitive cells, high doses of fumonisin B₁ and long incubation periods (> 24 h) are required to produce toxicity even in sensitive cells. Levels of free sphingoid bases decreased consistently in fumonisin B₁ treated cells between 48 and 72 h, which indicated temporal sphingoid base metabolism [19]. In J774A.1 cells exogenous sphingoid base initially accumulated and then were rapidly metabolized to their 1-phosphate derivatives; fumonisin B₁ caused inhibition of acylation of sphingoid bases and diverted them more towards phosphorylation [19]. About one third of the ethanolamine within phosphatidylethanolamine in J774A.1 cells was derived from long-chain base catabolism when fumonisin B₁ was added [35].

The role of sphingoid bases in cell death depends upon the balance between levels of ceramide and sphingosine both of which mediate apoptosis, and sphingosine-1-phosphate that promotes proliferation and survival. For instance, increases in ceramide and sphingosine levels by TNF α and Fas ligand lead to apoptosis of T lymphocytes, whereas survival factors like protein kinase C stimulate sphingosine kinase, leading to increased sphingosine-1-phosphate levels, which suppress apoptosis [36]. Recently, the balance of sphingosine-1-

phosphate and sphingosine was reported to have a role in activation of mast cells, where high intracellular concentration of sphingosine inhibited cytokine production by preventing activation of extracellular signal-regulated kinase (ERK) pathway, while high intracellular concentration of sphingosine-1-phosphate activated ERK to stimulate cytokine production [37]. Study by Olivera et al. [38] emphasizes the importance of sphingosine kinase in determining cell fate as expression of sphingosine kinase in HEK-293 cells markedly increased production of sphingosine-1-phosphate, which induced proliferation.

The *threo* enantiomers of sphingosine and dihydrosphingosine were not phosphorylated by sphingosine kinase and were found to be potent competitive inhibitors of platelet sphingosine kinase activity *in vitro* [39]. Substrate and inhibition studies showed that the mixture of DL-*threo*-dihydrosphingosine was more potent and highly specific inhibitor of platelet sphingosine kinase [39]. DL-*threo*-dihydrosphingosine inhibits the production of sphingosine-1-phosphate by competitive inhibition of sphingosine kinase and is useful to investigate the function of sphingosine-1-phosphate in signal transduction processes.

In the current study SKI increased sensitivity of HEK-293 cells to fumonisin B₁ toxicity as treatment of these cells with fumonisin B₁ and SKI together increased apoptosis; whereas fumonisin B₁ alone or inhibitor alone were not cytotoxic. Inhibition of sphingosine kinase by DL-*threo*-dihydrosphingosine prevented conversion of sphingoid bases to their 1- phosphate derivatives and resulted in higher accumulation of sphingosine and sphinganine in fumonisin B₁-treated HEK-293 cells. Increased apoptosis with co-incubation of SKI and fumonisin B₁ can be explained by the loss of protective role of sphingosine-1-phosphate and toxic effects of

increased levels of sphingoid bases. Sphingoid bases (sphinganine or sphingosine) added to cell cultures induced apoptosis by itself and their effects were potentiated by sphingosine kinase inhibitor and fumonisin B₁, supporting our hypothesis.

Sphingosine-1-phosphate prevented the apoptosis caused by sphingosine kinase inhibition, when added to cells treated with fumonisin B₁ and SKI. However only very small concentrations of sphingosine-1-phosphate were able to prevent apoptosis and higher concentrations further increased the toxicity of fumonisin B₁ and SKI (data not shown). Intracellular concentration of sphingosine-1-phosphate is tightly regulated through its synthesis catalyzed by sphingosine kinase and degradation by sphingosine-1-phosphate lyase and phosphohydrolase. Recently two different kinds of enzymes with sphingosine-1-phosphate phosphohydrolase (SPP) activity, SPP-1 [40] and SPP-2 [41] have been characterized in HEK-293 cells. These enzymes are known to degrade exogenously added sphingosine-1-phosphate in cell cultures to sphingosine and subsequently produce apoptosis [40]. It is possible that in our study, higher concentrations of sphingosine-1-phosphate increased the apoptosis by getting converted to sphingosine by sphingosine-1-phosphate phosphohydrolase. It would be desirable to look at the effect of higher concentrations of sphingosine-1-phosphate after inhibiting the sphingosine-1-phosphate phosphohydrolase enzyme but the lack of specific inhibitor of this enzyme restricts such possibility.

In summary our results indicate that HEK-293 cells are resistant to apoptotic effects of fumonisin B₁ due to higher activity of sphingosine kinase, which enhances cell survival by forming sphingosine-1-phosphate. Activity of sphingosine kinase enzyme may have substantial bearing on different responses of fumonisin B₁ in other cell types. It is also possible that

fumonisin B₁ or SKI sensitized cells to each other by some other mechanisms. However, our findings are applicable to only HEK-293 cells and further investigations are required to determine whether or not this is a general mechanism for resistance to fumonisin B₁ in other cells *in vitro* and tissues *in vivo*.

Acknowledgement

Studies reported in this paper were supported in part by USPHS grant ES09403 from the National Institute of Environmental Health Services and the Center for Academic Excellence in Toxicology at the University of Georgia.

References

- [1] M.F. Dutton, Fumonisin, mycotoxins of increasing importance: their nature and their effects, *Pharmacol. Ther.* 70 (1996) 137-161.
- [2] W.M. Haschek, L.A. Gumprecht, G. Smith, M.E. Tumbleson, P.D. Constable, Fumonisin toxicosis in swine: an overview of porcine pulmonary edema and current perspectives, *Environ. Health Perspect.* 109 (Suppl 2) (2001) 251-257.
- [3] P.F. Ross, L.G. Rice, G.D. Osweiler, P.E. Nelson, J.L. Richard, T.M. Wilson, A review and update of animal toxicoses associated with fumonisin-contaminated feeds and production of fumonisins by *Fusarium* isolates, *Mycopathologia* 117 (1992) 109-114.
- [4] C.W. Lim, H.M. Parker, R.F. Vesonder, W.M. Haschek, Intravenous fumonisin B₁ induces cell proliferation and apoptosis in the rat, *Nat. Toxins* 4 (1996) 34-41.

- [5] R.P. Sharma, R.R. Dugyala, K.A. Voss, Demonstration of in-situ apoptosis in mouse liver and kidney after short-term repeated exposure to fumonisin B₁, *J. Comp. Pathol.* 117 (1997) 371-381.
- [6] W.H. Tolleson, K.L. Dooley, W.G. Sheldon, J.D. Thurman, T.J. Bucci, P.C. Howard, The mycotoxin fumonisin induces apoptosis in cultured human cells and in livers and kidneys of rats, *Adv. Exp. Med. Biol.* 392 (1996) 237-250.
- [7] W.C. Gelderblom, S. Abel, C.M. Smuts, J. Marnewick, W.F. Marasas, E.R. Lemmer, D. Ramljak, Fumonisin-induced hepatocarcinogenesis: mechanisms related to cancer initiation and promotion, *Environ. Health Perspect.* 109 (Suppl 2) (2001) 291-300.
- [8] K.A. Voss, R.T. Riley, W.P. Norred, C.W. Bacon, F.I. Meredith, P.C. Howard, R.D. Plattner, T.F. Collins, D.K. Hansen, J.K. Porter, An overview of rodent toxicities: liver and kidney effects of fumonisins and *Fusarium moniliforme*, *Environ. Health Perspect.* 109 (Suppl 2) (2001) 259-266.
- [9] P.C. Howard, R.M. Eppley, M.E. Stack, A. Warbritton, K.A. Voss, R.J. Lorentzen, R.M. Kovach, T.J. Bucci, Fumonisin B₁ carcinogenicity in a two-year feeding study using F344 rats and B6C3F1 mice, *Environ. Health Perspect.* 109 (Suppl 2) (2001) 277-282.
- [10] E. Wang, P.F. Ross, T.M. Wilson, R.T. Riley, A.H. Merrill, Jr., Increases in serum sphingosine and sphinganine and decreases in complex sphingolipids in ponies given feed

- containing fumonisins, mycotoxins produced by *Fusarium moniliforme*, *J. Nutr.* 122 (1992) 1706-1716.
- [11] E. Wang, W.P. Norred, C.W. Bacon, R.T. Riley, A.H. Merrill, Jr., Inhibition of sphingolipid biosynthesis by fumonisins. Implications for diseases associated with *Fusarium moniliforme*, *J. Biol. Chem.* 266 (1991) 14486-14490.
- [12] A.H. Merrill, Jr., M.C. Sullards, E. Wang, K.A. Voss, R.T. Riley, Sphingolipid metabolism: roles in signal transduction and disruption by fumonisins, *Environ. Health Perspect.* 109 (Suppl 2) (2001) 283-289.
- [13] H.S. Yoo, W.P. Norred, E. Wang, A.H. Merrill, Jr., R.T. Riley, Fumonisin inhibition of de novo sphingolipid biosynthesis and cytotoxicity are correlated in LLC-PK1 cells, *Toxicol. Appl. Pharmacol.* 114 (1992) 9-15.
- [14] E.M. Schmelz, M.A. Dombrink-Kurtzman, P.C. Roberts, Y. Kozutsumi, T. Kawasaki, A.H. Merrill, Jr., Induction of apoptosis by fumonisin B₁ in HT29 cells is mediated by the accumulation of endogenous free sphingoid bases, *Toxicol. Appl. Pharmacol.* 148 (1998) 252-260.
- [15] W.H. Tolleson, L.H. Couch, W.B. Melchior, Jr., G.R. Jenkins, M. Muskhelishvili, L. Muskhelishvili, L.J. McGarrity, O. Domon, S.M. Morris, P.C. Howard, Fumonisin B₁ induces apoptosis in cultured human keratinocytes through sphinganine accumulation and ceramide depletion, *Int. J. Oncol.* 14 (1999) 833-843.

- [16] W. Wang, C. Jones, J. Ciacci-Zanella, T. Holt, D.G. Gilchrist, M.B. Dickman, Fumonisin and *Alternaria alternata* lycopersici toxins: sphinganine analog mycotoxins induce apoptosis in monkey kidney cells, Proc. Natl. Acad. Sci. USA 93 (1996) 3461-3465.
- [17] P.P. Van Veldhoven, G.P. Mannaerts, Subcellular localization and membrane topology of sphingosine-1-phosphate lyase in rat liver, J. Biol. Chem. 266 (1991) 12502-12507.
- [18] O. Cuvillier, L. Edsall, S. Spiegel, Involvement of sphingosine in mitochondria-dependent Fas-induced apoptosis of type II Jurkat T cells, J. Biol. Chem. 275 (2000) 15691-15700.
- [19] H.S. Yoo, W.P. Norred, J. Showker, R.T. Riley, Elevated sphingoid bases and complex sphingolipid depletion as contributing factors in fumonisin-induced cytotoxicity, Toxicol. Appl. Pharmacol. 138 (1996) 211-218.
- [20] W.D. Jarvis, F.A. Fornari, R.S. Traylor, H.A. Martin, L.B. Kramer, R.K. Erukulla, R. Bittman, S. Grant, Induction of apoptosis and potentiation of ceramide-mediated cytotoxicity by sphingoid bases in human myeloid leukemia cells, J. Biol. Chem. 271 (1996) 8275-8284.
- [21] E.A. Sweeney, J. Inokuchi, Y. Igarashi, Inhibition of sphingolipid induced apoptosis by caspase inhibitors indicates that sphingosine acts in an earlier part of the apoptotic pathway than ceramide, FEBS Lett. 425 (1998) 61-65.

- [22] W.C. Hung, H.C. Chang, L.Y. Chuang, Activation of caspase-3-like proteases in apoptosis induced by sphingosine and other long-chain bases in Hep3B hepatoma cells, *Biochem. J.* 338 (1999) 161-166.
- [23] H.C. Chang, L.H. Tsai, L.Y. Chuang, W.C. Hung, Role of AKT kinase in sphingosine-induced apoptosis in human hepatoma cells, *J. Cell Physiol.* 188 (2001) 188-193.
- [24] S. Basu, S. Bayoumy, Y. Zhang, J. Lozano, R. Kolesnick, BAD enables ceramide to signal apoptosis via Ras and Raf-1, *J. Biol. Chem.* 273 (1998) 30419-30426.
- [25] H. Zhou, S.A. Summers, M.J. Birnbaum, R.N. Pittman, Inhibition of Akt kinase by cell-permeable ceramide and its implications for ceramide-induced apoptosis, *J. Biol. Chem.* 273 (1998) 16568-16575.
- [26] J.R. Ciacci-Zanella, C. Jones, Fumonisin B₁, a mycotoxin contaminant of cereal grains, and inducer of apoptosis via the tumour necrosis factor pathway and caspase activation, *Food Chem. Toxicol.* 37 (1999) 703-712.
- [27] R.W. Keenan, B. Haegelin, Enzymatic Phosphorylation of Sphinganine, *Biochem. Biophys. Res. Commun.* 37 (1969) 888-894.
- [28] A.J. Melendez, E. Carlos-Dias, M. Gosink, J.M. Allen, L. Takacs, Human sphingosine kinase: molecular cloning, functional characterization and tissue distribution, *Gene* 251 (2000) 19-26.

- [29] S. Spiegel, S. Milstien, Sphingosine 1-phosphate, a key cell signaling molecule, *J. Biol. Chem.* 277 (2002) 25851-25854.
- [30] S. Spiegel, D. English, S. Milstien, Sphingosine 1-phosphate signaling: providing cells with a sense of direction, *Trends Cell Biol.* 12 (2002) 236-242.
- [31] S. Spiegel, R. Kolesnick, Sphingosine 1-phosphate as a therapeutic agent, *Leukemia* 16 (2002) 1596-1602.
- [32] P. Xia, L. Wang, P.A. Moretti, N. Albanese, F. Chai, S.M. Pitson, R.J. D'Andrea, J.R. Gamble, M.A. Vadas, Sphingosine kinase interacts with TRAF2 and dissects tumor necrosis factor-alpha signaling, *J. Biol. Chem.* 277 (2002) 7996-8003.
- [33] S.M. Pitson, P.A. Moretti, J.R. Zebol, P. Xia, J.R. Gamble, M.A. Vadas, R.J. D'Andrea, B.W. Wattenberg, Expression of a catalytically inactive sphingosine kinase mutant blocks agonist-induced sphingosine kinase activation. A dominant-negative sphingosine kinase, *J. Biol. Chem.* 275 (2000) 33945-33950.
- [34] Q. He, R.T. Riley, R.P. Sharma, Fumonisin-induced tumor necrosis factor- α expression in a porcine kidney cell line is independent of sphingoid base accumulation induced by ceramide synthase inhibition, *Toxicol. Appl. Pharmacol.* 174 (2001) 69-77.
- [35] E.R. Smith, A.H. Merrill, Jr., Differential roles of de novo sphingolipid biosynthesis and turnover in the "burst" of free sphingosine and sphinganine, and their 1-phosphates and N-acyl-derivatives, that occurs upon changing the medium of cells in culture, *J. Biol. Chem.* 270 (1995) 18749-18758.

- [36] O. Cuvillier, G. Pirianov, B. Kleuser, P.G. Vanek, O.A. Coso, S. Gutkind, S. Spiegel, Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate, *Nature* 381 (1996) 800-803.
- [37] E.E. Prieschl, R. Csonga, V. Novotny, G.E. Kikuchi, T. Baumruker, The balance between sphingosine and sphingosine-1-phosphate is decisive for mast cell activation after Fc epsilon receptor I triggering, *J. Exp. Med.* 190 (1999) 1-8.
- [38] A. Olivera, T. Kohama, L. Edsall, V. Nava, O. Cuvillier, S. Poulton, S. Spiegel, Sphingosine kinase expression increases intracellular sphingosine-1-phosphate and promotes cell growth and survival, *J. Cell Biol.* 147 (1999) 545-558.
- [39] B.M. Buehrer, R.M. Bell, Inhibition of sphingosine kinase in vitro and in platelets. Implications for signal transduction pathways, *J. Biol. Chem.* 267 (1992) 3154-3159.
- [40] H. Le Stunff, I. Galve-Roperh, C. Peterson, S. Milstien, S. Spiegel, Sphingosine-1-phosphate phosphohydrolase in regulation of sphingolipid metabolism and apoptosis, *J. Cell Biol.* 158 (2002) 1039-1049.
- [41] C. Ogawa, A. Kihara, M. Gokoh, Y. Igarashi, Identification and characterization of a novel human sphingosine-1-phosphate phosphohydrolase, hSPP2, *J. Biol. Chem.* 278 (2003) 1268-1272.




Fig. 3.1. HEK-293 cells were treated with 25 μ M fumonisin B₁ and 2.5 μ M SKI for 72 h. Cell viability was determined by MTT assay. Fumonisin B₁ and SKI alone were not toxic to HEK-293 cells but together they decreased cell viability significantly. Similar findings were noted in 3 independent experiments. The results expressed as mean \pm standard error are combined results from three experiments with each experiment performed in triplicates. Asterisk (*) indicates significantly different value at $p < 0.05$ from the control.




Fig. 3.2. HEK-293 cells are resistant to apoptotic effects of fumonisin B₁. Exposure to 25 μM fumonisin B₁ alone for 48 h did not induce apoptosis in HEK-293 cells whereas, treatment with SKI and fumonisin B₁ together for 48 h induced apoptosis. Induction of apoptosis measured by Hoechst 33258 fluorescence at 346/460 nm. Mean ± S.E., n= 9. Asterisk (*) indicates significantly different value at $p < 0.05$ from the fumonisin B₁ only treated group. (†) indicates significantly different value at $p < 0.05$ from the control group (not treated with either fumonisin B₁ or SKI).




Fig. 3.3. (a) HEK-293 cells were treated with 25 μ M fumonisin B₁ and 2.5 μ SKI for 48 h. Annexin V and Hoechst 33258 staining were used to detect apoptosis. Cells treated with fumonisin B₁ and SKI together had significantly greater number of cells stained with Annexin V and Hoechst 33258 compared to control, fumonisin B₁ and SKI alone. 3(b). Overlay of few propidium iodide stained (red) necrotic cells with blue (Hoechst 33258) and green (Annexin V) stained apoptotic cells was used to differentiate between necrosis and apoptosis. Similar findings were noted in 3 independent experiments.




Fig. 3.4. HEK-293 cells were treated with 25 μ M fumonisin B₁ and 2.5 μ M SKI for 48 h. Treatment of cells together with SKI and fumonisin B₁ caused higher elevation of intracellular level of sphinganine compared to fumonisin B₁ treatment alone. Fumonisin B₁ alone did not increase intracellular level of sphingosine, whereas exposure of cells to fumonisin B₁ and SKI together caused significantly higher accumulation of sphingosine. Mean \pm S.E., n=9. Asterisk (*) indicates significantly different value at $p < 0.05$ from the fumonisin B₁ only treated group. (‡) indicates significantly different value at $p < 0.05$ from the control group.




Fig. 3.5. HEK-293 cells were treated with 25 μM fumonisin B₁, 2.5 μM SKI and 5 μM sphingosine (So) for 48 h. Sphingosine when added to cell cultures induced apoptosis by itself and its effect was potentiated by sphingosine kinase inhibitor and fumonisin B₁. Apoptosis was measured by Hoechst 33258 fluorescence at 346/460 nm. Mean ± S.E., n=9. (¶) indicates significantly different value at $p < 0.05$ from the fumonisin B₁-treated group. (#) indicates significantly different value at $p < 0.05$ from the group treated with sphingosine only. Asterisk (*) indicates significantly different value at $p < 0.05$ from the group treated with fumonisin B₁ and SKI together.




Fig. 3.6. HEK-293 cells were treated with 25 μM fumonisin B₁, 2.5 μM SKI and 5 μM sphinganine (Sa) for 48 h. Sphinganine also had synergistic effect with SKI and fumonisin B₁ in making HEK-293 cells more sensitive to fumonisin B₁ apoptosis. Apoptosis was measured by Hoechst 33258 fluorescence at 346/460 nm. Mean ± S.E., n= 9. (¶) indicates significantly different value at $p < 0.05$ from the fumonisin B₁ treated group. Asterisk (*) indicates significantly different value at $p < 0.05$ from the group treated with fumonisin B₁ and SKI together.




Fig. 3.7. HEK-293 cells were treated with 25 μ M fumonisin B₁, 2.5 μ M SKI and 1, 5 and 10 nM sphingosine-1-phosphate (S1P) for 48 h. Sphingosine-1-phosphate prevented the apoptosis induced by fumonisin B₁ and SKI together. Apoptosis was measured by Hoechst 33258 fluorescence at 346/460 nm. Mean \pm S.E., n=9. ‡ indicates significantly different value at $p < 0.05$ from the fumonisin B₁-treated group. Asterisk (*) indicates significantly different value at $p < 0.05$ from the group treated with fumonisin B₁ and SKI together

CHAPTER 4

AUGMENTED FUMONISIN B₁ TOXICITY IN CO-CULTURES: EVIDENCE FOR CROSSTALK BETWEEN MACROPHAGES AND NONPARANCHYMATOUS LIVER EPITHELIAL CELLS INVOLVING PROINFLAMMATORY CYTOKINES¹

¹Sharma N., He Q., and Sharma R.P. 2004. *Toxicology*. 15;203(1-3):239-51.

Reprinted here with permission of the publisher.

Abstract

Fumonisin B₁, a common mycotoxin produced by *Fusarium verticillioides* found in corn, causes several fatal animal diseases. Liver and kidney are target organs of fumonisin B₁ in laboratory animals, but primary rodent hepatocytes and liver slices were resistant to fumonisin B₁ induced cytotoxic effects. We have shown that fumonisin B₁ induces expression of tumor necrosis factor (TNF) α , interferon (IFN) γ , and interleukine (IL) 12, in mouse liver. In various models of acute liver injury a positive amplification loop involving TNF α , IFN γ and IL-12 has been implied that involves Kupffer cells (macrophages), hepatic lymphocytes and nonparenchymatous liver epithelial cells (NPECs). In the current study cellular interactions in fumonisin B₁ induced toxicity were investigated using co-cultures of murine macrophages (J774A.1) and nonparenchymatous liver epithelial cells (NMuLi). Treatment of the co-cultures with fumonisin B₁ produced cytotoxicity whereas either J774A.1 or NMuLi cultures alone showed no response to the mycotoxin. Accumulation of sphinganine occurred to the similar extent in individual cultures as well as co-cultures. Expression of TNF α and IL-12 was increased in co-cultures but not in individual cultures. Transfer of conditioned medium from fumonisin B₁ treated J774A.1 cells to NMuLi cultures produced an increase in IFN γ expression in NMuLi cells. Results indicated that macrophages and liver epithelial cells interact in response to fumonisin B₁ and potentiate the cytokines expression, which may have implications in making hepatocytes responsive to cytotoxicity of fumonisin B₁.

Key words: Fumonisin B₁; Tumor necrosis factor α ; Interferon γ ; murine macrophages; Nonparenchymatous liver epithelial cells;

1. Introduction

Fumonisin is a group of structurally related mycotoxins produced by *Fusarium verticillioides*, which are commonly found on corn (Riley et al., 1993). Fumonisin B₁ is the most abundant naturally occurring fumonisin in contaminated foods and feeds. It is hepatotoxic and nephrotoxic in domestic and laboratory animals and causes equine leukoencephalomalacia and porcine pulmonary edema (Riley et al., 1993). In National Toxicology Program study in Fischer rats and B6C3F mice fumonisin B₁ caused renal carcinoma in male rats and hepatic cancer in female mice (Howard et al., 2001). Fumonisin B₁ has been identified as cardiotoxic in swine (Constable et al., 2000). An association between human esophageal cancer and fumonisins in areas highly contaminated with these mycotoxins was reported (Sydenham et al., 1990).

Fumonisin is structurally related to sphingoid bases and cause inhibition of ceramide biosynthesis (sphinganine and sphingosine *N*-acyltransferase) leading to accumulation of free sphingoid bases, sphingoid base metabolites, and depletion of more complex sphingolipids (Riley et al., 1996). Studies in pig renal epithelial cells, colonic cells, and human keratinocytes have shown that fumonisin B₁ induced apoptosis, necrosis, and inhibition of proliferation are sphinganine-dependent (Yoo et al., 1996; Schmelz et al., 1998; Tolleson et al., 1999). There is a close correlation between increased apoptosis in liver and kidney and the disruption of sphingolipid metabolism (Voss et al., 2002).

It has been demonstrated that fumonisin B₁ induces apoptosis in rat kidney and mouse liver (Sharma et al., 1997; Tolleson et al., 1996). Fumonisin B₁ also induces apoptosis in several different mammalian cells (Ciacci-Zanella et al., 1999; Wang et al., 1996), where

direct treatment to cells leads to apoptosis. A previous study demonstrated that fumonisin B₁ induced cell cycle arrest in the G1 phase in African green monkey kidney cells (CV-1) but CV-1 cells transformed by the simian virus 40 (SV40) large T antigen (COS-7) were unaffected by the same levels of fumonisin B₁ (Wang et al., 1996; Ciacci-Zanella et al., 1998). Wang et al. (1991) and Schmelz et al. (1998) showed that concentrations of fumonisin B₁ as low as 1 μM caused an almost complete inhibition of ceramide formation by primary hepatocytes, while much higher (>75 μM) concentrations of fumonisin B₁ did not induce cytotoxicity.

There is considerable evidence that tumor necrosis factor (TNF) α signaling pathway plays an important role in fumonisin B₁ induced toxicity in sensitive cells *in vitro* and *in vivo*. Fumonisin B₁ hepatotoxicity was reduced in mice lacking either TNF receptor 1 or 2 (Sharma et al., 2000; Sharma et al., 2001). Interferon knockout mice show reduced hepatotoxicity and TNFα expression in response to fumonisin B₁ (Sharma et al., 2003). In the current study we hypothesize that the resistance of primary hepatocytes to the cytotoxic effects of fumonisin B₁ may be due to a lack of interactions between the cytokines that are produced by different types of cells in liver.

In various models of acute liver injury a positive amplification loop involving TNFα, IFNγ and IL-12 has been implied and involves Kupffer cells (liver macrophages) hepatic lymphocytes and nonparenchymatous liver epithelial cells (NPECs). We speculated that fumonisin B₁ induces localized activation of cytokine network in mouse liver; expression of TNFα, interferon (IFN) γ and interleukine (IL)-12 in mouse liver was increased in response to fumonisin B₁ (Bhandari et al, 2002a). A remarkable crosstalk between macrophages and T cells involving TNFα and IFNγ has been suggested using *in vitro* co-culture experiments

(Gantner et al., 1996). Similar crosstalk between macrophages and cell types other than the T cells is also important to amplify the cytokine release in response to various toxins. Interactions of this kind have been reported in several co-culture experiments involving alveolar macrophages and type II pneumocytes (Tao et al., 2002) or microglia and neurons (Hemmer et al., 2001).

In the present study we hereby show that co-cultures of macrophages (J774A.1) and nonparanchymatous liver epithelial cells (NMuLi) are more responsive to fumonisin B₁ induced cytotoxicity compared to individual cultures and interaction of the two cell types resulted in increased expression of proinflammatory cytokines in the co-cultures.

2. Materials and Methods

2.1. Materials

Fumonisin B₁ (purity>98%) was obtained from Programme on Mycotoxin and Experimental Carcinogenesis (Tygerberg, South Africa). Mouse macrophage cells J774A.1 (TIB-67) and NMuLi cells (CRL-1638) were obtained from American type culture collection (Rockville, MD). Delbeco's Modified Eagle's Medium (DMEM) was purchased from Gibco (Carlsbad, CA). Recombinant IFN γ was procured from Biocompare, Inc (South San Francisco, CA) and TNF α from Endogen (Woburn, MA). Anti-TNF α was purchased from Santa Cruz Biotechnology (Santa Cruz, CA) and anti-IFN γ was procured from Chemicon

International (Temecula, CA). Annexin V, Hoechst 33258 and propidium iodide were purchased from Molecular Probes (Eugene, OR). All other reagents were obtained from Sigma (St. Louis, MO) and were of tissue culture grade.

2.2. Cell Culture and Treatment

Macrophages (J774A.1) and liver epithelial cells (NMuLi) were grown in separate flasks containing DMEM with 10% fetal bovine serum at 37°C and 5% CO₂. Early passage clones were mixed in different ratios in 96 or 24 well plates, 16 h before the treatment. For co-culture, ratio of 1 (J774A.1): 7 (NMuLi) [i.e., 5×10^3 J774A.1 cells and 35×10^3 NMuLi cells] was found to be optimal and used for all experiments. Cells were treated with 10 μM fumonisin B₁ for various time points depending on the experiment; the concentration of fumonisin B₁ and time periods were optimized in preliminary trials. For experiments involving transfer of supernatant, individual cultures were treated with 10 μM fumonisin B₁ and their media was transferred to the other cell types for 6 h to determine cytokine expression, or longer to evaluate toxicity.

2.3. Determination of Cytotoxicity

The cytotoxic effect of fumonisin B₁ on individual cultures and co-cultures (J774A.1 and NMuLi) was determined by measuring the release of lactate dehydrogenase (LDH) as previously described (He et al., 2002). For the total LDH determination, LDH was released from the cells by adding 1 μl of Triton X-100 (1% final concentration), and incubating for 20-30 min. at 37° C. The change in absorbance of the reaction mixture at 340 nm (an index of

NADH oxidation) was read kinetically at 1 min intervals using a Scanning spectrophotometer (Bio-Tek Instrument, INC, Winooski, VT, USA)

The fluorescent probes annexin V or Hoechst 33258 and propidium iodide (PI) were used to detect the apoptotic and necrotic cells, respectively. Cells were grown and treated in 96 well plates. At the end of treatment, cells were incubated with annexin V (5 μ L/100 μ L in annexin binding buffer) or Hoechst 33258 (8 μ g/ml in 30 % glycerol in PBS) and PI (20 μ g/ml) and fluorescence intensity was recorded using Spectramax Gemini fluorescent plate reader (Molecular Devices, Irvine, CA). Propidium iodide fluorescence was detected with excitation 535 nm and emission at 617 nm; excitation at 495 nm and emission at 520 nm detected the fluorescence of annexin V. Hoechst 33258 fluorescence was detected with excitation at 346 nm and emission at 460 nm. Visual documentation of cellular effects was performed using Olympus IX71 inverted microscope (Olympus America, Melville, NY). Digital images were acquired using Magnafire SP digital camera.

2.4. Immunohistochemistry

Cells grown in microchambered slides were fixed and permeabilized in cold 1:1 methanol-acetone for 30 min. Primary rat anti-mouse Mac-3 antibody (PharMingen, San Diego, CA, USA), diluted as 1:1000, was used at 37°C for 2 h followed by biotinylated secondary anti-rat antibody at 37°C for 1 h. Mac-3 antibody reacts with the glycoprotein Mac-3 antigen expressed on mouse mononuclear phagocytes. The slides were incubated with avidin–biotin peroxidase complex for 1 h followed by 3,3'-diaminobenzidine as a substrate.

2.5. Determination of intracellular free sphingoid bases

At the end of 24 h or 48 h treatment with fumonisin B₁, the medium was aspirated, and cells were washed once with ice-cold PBS and then scraped into 1 ml ice-cold PBS. An aliquot (0.1 ml) of cell suspension in PBS was transferred to another tube, spun at 2,000g, 4°C for 5 min. The cell pellet was lysed and stored at -85°C until analysis of total protein by Bio-Rad Bradford reagent (Bio-Rad Laboratories, Hercules, CA) using 96-well plate according to the manufacturer's protocol. Free sphingoid bases were extracted from the remainder of cells by using the modified method of Yoo et al. (1996). The relative amounts of free sphinganine and sphingosine in base-treated cell extracts were determined by high performance liquid chromatography (HPLC) as described earlier (He et al., 2002). Sphingoid bases were quantified based on the recovery of a C₂₀ sphinganine internal standard. The limit of detection for C₂₀ was 26.8 fmol/assay (equivalent to 1 fmol/μg protein).

2.6. Analysis of cytokine expression

Total RNA was isolated from cells using TRI[®] reagent (Molecular Research Center, Cincinnati, OH) according to the manufacturer's protocol. Reverse-transcriptase polymerase chain reaction (RT-PCR) was used to analyze the expression of mRNA for TNFα, IL-12, IFNγ and β-actin as internal control (He et al., 2001). The amplification products were fractionated on ethidium bromide containing 2% agarose gel and documented using a Kodak DC290 digital camera and digitized using UN-SCAN-IT software (Silk Scientific, Orem, UT). Band intensities (pixel values) for each cytokines were normalized to that of β-actin or glyceraldehyde-3-phosphate dehydrogenase (GAPDH).

2.7. Statistical analysis of data

Each experiment was repeated several times with consistent trends; data from different experiments were pooled. The results are expressed as mean \pm standard error (SE) of independent experiments. Differences among treatments were analyzed by one-way analysis of variance (ANOVA) followed by Duncan's multiple comparison test. The level of $p \leq 0.05$ was considered as significant for all comparison.

3. Results

3.1. Fumonisin B₁ induced cell death in mixed cultures while individual cultures were resistant

Treatment with 10 μ M fumonisin B₁ for 72 h induced toxicity in co-cultures of mouse macrophage cells (J774A.1) and nonparenchymatous liver epithelial cells (NMuLi), as indicated by increased lactate dehydrogenase (LDH) release (Fig. 4.1). Individual cells alone were unresponsive and showed significantly less LDH release compared to co cultures with the same treatment. Preliminary studies indicated that concentrations of fumonisin B₁ up to 50 μ M were not toxic to either J774A.1 or NMuLi cells but were cytotoxic in co-cultures (data not shown). The effects were time and concentration dependent (not illustrated).

3.2. Induction of apoptosis in co-cultures exposed to Fumonisin B₁

Treatment of co-culture with 10 μ M fumonisin B₁ for 24 h resulted in increased apoptosis, which was measured by recording the fluorescence of Annexin V dye at 495/520 nm

(Fig. 4.1). Cell death in co-culture was confirmed by nuclear staining with membrane impermeant dye propidium iodide (PI), which is taken up only by necrotic cells as their cell membrane is damaged. Fumonisin B₁ treated co-culture had significantly greater number of PI stained cells as compared to control (Fig. 4.2A). We determined apoptosis by Annexin V staining in fumonisin B₁ treated co-cultures. Visual inspection under fluorescence microscope confirmed the presence of increased number of cells exhibiting bright green staining of Annexin V on cell surface indicating apoptotic cells (Fig. 4.2A). Early apoptotic cells with exposed phosphatidyl serine and intact cell membrane bind annexin V but exclude PI. Overlay of annexin V and PI stained cells showed predominance of annexin V stained cells after 24 h of fumonisin B₁ treatment.

Immunohistochemical staining of macrophages with surface marker Mac-3 in the co-culture showed that fumonisin B₁ treatment did not change the number of macrophages while reduced the density of cells not stained with Mac-3 marker i.e. nonparenchymatous liver epithelial cells (Fig. 4.2B).

3.3. Increase in cytotoxicity is not related to sphingoid base accumulation

Intracellular levels of sphinganine were increased to similar extent in individual cell types and co-culture upon treatment with 10 μ M fumonisin B₁ for 24 h or 48 h. Sphingosine levels decreased significantly in NMuLi cells and co-culture treated with 10 μ M fumonisin B₁ for 24 h or 48 h while remained unchanged in J774A.1 cells (Fig. 4.3).

3.4. Potentiation of cytokine expression in Fumonisin B₁ treated co-culture

In fumonisin B₁ sensitive cell lines or *in vivo* experiments, increased production of proinflammatory cytokines has been implicated in fumonisin B₁ toxicity. To evaluate the role of cytokines, we measured the expression of TNF α , IL-12, and IFN γ in co-cultures and individual cell types treated with 10 μ M fumonisin B₁. NMuLi cells had little expression of TNF α . None of the cytokines expression changed in individual cultures; co-cultures had increased expression of TNF α after 24 h treatment with fumonisin B₁ (Fig. 4.4). There was no change in expression of IFN γ and IL-12 in co-culture treated with fumonisin B₁ for 24 h but expression increased significantly after 48 h incubation with fumonisin B₁ (Fig. 4.4).

3.5. Fumonisin cytotoxicity in co-cultures is reduced by anti TNF α and anti IFN γ

Treatment of co-culture with neutralizing antibodies for either TNF α or IFN γ decreased the fumonisin B₁-induced apoptosis. Co-cultures were treated with 10 μ M fumonisin B₁ in the presence of neutralizing antibodies for TNF α (1 μ g/ml) or IFN γ (1 μ g/ml) for 24 h (Fig. 4.5).

3.6. Transfer of medium produced alterations in cytokine expression similar to co-cultures

Interactions of epithelial cells and macrophages have been shown to be mediated by soluble mediators such as cytokines. We investigated possibility of such interaction between NMuLi and J774A.1 cells. Both cells were treated with 10 μ M fumonisin B₁ for 24 h. The supernatant from NMuLi cells was transferred to untreated J774A.1 cells and that of J774A.1 cells to untreated NMuLi cells. After 6 h of incubation with the preconditioned media TNF α expression was examined in J774A.1 cells and IFN γ expression in NMuLi cells. We

observed, increase in IFN γ expression in NMuLi cells after media transfer while change of media did not alter the expression of TNF α in J774A.1 cells (Fig. 4.6).

3.7. Effect of transfer of conditioned supernatant from Fumonisin B₁ treated co-culture to individual cultures

Co-cultures were treated for 24, 36 and 48 h with 10 μ M fumonisin B₁ and their conditioned media was transferred to individual cultures to evaluate the effect of soluble mediators of crosstalk on cell viability. LDH release was measured from individual cultures at the same time, 48 h after the transfer of supernatant. Supernatant from cultures that was conditioned for 24 h in co-culture did not induce any increase in LDH release from NMuLi cells. Preconditioning of 36 and 48 h in treated co-cultures induced increased LDH release from NMuLi cells (Fig. 4.7). There was no significant change in LDH release when media preconditioned in treated co-cultures were transferred to J774A.1 cells (Fig. 4.7).

3.8. Recombinant TNF α and IFN γ induce expression of each other in NMuLi and J774A.1 cells

In order to confirm whether individual cells in co-culture respond to cytokines produced by the other cells, we treated J774A.1 cells with 15 ng/ml recombinant IFN γ (Hemmer et al., 2001) and NMuLi cells with 10 ng/ml recombinant TNF α (Johnson et al., 2003). Treatment of J774A.1 cells with IFN γ for 6 h produced increased expression of TNF α (Fig. 4.8). Similarly treatment of NMuLi cells with TNF α for 6 h produced increased expression of IFN γ (Fig. 4.8).

3.9. Replacement with fresh medium did not prevent cell death in co-culture

In order to investigate if the effect of fumonisin B₁ induced signaling lasted until cell death, the fumonisin B₁ containing media was replaced with fresh media with no fumonisin B₁. Release of LDH was measured at 72 h after the first addition of fumonisin B₁. Cytotoxicity of fumonisin B₁ in co-culture was prevented when fumonisin B₁ containing media was replaced with fresh media at 24 h. Replacing with fresh media after fumonisin B₁ treatment for 36 or 48 h did not prevent cell death in co-culture as evident by increased LDH release from these cells at 72 h (Fig. 4.9).

4. Discussion

Liver and kidney are primary target organs of fumonisin B₁ in rodents. However primary hepatocyte cultures (Wang et al., 1991) and liver slices (Norred et al., 1996) are quite resistant to fumonisin B₁-induced cytotoxic effects. In primary rat hepatocytes, higher concentrations of fumonisin B₁ were required to elicit lactate dehydrogenase (LDH) release (van der Westhuizen et al., 1998). We found that mouse macrophage cells (J774A.1) and liver nonparenchymatous epithelial cells (NMuLi) are also resistant to fumonisin B₁ toxicity when cultured separately but become responsive when grown in co-culture at concentrations as low as 10 μM. Cytotoxicity in treated co-culture was evident by lactate dehydrogenase release.

This suggested the possibility of interactions between these two cell types that amplify their response to fumonisin B₁.

In agreement with previous studies in fumonisin B₁ sensitive cell lines (Tolleson et al., 1999), we also found that apoptosis is the primary mode of cell death in fumonisin B₁ treated co-cultures. Although accumulation of sphingoid bases has been established as a mechanism for fumonisin B₁ induced apoptosis in various cells, in current study results showed that accumulation of sphinganine was not sufficient to cause apoptosis. Intracellular levels of sphingoid bases changed to similar extent in co-cultures and individual cell types.

We observed that TNF α , IL-12 and IFN γ expressions were higher in co-cultures compared to individual cell lines after fumonisin B₁ treatment. Cytotoxicity observed in the current study was due to potentiation of cytokines as neutralizing antibodies of TNF α and IFN γ partially inhibited the fumonisin B₁-induced apoptosis. There is considerable evidence that cytokine signaling pathways play an important role in fumonisin B₁ induced toxicity *in vitro* and *in vivo*. Jones et al. (2001) reported that fumonisin B₁ toxicity was effectively prevented by inhibition of caspases, which are downstream of TNF α cellular signaling. Fumonisin B₁ toxicity was reduced in mice lacking either TNF α receptor (TNFR) 1 or TNFR 2 (Sharma et al., 2000; Sharma et al., 2001).

Fumonisin B₁ treatment causes an increased expression of TNF α , IFN γ and IL-12 in liver; cells involved in TNF α production were identified as Kupffer cell (Bhandari et al., 2002b). Previous studies showed that TNF α and IL-12 produced by the Kupffer cells in liver

could act on natural killer (NK) cells or Th 1 cells to produce IFN γ (Gantner et al., 1996). This IFN γ can then further activate the Kupffer cells to produce more TNF α and IL-12 eventually producing more IFN γ from the Th1 cells, thus generating a positive feedback loop between the two cell types (Bhandari et al., 2002b). The two cytokines, TNF α and IFN γ , have synergistic effects in producing liver damage (Ozmen et al., 1994).

Our laboratory has previously demonstrated that fumonisin B₁ treatment increases TNF α production from J774A.1 cells (Dugyala et al., 1998). In the present study we found that transfer of supernatant from fumonisin B₁ treated J774A.1 cells, leads to increased expression of IFN γ in NMuLi cells. This correlated well with our hypothesis that TNF α production from macrophages (J774A.1) can increase IFN γ production from liver epithelial cells (NMuLi). This is also evident by our findings that increase in IFN γ expression in co-culture is delayed until 48 h; the effect was expected considering that accumulation of TNF α in the medium from J774A.1 cells would require about 24 h to be synthesized and secreted in the medium. Transfer of medium from fumonisin B₁ treated epithelial cells to macrophage cells did not increase TNF α expression, indicating that fumonisin B₁ has no direct effect on IFN γ expression in epithelial cells only TNF α produced from macrophages stimulates them to produce IFN γ .

To confirm that J774A.1 cells respond to IFN γ , we treated them with recombinant IFN γ , providing the anticipated increased expression of TNF α in J774A.1 cells. Similarly treatment of NMuLi cells with recombinant TNF α resulted in increased expression of IFN γ , supporting our hypothesis that TNF α produced from macrophages stimulated NMuLi cells in co-culture to

produce IFN γ . Transfer of supernatant from fumonisin B₁ treated co-cultures to liver epithelial cells induced toxicity in the latter, which suggested that cross talk involved soluble mediators. A preconditioning of 36 h was required for the observed toxicity, indicating that toxic factor in co-cultures requires that period to accumulate in concentrations sufficient enough to induce toxicity. In a similar experiment transfer of supernatant from fumonisin B₁ treated co-cultures to macrophage cells did not induce cytotoxicity in macrophages. It indicated that death of epithelial cells might be responsible for the observed cytotoxicity in co-culture; however, it needs to be verified by direct immunohistochemistry.

Persistent exposure to fumonisin B₁ is not necessary for cytotoxicity as replacement with fresh medium in place of fumonisin B₁ containing medium after 36 h and 48 h did not prevent cell death in co-cultures. These results suggest that presence of fumonisin B₁ is dispensable after 36 h. A persistent inhibition of the ceramide synthase may have occurred despite removal of fumonisin B₁ from the medium. Alternatively, production of some cytotoxic factor might have triggered an irreversible pathway leading to cell death without fumonisin B₁.

Recent studies have demonstrated that apart from hepatocyte multipotential NPEC system generates differentiated lineages needed for liver regeneration under conditions where hepatocytes are unable to respond or are functionally compromised (Thorgeirsson, 1996; Fausto, 2000). NMuLi cells were shown to exhibit characters of such nonparenchymal bipotential progenitor cells. Sections of hepatocyte growth factor treated NMuLi colonies resembled ductules proliferating in liver damage caused by hepatotoxins and biliary tract obstruction (Johnson et al., 1993). NMuLi cells produce a variety of tumors when inoculated

in subcutaneous sites in newborn mice (Anderson et al., 1979) and show selective tumorigenesis when transfected with hepatocyte growth factor (Johnson et al., 1995). This further suggested the potential of NmuLi cells as stem cells to differentiate into hepatocytes and biliary epithelial cells.

Role of NPECs in liver regeneration following fumonisin B₁ hepatotoxicity seems conceivable as NPECs are the major regenerating cells in other models, where hepatocyte proliferation is impaired or slowed (Thorgeirsson, 1996). Fumonisin B₁ inhibits hepatocyte proliferation in rats fed fumonisin B₁ before or after partial hepatectomy (Gelderblom et al., 1994). Fumonisin B₁ also inhibits epidermal growth factor induced DNA synthesis in primary rat hepatocytes (Gelderblom et al., 1995). NPECs were noted as oval cell proliferation inside regenerating nodules in rats fed fumonisin B₁ containing diet (Lemmer et al., 1999; 2004). Our results indicated that fumonisin B₁ is toxic to NPECs; therefore lack of regeneration in response to fumonisin B₁ may contribute to observed hepatotoxicity of fumonisin B₁ *in vivo*.

In summary our results indicate that macrophage and NPECs interact in co-culture in response to fumonisin B₁ and potentiate expression of various cytokines, which may have implications in making hepatocytes more responsive to fumonisin B₁-induced cytotoxicity.

Acknowledgement

This work was supported in part by US Public Health Service grant ES09403 from the National Institute of Environmental Health Sciences

References

Anderson, L.W., Smith, H.S., 1979. Premalignancy in vitro: progression of an initially benign epithelial cell line to malignancy. *Br. J. Exp. Pathol.* 60, 575-581.

Bhandari, N., Sharma, R.P., 2002a. Fumonisin B₁ induced alterations in cytokine expression and apoptosis signaling genes in mouse liver and kidney after an acute exposure. *Toxicology.* 172, 81-92.

Bhandari, N., Brown, C.C., Sharma, R.P., 2002b. Fumonisin B₁ induced localized activation of cytokine network in mouse liver. *Food Chem. Toxicol.* 40, 1483-1491.

Ciacci-Zanella, J.R., Merrill, A.H., Jr., Wang, E., Jones, C., 1998. Characterization of cell-cycle arrest by fumonisin B₁ in CV-1 cells. *Food Chem. Toxicol.* 36, 791-804.

Ciacci-Zanella, J.R., Jones, C., 1999. Fumonisin B₁, a mycotoxin contaminant of cereal grains, and inducer of apoptosis via the tumour necrosis factor pathway and caspase activation. *Food Chem. Toxicol.* 37, 703-712.

Constable, P.D., Smith, G.W., Rottinghaus, G.E., Haschek, W.M., 2000. Ingestion of fumonisin B₁ containing culture material decreases cardiac contractility and mechanical efficiency in swine. *Toxicol. Appl. Pharmacol.* 162, 151-160.

Dugyala, R.R., Sharma, R.P., Tsunoda, M., Riley, R.T., 1998. Tumor necrosis factor- α as a contributor in fumonisin B₁ toxicity. *J. Pharmacol. Exp. Ther.* 285, 317-324.

Fausto, N., 2000. Liver regeneration. *J. Hepatol.* 32, 19-31.

Gantner, F., Leist, M., Kusters, S., Vogt, K., Volk, H.D., Tiegs, G., 1996. T cell stimulus-induced crosstalk between lymphocytes and liver macrophages results in augmented cytokine release. *Exp. Cell Res.* 229, 137-146.

Gelderblom, W.C., Cawood, M.E., Snyman, S.D., Marasas, W.F., 1994. Fumonisin B₁ dosimetry in relation to cancer initiation in rat liver. *Carcinogenesis* 15, 209-214.

Gelderblom, W.C., Snyman, S.D., van der, W.L., Marasas, W.F., 1995. Mitoinhibitory effect of fumonisin B₁ on rat hepatocytes in primary culture. *Carcinogenesis* 16, 625-631.

He, Q., Riley, R.T., Sharma, R.P., 2001. Fumonisin B₁ induced tumor necrosis factor- α expression in a porcine kidney cell line is independent of sphingoid base accumulation induced by ceramide synthase inhibition. *Toxicol. Appl. Pharmacol.* 174, 69-77.

He, Q., Riley, R.T., Sharma, R.P., 2002. Pharmacological antagonism of fumonisin B₁ cytotoxicity in porcine renal epithelial cells (LLC-PK1): a model for reducing fumonisin B₁ induced nephrotoxicity *in vivo*. *Pharmacol. Toxicol.* 90, 268-277.

Hemmer, K., Fransen, L., Vanderstichele, H., Vanmechelen, E., Heuschling, P., 2001. An *in vitro* model for the study of microglia-induced neurodegeneration: involvement of nitric oxide and tumor necrosis factor- α . *Neurochem. Int.* 38, 557-565.

Howard, P.C., Eppley, R.M., Stack, M.E., Warbritton, A., Voss, K.A., Lorentzen, R.J., Kovach, R.M., Bucci, T.J., 2001. Fumonisin B₁ carcinogenicity in a two-year feeding study using F344 rats and B6C3F1 mice. *Environ. Health Perspect.* 109 Suppl 2, 277-282.

Johnson, M., Koukoulis, G., Matsumoto, K., Nakamura, T., Iyer, A., 1993. Hepatocyte growth factor induces proliferation and morphogenesis in nonparenchymal epithelial liver cells. *Hepatology* 17, 1052-1061.

Johnson, M., Koukoulis, G., Kochhar, K., Kubo, C., Nakamura, T., Iyer, A., 1995. Selective tumorigenesis in non-parenchymal liver epithelial cell lines by hepatocyte growth factor transfection. *Cancer Lett.* 96, 37-48.

Johnson, V.J., He, Q., Kim, S.H., Kanti, A., Sharma, R.P., 2003. Increased susceptibility of renal epithelial cells to TNF α -induced apoptosis following treatment with fumonisin B₁. *Chem. Biol. Interact.* 145, 297-309.

Jones, C., Ciacci-Zanella, J.R., Zhang, Y., Henderson, G., Dickman, M., 2001. Analysis of fumonisin B₁ induced apoptosis. *Environ. Health Perspect.* 109 Suppl 2, 315-320.

Lemmer, E.R., de la Motte, H.P., Omori, N., Omori, M., Shephard, E.G., Gelderblom, W.C., Cruse, J.P., Barnard, R.A., Marasas, W.F., Kirsch, R.E., Thorgeirsson, S.S., 1999. Histopathology and gene expression changes in rat liver during feeding of fumonisin B₁, a carcinogenic mycotoxin produced by *Fusarium moniliforme*. *Carcinogenesis* 20, 817-824.

Lemmer, E.R., Vessey, C.J., Gelderblom, W.C., Shephard, E.G., Van Schalkwyk, D.J., Van Wijk, R.A., Marasas, W.F., Kirsch, R.E., Hall Pd, P., 2004. Fumonisin B₁-induced hepatocellular and cholangiocellular tumors in male Fischer 344 rats: potentiating

effects of 2-acetylaminofluorene on oval cell proliferation and neoplastic development in a discontinued feeding study. *Carcinogenesis*, in press.

Norred, W.P., Riley, R.T., Meredith, F.I., Bacon, C.W., Voss, K.A., 1996. Time and dose-response effects of the mycotoxin, fumonisin B₁ on sphingoid base elevations in precision-cut rat liver and kidney slices. *Toxicol. in Vitro* 10, 349-358.

Ozmen, L., Pericin, M., Hakimi, J., Chizzonite, R.A., Wysocka, M., Trinchieri, G., Gately, M., Garotta, G., 1994. Interleukin 12, interferon gamma, and tumor necrosis factor alpha are the key cytokines of the generalized Shwartzman reaction. *J. Exp. Med.* 180, 907-915.

Riley, R.T., Norred, W.P., Bacon, C.W., 1993. Fungal toxins in foods: recent concerns. *Annu. Rev. Nutr.* 13, 167-189.

Riley, R.T., Wang, E., Schroeder, J.J., Smith, E.R., Plattner, R.D., Abbas, H., Yoo, H.S., Merrill, A.H., Jr., 1996. Evidence for disruption of sphingolipid metabolism as a contributing factor in the toxicity and carcinogenicity of fumonisins. *Nat. Toxins* 4, 3-15.

Schmelz, E.M., Dombrink-Kurtzman, M.A., Roberts, P.C., Kozutsumi, Y., Kawasaki, T., Merrill, A.H., Jr., 1998. Induction of apoptosis by fumonisin B₁ in HT29 cells is mediated by the accumulation of endogenous free sphingoid bases. *Toxicol. Appl. Pharmacol.* 148, 252-260.

Sharma, R.P., Dugyala, R.R., Voss, K.A., 1997. Demonstration of in-situ apoptosis in mouse liver and kidney after short-term repeated exposure to fumonisin B₁. *J. Comp Pathol.* 117, 371-381.

Sharma, R.P., Bhandari, N., Riley, R.T., Voss, K.A., Meredith, F.I., 2000. Tolerance to fumonisin toxicity in a mouse strain lacking the P75 tumor necrosis factor receptor. *Toxicology*. 143, 183-194.

Sharma, R.P., Bhandari, N., He, Q., Riley, R.T., Voss, K.A., 2001. Decreased fumonisin hepatotoxicity in mice with a targeted deletion of tumor necrosis factor receptor 1. *Toxicology*. 159, 69-79.

Sharma, R.P., He, Q., Johnson, V.J., 2003. Deletion of IFN- γ reduces fumonisin-induced hepatotoxicity in mice via alterations in inflammatory cytokines and apoptotic factors. *J. Interferon Cytokine Res.* 23, 13-23.

Sydenham, E.W., Gelderblom, W.C.A., Thiel, P.G., Marasas, W.F.O., 1990. Evidence for the natural occurrence of fumonisin B₁, a mycotoxin produced by *Fusarium moniliforme*, in Corn. *J. Ag. Food Chem.* 38, 285-290.

Tao, F., Kobzik, L., 2002. Lung macrophage-epithelial cell interactions amplify particle-mediated cytokine release. *Am. J. Respir. Cell Molec. Biol.* 26, 499-505.

Thorgeirsson, S.S., 1996. Hepatic stem cells in liver regeneration. *FASEB J.* 10, 1249-1256.

Tolleson, W.H., Dooley, K.L., Sheldon, W.G., Thurman, J.D., Bucci, T.J., Howard, P.C., 1996. The mycotoxin fumonisin induces apoptosis in cultured human cells and in livers and kidneys of rats. *Adv. Exp. Med. Biol.* 392, 237-250.

Tolleson, W.H., Couch, L.H., Melchior, W.B., Jr., Jenkins, G.R., Muskhelishvili, M., Muskhelishvili, L., McGarrity, L.J., Domon, O., Morris, S.M., Howard, P.C., 1999.

Fumonisin B₁ induces apoptosis in cultured human keratinocytes through sphinganine accumulation and ceramide depletion. *Int. J. Oncol.* 14, 833-843.

Van der Westhuizen, L., Shephard, G.S., Snyman, S.D., Abel, S., Swanevelder, S., Gelderblom, W.C., 1998. Inhibition of sphingolipid biosynthesis in rat primary hepatocyte cultures by fumonisin B₁ and other structurally related compounds. *Food Chem. Toxicol.* 36, 497-503.

Voss, K.A., Howard, P.C., Riley, R.T., Sharma, R.P., Bucci, T.J., Lorentzen, R.J., 2002. Carcinogenicity and mechanism of action of fumonisin B₁: a mycotoxin produced by *Fusarium moniliforme* (= *F. verticillioides*). *Cancer Detect. Prev.* 26, 1-9

Wang, E., Norred, W.P., Bacon, C.W., Riley, R.T., Merrill, A.H., Jr., 1991. Inhibition of sphingolipid biosynthesis by fumonisins. Implications for diseases associated with *Fusarium moniliforme*. *J. Biol. Chem.* 266, 14486-14490.

Wang, W., Jones, C., Ciacci-Zanella, J., Holt, T., Gilchrist, D.G., Dickman, M.B., 1996. Fumonisin and *Alternaria alternata* lycopersici toxins: sphinganine analog mycotoxins induce apoptosis in monkey kidney cells. *Proc. Natl. Acad. Sci. U. S. A.* 93, 3461-3465.

Yoo, H.S., Norred, W.P., Showker, J., Riley, R.T., 1996. Elevated sphingoid bases and complex sphingolipid depletion as contributing factors in fumonisin-induced cytotoxicity. *Toxicol. Appl. Pharmacol.* 138, 211-218.




Fig. 4.1. (A) Treatment of individual cultures and co-culture (J774A.1 and NMuLi) with 10 μM fumonisin B₁ for 72 h resulted in higher lactate dehydrogenase (LDH) release from co-culture, compared to individual cultures. For Individual cultures, cells were plated in 96 well

plates at 4×10^4 cell/well. For co-culture, cells were mixed in a ratio of 1 (J774A.1) : 7 (NMuLi) i.e. 5×10^3 J774A.1 cells and 35×10^3 NMuLi cells. At the end of treatment LDH release was measured separately in supernatant and cells, lysed with 1% triton X-100 (for determination of total LDH release). Data are expressed as percentage of total LDH released from cells. (B) Fumonisin B₁ induced apoptosis in co-culture. After treatment with 10 μ M fumonisin B₁ for 24 h, cells were incubated with annexin V for 15 min and fluorescence intensity was recorded by fluorescent plate reader at 495/520 nm. Relative fluorescence units are arbitrarily defined based on fluorescence recorded at 495/520 nm. Mean \pm S.E. of 3 independent experiments. Asterisk (*) indicates significantly different value ($p < 0.05$) from the control.




Fig. 4.2. Fumonisin B₁ induced cell death in co-culture. (A) Co-culture was treated with 10 μM fumonisin B₁ for 24 h and examined using annexin V or propidium iodide under phase contrast or fluorescence microscope. Annexin V binds with exposed phosphatidyl serine on

the surface of apoptotic cells and imparts cell surface a bright green staining while PI binds with chromatin of necrotic cells and stains cell nucleus red. Overlay of same fields of annexin V and PI stained cells shows predominance of apoptotic cells, which are stained green on surface and lack red nuclear staining. Representative fields are illustrated. (B) Fumonisin B₁-induced cell death in co-cultures treated with 10 μM fumonisin B₁ for 48 h involved predominantly nonparenchymatous epithelial cells (NMuLi). Macrophages in the co-culture were stained brown by Mac-3 antibody, which specifically binds with Mac-3 surface antigen on macrophages. In control culture the NMuLi cells are visualized as light blue hematoxylin-stained cells; these cells are largely absent in the treated culture. Bar on lower left represents 50 μm.




Fig. 4.3. Concentrations of free sphinganine and sphingosine after exposure of J774A.1, NMuLi and co-culture to 10 μM fumonisin B₁ for 24 h (A and C) or 48 h (B and D). Mean ± SE (n= 3). Asterisk (*) indicates significantly different value ($p < 0.05$) from the concurrent control.




Fig. 4.4. Effect of fumonisin B₁ on expressions of TNF α (A), IFN γ (B) and IL-12 (C) in individual and co-cultures. In co-culture, cells were mixed in a ratio of 1 (J774A.1) : 7 (NMuLi) cells. All cultures were incubated for 16 h for conditioning with the media before treatment with 10 μ M fumonisin B₁. Expression of TNF α was measured after treatment with fumonisin B₁ for 24 h and that of IFN γ and IL-12 after treatment for 48 h. Expression of specific mRNA was quantified by RT-PCR and normalized to that of β -actin in the same sample. Mean \pm SE of 3 independent experiments. Asterisk (*) indicates significant difference ($p < 0.05$) from the control.




Fig. 4.5. Inhibition of cytotoxicity by anti-TNF α and anti-IFN γ antibodies. Co-cultures were treated with 10 μ M fumonisin B₁ in the presence of neutralizing antibodies for TNF α (1 μ g/ml) or IFN γ (1 μ g/ml) for 24 h. At the end of treatment, cells were incubated with Hoechst 33258 dye for 10 min and fluorescence intensity was recorded by fluorescent plate reader at 346/460 nm. Relative arbitrarily fluorescence units are indicated at excitation/emission of 346/460 nm. Mean \pm SE of 3 independent experiments. * indicates significantly different value ($p < 0.05$) from the control; ¶ represents significant ($p = < 0.05$) difference from the fumonisin B₁-treated culture with no antibody.




Fig. 4.6. Effect of transfer of preconditioned supernatant from J774A.1 cells to NMuLi cells (A) and NMuLi cells to J774A.1 cells (B) on expressions of IFN γ and TNF α respectively. J774A.1 or NMuLi cells (5×10^5 /well) were grown and treated with 10 μ M fumonisin B $_1$ in 6 well plates for 24 h before transferring their supernatant to the other untreated cells. After 6 h incubation of cells in preconditioned supernatant, total RNA was extracted and mRNA levels were quantified by RT-PCR. Mean \pm SE of 3 independent experiments. Asterisk (*) indicates significantly different value ($p < 0.05$) from the control.




Fig. 4.7. Effect of transfer of conditioned supernatant from fumonisin B₁ treated co-culture to individual cultures. (A) Supernatant of 10 μ M fumonisin B₁ treated or untreated co-culture was transferred to NMuLi cultures after conditioning for 36 h in co-culture. LDH released in the medium from NMuLi cells was measured 48 h after the transfer. (B) Supernatant of 10 μ M fumonisin B₁ treated or untreated co-culture was transferred to J774A.1 cultures after conditioning for 48 h in co-culture. LDH released in the medium from J774A.1 cells was measured 48 h after the transfer. The relative LDH activity was calculated as mean of change in absorbance (ΔA) at 340 nm. Mean \pm SE (n=3). Asterisk (*) indicates significantly different value ($p < 0.05$) from the control.




Fig. 4.8. (A) To confirm that IFN γ produced from NMuLi cells can stimulate J774A.1 cells to augment expression of TNF α , J774A.1 cells were treated with 15 ng/ml recombinant IFN γ for 6 hr. The mRNA level of TNF α were quantified by RT-PCR and normalized against GAPDH. (B) NMuLi cells were treated with 10 ng/ml recombinant TNF α for 6 h and mRNA levels of IFN γ were quantified by RT-PCR and normalized against β actin. Mean \pm SE (n= 3). Asterisk (*) indicates significantly different value ($p < 0.05$) from the control.




Fig. 4.9. Effect of replacing fumonisin B₁ treated media with fresh media (without fumonisin B₁). Co-culture was treated with 10 μM fumonisin B₁ and its medium was replaced with fresh medium (without fumonisin B₁) 24, 36 and 48 h after the fumonisin B₁ treatment. LDH released in the replaced fresh medium and in the medium without replacement was measured 72 h after the beginning of fumonisin B₁ treatment. The relative LDH activity was calculated as mean of change in absorbance (ΔA) at 340 nm. Mean ± SE (n= 3). Asterisk (*) indicates significant difference ($p < 0.05$) from the control.

CHAPTER 5

TUMOR NECROSIS FACTOR α -MEDIATED ACTIVATION OF C-JUN NH2- TERMINAL KINASE AS A MECHANISM FOR FUMONISIN B₁-INDUCED APOPTOSIS IN MURINE PRIMARY HEPATOCYTES¹

¹Sharma N., Suzuki H., He Q., and Sharma R.P. 2005. To be submitted to *Journal of Biochemical and Molecular Toxicology*

ABSTRACT

Fumonisin B₁ is a mycotoxin produced by *Fusarium verticillioides*, frequently associated with corn. It produces hepatic or renal damage in most animal species. Fumonisin B₁ perturbs sphingolipid metabolism by inhibiting ceramide synthase. Our previous studies indicated that fumonisin B₁ caused localized activation of cytokines in liver produced by macrophages and other cell types that modulate fumonisin B₁-induced hepatic apoptosis in mice. The role of tumor necrosis factor α (TNF α) in fumonisin B₁-mediated hepatocyte apoptosis has been established; however, not much is known about the downstream events leading to apoptosis. In the current study, fumonisin B₁ induced apoptosis in primary cultures of mouse liver cells. In agreement with previous reports, fumonisin B₁ caused accumulation of sphingoid bases and led to increase in TNF α expression. Phosphorylated and total c-Jun NH₂-terminal kinase (JNK) activities were increased after 24 h fumonisin B₁ treatment. JNK inhibitor (SP600125) and anti-TNF α reduced the apoptosis induced by fumonisin B₁. The role of JNK signaling in fumonisin B₁ induced apoptosis is downstream of TNF α production, as fumonisin B₁ mediated activation of JNK was reduced by the presence of anti TNF α in the medium, whereas presence of JNK inhibitor did not change the fumonisin B₁ induced TNF α expression. Results of this study imply that generation of fumonisin B₁-induced TNF α results in modulation of mitogen activated protein kinases, particularly of JNK and provides a possible mechanism for apoptosis in murine hepatocytes.

Key words: Fumonisin B₁; hepatotoxicity; c-Jun NH₂-terminal kinase; tumor necrosis factor α ; mitogen activated protein kinase

INTRODUCTION

Fumonisin B₁ is a group of structurally related mycotoxins produced by *Fusarium verticillioides* and related species, which are commonly found on corn [1]. Fumonisin B₁ is the most abundant fumonisin in naturally contaminated foods and feeds. Liver and kidney are the targets of fumonisin B₁ toxicity in most domestic and experimental animals [2,3,4]. It causes equine leukoencephalomalacia and porcine pulmonary edema [5]. It is hepatocarcinogenic in male BD IX rats [6], nephrocarcinogen in male F344/N rats and has been associated with human esophageal cancer in southern Africa [7] and primary liver cancer in China [8]. In mouse embryo cultures, fumonisin B₁ has been shown to produce embryotoxicity and neural tube defects [9]. It has been suggested that high incidences of neural tube defects occur in some regions of the world (Guatemala, South Africa, and China), where consumption of fumonisin in diet is high [10].

Fumonisin B₁ is structurally similar to free sphingoid bases, i.e., sphinganine and sphingosine and is a potent inhibitor of ceramide synthase (sphinganine and sphingosine-N-acyl transferase), a key enzyme responsible for acylation of sphinganine in the *de novo* synthesis of sphingolipids and the reacylation of sphingosine [11,12]. The inhibition of ceramide synthase by fumonisin B₁ results in apoptosis caused by accumulation of free sphingoid bases (sphinganine and sphingosine), increased proliferation caused by increased sphingosine-1-phosphate, or/and decreased ceramide and altered lipid raft function due to disruption of complex sphingolipids synthesis/transport [13]. Studies in pig renal epithelial cells have shown that fumonisin B₁-induced apoptosis and necrosis are sphinganine-dependent [14]. There is a

close correlation between increased apoptosis in liver and kidney and the disruption of sphingolipid metabolism [15].

Different cell lines respond differently to fumonisin B₁ treatment. Diverse cellular responses credited to fumonisin B₁ exposure include apoptosis, proliferation and cell cycle arrest. Fumonisin B₁ induces apoptosis in various cell lines such as HT29 cells (human colonic cell line) [16], and porcine renal epithelial (LLC-PK1) cells [17], while murine or human leukemia cells (U937), human embryonic kidney cells (HEK-293) do not undergo apoptosis, when treated with fumonisin B₁ [18,19,20]. Primary rat hepatocytes and liver slices [21] are quite resistant to fumonisin B₁-induced apoptosis. Fumonisin B₁ induced cell cycle arrest in the G1 phase in African green monkey kidney cells (CV-1) but CV-1 cells transformed by the simian virus 40 (SV40) large T antigen (COS-7) are unaffected by the same levels of fumonisin B₁ [22].

We have demonstrated the role of tumor necrosis factor α (TNF α) in fumonisin B₁-induced toxic responses in Balb/c mice [2]. Increased TNF α release was documented in lipopolysaccharide-stimulated macrophages from mice treated with different doses of fumonisin B₁. Mouse macrophages also produced TNF α when cultured in the presence of fumonisin B₁; acute hematologic effects of fumonisin B₁ were neutralized after pretreatment of mice with anti-TNF α [2]. Increase of proinflammatory cytokines from immune cells has been implicated in fumonisin B₁-induced hepatotoxicity. Depletion of Kupffer cells by gadolinium chloride attenuated fumonisin B₁ induced hepatotoxicity [23]. A positive amplification loop involving TNF α and interferon γ (IFN γ) has been implicated in hepatotoxicity that involves Kupffer cells, hepatic lymphocytes and nonparenchymatous liver epithelial cells [24]. Deletion of

tumor necrosis factor receptors 1 and 2 and IFN γ genes reduced fumonisin B₁-induced hepatotoxicity in mice [25,26,27]. The hepatotoxicity in mice in response to fumonisin B₁ was abolished after pretreatment of animals with antibody against Thy-1.2 surface antigen of mature T lymphocytes [unpublished].

Taken together, these studies have demonstrated that fumonisin B₁ can induce apoptosis *in vitro*, in different cultured cell lines and *in vivo* in liver and kidney of rodents, where production of pro inflammatory cytokines such as TNF α and IFN γ is an important mediator of apoptosis. Although role of TNF α and IFN γ in fumonisin B₁-mediated apoptosis of mouse hepatocytes has been established, not much is known about the downstream signaling events leading to cytotoxicity. In this study, we hypothesized that fumonisin B₁ induced apoptosis involves TNF α and downstream signaling events such as mitogen activated protein kinases (MAPKs) that lead to cytotoxic outcome in murine hepatocytes. The role of MAPKs in fumonisin B₁ toxicity is not well explored [28,29,30]. Our previous studies in porcine renal cells (LLC-PK-1) indicated differential effects of fumonisin B₁ on MAPKs involving selective activation of c-Jun NH₂-terminal kinase (JNK).

MATERIALS AND METHODS

Chemicals

Six to eight week old male C57BL/6 mice weighing 20 to 30 g were obtained from Jackson Laboratory (Bar Harbor, Maine). Fumonisin B₁ (purity > 98%) was obtained from Programme on Mycotoxins and Experimental Carcinogenesis (PROMEC, Tygerberg, South

Africa). Antibodies specific for the total and phosphorylated forms of JNK (p54/46) were obtained from Cell Signaling (Beverly, MA). Specific JNK inhibitor (SP600125) was purchased from Calbiochem (La Jolla, CA). Anti-TNF α was procured from Santa Cruz Biotechnology (Santa Cruz, CA). Annexin V and Hoechst 33258 dyes were purchased from Molecular Probes (Eugene, OR). All other reagents were obtained from Sigma (St. Louis, MO) and were of tissue culture grade.

Isolation of parenchymatous liver cells

Livers from 6-8 week old male C57BL/6 mice were perfused through the portal vein with 10 ml of enzyme solution (0.05% collagenase dissolved in calcium free Hanks solution). Liver tissue was then cut into slices and placed in to each of three 50 ml Erlenmeyer flasks containing 10 ml of the enzyme solution [31]. The flasks were incubated at 37°C in an atmosphere of 95% O₂ and 5% CO₂ for 70 min, with constant shaking. After incubation, contents of the flasks were filtered through a single layer of nylon mesh of 61 μ m pore size (Sefar America, Depew, NY). Calcium free Hanks solution was added to a final filtrate volume of 40 ml. The resultant cell suspension was centrifuged (50 \times *g* for 2 min), hepatocyte pellet was washed and cultured in Williams's medium supplemented with 10% fetal calf serum (heat inactivated), 10 μ g/ml insulin, 0.1 mM hydrocortisone, 2 mM L-glutamine, 100 U/ml penicillin and 100 μ g/ml streptomycin. The non-parenchymal cells (NPCs) were separated from the supernatant by centrifugation (1400 \times *g* for 6 min) and cultured in Williams's medium. For co-culture, hepatocytes and NPCs were mixed together in 7:1 proportion as in the original cell preparation. Cultures were maintained at 37°C in a humidified atmosphere

and were allowed to grow overnight (15 h) prior to the treatment. The concentration of fumonisin B₁ and time periods for the experiments were optimized in preliminary trials. The concentration used for JNK inhibitor (SP 600125) was 20 μM, added 30 min prior to fumonisin B₁ treatment.

Determination of apoptosis

The apoptotic effect of fumonisin B₁ on mice primary hepatocytes was determined by measuring the fluorescence intensity of Hoechst 33258 using Spectramax Gemini fluorescent plate reader (Molecular Devices, Irvine, CA). Cells were grown and treated in 96 well plates. At the end of treatment, cells were incubated with annexin V (5 μL/100 μL in annexin binding buffer) or Hoechst 33258 (8 μg/ml in 30 % glycerol in phosphate buffered saline). Hoechst 33258 fluorescence was detected at excitation/emission of 346/460 nm and that of annexin V at excitation/emission of 495 /520 nm. Visual documentation of cellular effects was performed using Olympus IX71 inverted microscope (Olympus America, Melville, NY). Digital images were acquired using Olympus Magnafire digital camera.

Analyses of sphingolipids

Levels of free sphinganine and sphingosine in hepatic tissues were determined after base treatment of lipid extracts by high performance liquid chromatography according to the methods reported previously [15]. The concentration of sphingoid bases, sphinganine and sphingosine, was quantified based on the recovery of the C₂₀-sphinganine (D-erythro-C₂₀-dihydro-sphingosine; Matreya, Pleasant Gap, PA) as the internal standard.

Western blot analysis of JNK

Levels of total and phosphorylated JNK were determined using antibodies for total and phospho specific JNK, as described previously [32]. Cells were grown at 1.5×10^6 cells/well in 6-well microplates and treated with 20 μ M fumonisin B₁ for 24 h. Following treatment, cells were washed with phosphate buffered saline (PBS) and cell lysates were prepared by scraping in 100 μ l of lysis buffer [20 mM Tris-HCl (pH 8.0), 1 mM sodium orthovanadate, 10% glycerol, 1 mM phenylmethylsulfonyl fluoride, 2 mM ethyl-enediaminetetraacetate (EDTA), 1% Triton X-100, 50 mM β -glycerolphosphate, and 10 μ g/ml each of aprotinin, leupeptin, and pepstatin]. Twenty micrograms of protein, determined by Bradford assay, was separated electrophoretically using a 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gel and transferred to nitrocellulose paper followed by antibody staining. Equal loading and transfer of total protein was verified with the reversible Ponceau S stain (Sigma) dye. Immunodetection was performed using enhanced chemiluminescence (ECL) detection kit (Amersham Pharmacia, Piscataway, NJ).

Estimation of the presence of Thy-1.2 bearing T cells in parenchymatous cultures

Primary hepatocytes were grown in sterile four-chambered collagen coated slides (Nunc International, Naperville, IL, USA). Cells were fixed in 1:1 cold methanol: acetone for 30 min, washed gently in PBS and blocked in PBS containing 10% horse serum for 20 minutes. Monoclonal anti-mouse fluorescein conjugated Thy-1.2 (CD90.2) antibody (Southern Biotech, Birmingham, AL) diluted (0.3 μ g/ 10^6 cells) in PBS containing 10% horse serum was applied to the slides and incubated for 30 min. Slides were washed, mounted and viewed with an

Olympus IX71 inverted fluorescence microscope (Olympus America, Melville, NY). Images from microscope were recorded by Olympus digital camera using Olympus MagnaFire software.

Analysis of gene expression

Total RNA was isolated from cells using TRI[®] reagent (Molecular Research Center, Cincinnati, OH) according to the manufacturer's protocol. Reverse-transcriptase polymerase chain reaction (RT-PCR) was used to analyze the expression of mRNA for TNF α and β -actin as internal control [33]. The amplification products were fractionated on ethidium bromide containing 2% agarose gel and documented using a Kodak DC290 digital camera and digitized using UN-SCAN-IT software (Silk Scientific, Orem, UT).

Statistical analysis

The studies were repeated 2-3 times, each time with 3-4 replicates, with similar results. Data from these experiments were analyzed by two-way analysis of variance (ANOVA) followed by Duncan's multiple range test. Results are presented as mean \pm standard error (SE). All tests were performed using an SAS computer program (SAS Institute, Cary, NC). The level of $p \leq 0.05$ was considered statistically significant.

RESULTS

Fumonisin B₁ induced apoptosis in primary cultures of mice hepatocytes

Treatment of various cultures with 20 μ M fumonisin B₁ for 48 h resulted in increased apoptosis in the primary culture of mice hepatocytes, measured by recording the fluorescence

of Hoechst 33258 dye (Fig. 5.1). Isolated hepatocytes, NPCs or co-culture were equally sensitive to fumonisin B₁ induced apoptosis. To confirm apoptosis, cells were visualized under Olympus IX71 inverted fluorescence microscope (Olympus America, Melville, NY), which confirmed the presence of increased number of apoptotic cells exhibiting bright green staining of Annexin V upon treatment with fumonisin B₁ (Fig. 5.2). To detect the presence of NPCs in the primary culture, cells were stained with fluorescein conjugated Thy-1.2 (CD90.2) antibody (Southern Biotech, Birmingham, AL), which indicated that Thy 1.2 surface antigen bearing mature T cells were isolated with the parenchymatous cells (Fig. 5.3).

Fumonisin B₁-induced accumulation of sphingolipids

Intracellular levels of sphinganine and sphingosine were increased in hepatocytes exposed to 20 μM fumonisin B₁ for 24 h. Over the 48 h incubation period with fumonisin B₁, sphingosine and sphinganine concentrations decreased compared to 24 h fumonisin B₁ treatment (Figure 4).

Role of activated JNK in fumonisin B₁ induced apoptosis

To examine the relationship between fumonisin B₁ induced JNK activation and apoptosis, we employed the JNK inhibitor anthra-pyrazolone (SP600125) [34]. Primary hepatocyte cultures were incubated with different doses of fumonisin B₁ in the absence or presence of 20 μM SP600125 and assayed for apoptosis by measuring the fluorescence of Hoechst 33258. Hoechst 33258 fluorescence was similar in SP600125-treated or control cultures, but it significantly decreased in cultures, treated with 10 μM or higher concentrations of fumonisin B₁ in the presence of SP600125 compared to cultures treated with fumonisin B₁ only (Fig. 5.5).

Activation of JNK in fumonisin B₁ treated primary hepatocytes

To investigate whether fumonisin B₁ alters activity of phosphorylated JNK and total JNK, the cell lysates were examined by Western blots. In mice primary hepatocyte cultures, the levels of phosphorylated forms of p46 (JNK1) and p 54 (JNK2) increased after 24 h treatment with 20 μM fumonisin B₁ (Fig. 5.6). Total JNK levels also increased upon treatment with fumonisin B₁ for 24 h (Fig. 5.6).

Fumonisin B₁ induced apoptosis is inhibited by anti-TNFα

In fumonisin B₁ sensitive cell lines or *in vivo* experiments, increased production of TNFα and IFNγ has been implicated in fumonisin B₁ toxicity. To evaluate the role of these cytokines in fumonisin B₁ mediated apoptosis in primary hepatocyte culture; we measured the induction of apoptosis in the presence of neutralizing antibodies for TNFα and IFNγ. Results indicated that elevation of Hoechst 33258 fluorescence by fumonisin B₁ was reduced in cultures treated with anti-TNFα and but not by anti-IFNγ alone. The combination of anti-TNFα and IFNγ did not provide additional protection (Fig. 5.7).

Inhibition of JNK activation by anti-TNFα

To delineate the role of JNK in fumonisin B₁-activated signaling pathways, we examined the phosphorylation JNK in primary hepatocyte cultures in the presence of anti-TNFα. The immunoblot with phosphorylated form of JNK specific antibody revealed that presence of anti TNFα significantly reduced fumonisin B₁-induced JNK activation (Fig. 5.8). Similarly, the fumonisin B₁ -mediated increase in total JNK was also inhibited by anti-TNFα but not

significantly and the total JNK in the presence of anti-TNF α was not significantly different between control and fumonisin B₁-treated cultures (Fig. 5.8).

JNK inhibitor does not influence TNF α expression

To establish that JNK modulation was downstream of TNF α induction by fumonisin B₁, the relationship of JNK activation and TNF α production was examined by measuring the expression of TNF α in primary hepatocyte culture in the presence of 20 μ M JNK inhibitor SP600125. Expression of TNF α was increased with fumonisin B₁ treatment of primary hepatocyte culture for 24 h and inhibition of JNK did not change such induction in TNF α expression suggesting that production of TNF α is not a consequence of JNK activation (Fig. 5.9).

DISCUSSION

Fumonisin B₁ causes *in vivo* hepatotoxicity in rats and mice. We previously reported that mice injected with different doses of fumonisin B₁ exhibited dose related apoptosis in hepatocytes [3]. Hepatopathy in mice in another study was described as presence of small, round to slightly ovoid cells separated from neighboring cells with condensed chromatin; features consistent with apoptosis [4]. Increase in the activity of hepatic enzymes, a marker for hepatotoxicity has been a regular feature of fumonisin B₁ toxicity in mice but not in rats [35]. Liver is the primary site of fumonisin B₁ toxicity in male mice, whereas in rats nephrotoxicity appears to predominate [3].

In this study, we found that fumonisin B₁ induces apoptosis in primary culture of mouse liver cells, which is consistent with other *in vivo* studies. Earlier we reported that fumonisin B₁ is more toxic to non-parenchymatous cells in a coculture of macrophage and non-parenchymatous epithelial cells (NPECs) due to interaction of different cytokines produced by them [33]. In this study the ability of fumonisin B₁ to induce apoptosis in isolated hepatocytes, NPCs or their coculture was similar. However, the separation procedure does not allow removal of lymphocytes from the hepatocytes as we noted the presence of lymphocytes in hepatocyte cultures and no additive effect on cytotoxicity of fumonisin B₁ in co-culture further confirms that lymphocytes may be integral for fumonisin B₁-mediated apoptosis in parenchymal cells.

There is increasing evidence that sphingolipids play a key role in fumonisin B₁ toxicity by modulating numerous intracellular pathways controlling differentiation, growth, and apoptosis [36]. Fumonisin B₁ induced hepatotoxicity in several strains of mice or with different doses of fumonisin B₁, has been shown to correlate well with intracellular accumulation of sphinganine and sphingosine [15]. In this study, fumonisin B₁ induced accumulation of sphinganine and sphingosine in primary mice hepatocyte culture during 24 hr treatment. After fumonisin B₁ treatment for 48 h, levels of sphingosine decreased to the baseline level i.e. same as in control group and level of sphinganine also decreased compared to the level at 24 h fumonisin B₁ treatment. Decrease in free sphingoid bases observed in fumonisin B₁-treated cells between 48 and 72 h was also reported earlier and may indicate the induction of sphinganine metabolism or down regulation of the *de novo* pathway [14].

Fumonisin B₁ exposure of primary hepatocytes for 24 h resulted in increased TNF α expression, which was consistent with our earlier studies, where peritoneal macrophages isolated from fumonisin B₁ treated mice produced increasing levels of TNF α when stimulated with bacterial lipopolysaccharide *in vitro*, and a macrophage cell line (J774A.1) treated with fumonisin B₁ also produced higher levels of TNF α after 24 h [2]. There is considerable evidence that TNF α signaling pathways play an important role in fumonisin B₁-induced hepatotoxicity. Fumonisin B₁ toxicity was reduced in mice lacking either TNF α receptor (TNFR) 1 or TNFR 2 [25,26]. The acute hematological effects of fumonisin B₁ were neutralized after pretreatment of mice with anti- TNF α [2]. It was reported that fumonisin B₁ toxicity was effectively prevented by inhibition of caspases, which are downstream of TNF α cellular signaling [37].

JNK is a member of the mitogen-activated protein (MAP) kinase family and is activated by a variety of extracellular stimuli through JNK kinases and multiple MAP kinase kinase kinases [38]. Activated JNK, phosphorylates and activates c-Jun, a component of the transcription factor AP-1 and many other targets as well [38]. Our results showed that fumonisin B₁ stimulated JNK activity as phosphorylated and total JNK both were increased in primary hepatocyte cultures after 24 h exposure of fumonisin B₁. SP600125, a specific JNK inhibitor decreased the extent of apoptosis by fumonisin B₁ indicating that fumonisin B₁ mediated activation of JNK was at least partly responsible for the induction of apoptosis in primary hepatocyte cultures.

There are only few reports indicating the role of MAPKs in fumonisin B₁ induced toxicity in mammalian cells [28,29,30]. A differential activation of JNK but not of ERK or p38 was reported on LLC-PK1 cells by fumonisin B₁ [32]. Recently, a decrease in ERK has been reported in LLC-PK1 cells at 24 h [29]. In our other studies, we have noticed the induction of both total and phosphorylated JNK in livers of fumonisin B₁-treated mice (unpublished data).

Fumonisin B₁ stimulated JNK activity is downstream of TNF α production, as fumonisin B₁ mediated activation of JNK was reduced by the presence of anti TNF α in the medium whereas presence of JNK inhibitor did not change the fumonisin B₁ induced TNF α expression in primary hepatocyte culture. The role of JNK activation in mediating the TNF receptor signaling is uncertain, ranging from being protective, irrelevant or pro-apoptotic, which depends on the stimuli and cell types [39]. However, there is strong evidence indicating that JNK activation could increase TNF α -induced apoptosis in hepatocytes [40,41]. JNK-mediated apoptosis in hepatocytes was shown to involve mitochondrial permeability transition, release of cytochrome c and activation of caspase-3, -8 and -7, suggesting that JNK acts upstream of the mitochondria [40]. A recent report provided strong evidence that JNK activation in TNF α signaling involves release of Smac/DIABLO from the mitochondria, but not cytochrome c [42]. The released Smac/DIABLO then disrupts the TRAF2-cIAP1 complex, relieving the inhibition imposed by TRAF2-cIAP1 on caspase 8 activation and induction of apoptosis [42]. TRAF2 also mediates the activation of the JNK pathway, as shown by JNK inhibition by TRAF2 Δ and in TRAF2 (-/-) mice [43].

Increases in hepatocellular oxidation stress such as those that occur with hepatic overexpression of cytochrome *P*-450 isoforms promoted TNF α mediated apoptosis in hepatocytes through increased activity of c-Jun NH₂-terminal kinase [44]. Overexpression of CYP2E1 sensitized hepatocyte to TNF α -mediated cell death despite increased levels of nuclear factor- κ B transcriptional activity and was associated with increased lipid peroxidation and glutathione(GSH) depletion [44]. Fumonisin B₁ was reported to increase induction of cytochrome p450 isoforms and cause peroxidation of membrane lipids in isolated rat liver nuclei as well as GSH depletion of in pig kidney cells [45,46,47]. GSH depletion is known to activate JNK through redox inhibition of glutathione S-transferase Pi, which normally binds to and inhibits stress kinases [48].

To our knowledge this is the first report that fumonisin B₁ can induce apoptosis in hepatocytes by involving JNK activation. TNF α production is upstream of JNK signaling and is responsible for fumonisin B₁-induced apoptosis in mice primary hepatocytes.

ACKNOWLEDGMENTS

Studies reported in this paper were supported in part by US Public Health Service grant No. ES09403 from the National Institute of Environmental Health Sciences and the Center for Academic Excellence in Toxicology at the University of Georgia.

REFERENCES

- [1] Riley RT, Norred WP, Bacon CW. Fungal Toxins in Foods - Recent Concerns. *Annu. Rev. Nutr.* 1993; 13:167-189.
- [2] Dugyala RR, Sharma RP, Tsunoda M, Riley RT. Tumor necrosis factor-alpha as a contributor in fumonisin B₁ toxicity. *J.Pharmacol.Exp.Ther.* 1998; 285:317-324.
- [3] Sharma RP, Dugyala RR, Voss KA. Demonstration of in-situ apoptosis in mouse liver and kidney after short-term repeated exposure to fumonisin B₁. *J.Comp Pathol.* 1997; 117:371-381.
- [4] Voss KA, Riley RT, Bacon CW, Chamberlain WJ, Norred WP. Subchronic toxic effects of *Fusarium moniliforme* and fumonisin B₁ in rats and mice. *Nat.Toxins* 1996; 4:16-23.
- [5] Marasas WF, Kellerman TS, Gelderblom WC, Coetzer JA, Thiel PG, van der Lugt JJ. Leukoencephalomalacia in a horse induced by fumonisin B₁ isolated from *Fusarium moniliforme*. *Onderstepoort J.Vet.Res.* 1988; 55:197-203.

- [6] Gelderblom WC, Abel S, Smuts CM, Marnewick J, Marasas WF, Lemmer ER, Ramljak D. Fumonisin-induced hepatocarcinogenesis: mechanisms related to cancer initiation and promotion. *Environ. Health Perspect.* 2001; 109 Suppl 2:291-300.
- [7] Sydenham EW, Thiel PG, Marasas WFO, Shephard GS, Vanschalkwyk DJ, Koch KR. Natural Occurrence of Some *Fusarium* Mycotoxins in Corn from Low and High Esophageal Cancer Prevalence Areas of the Transkei, Southern Africa. *J. Agric. Food Chem.* 1990; 38:1900-1903.
- [8] Ueno Y, Iijima K, Wang SD, Sugiura Y, Sekijima M, Tanaka T, Chen C, Yu SZ. Fumonisin as a possible contributory risk factor for primary liver cancer: a 3-year study of corn harvested in Haimen, China, by HPLC and ELISA. *Food Chem. Toxicol.* 1997; 35:1143-1150.
- [9] Sadler TW, Merrill AH, Stevens VL, Sullards MC, Wang E, Wang P. Prevention of fumonisin B₁ -induced neural tube defects by folic acid. *Teratology* 2002; 66:169-176.
- [10] Marasas WF, Riley RT, Hendricks KA, Stevens VL, Sadler TW, Gelineau-van Waes J, Missmer SA, Cabrera J, Torres O, Gelderblom WC, Allegood J, Martinez C, Maddox J, Miller JD, Starr L, Sullards MC, Roman AV, Voss KA, Wang E, Merrill AH, Jr. Fumonisin disrupt sphingolipid metabolism, folate transport, and neural tube development in embryo culture and in vivo: a potential risk factor for human neural tube defects among populations consuming fumonisin-contaminated maize. *J. Nutr.* 2004; 134:711-716.

- [11] Wang E, Norred WP, Bacon CW, Riley RT, Merrill AH, Jr. Inhibition of sphingolipid biosynthesis by fumonisins. Implications for diseases associated with *Fusarium moniliforme*. J.Biol.Chem. 1991; 266:14486-14490.
- [12] Merrill AH, Jr., van Echten G, Wang E, Sandhoff K. Fumonisin B₁ inhibits sphingosine (sphinganine) N-acyltransferase and de novo sphingolipid biosynthesis in cultured neurons in situ. J.Biol.Chem. 1993; 268:27299-27306.
- [13] Merrill AH, Jr. De novo sphingolipid biosynthesis: a necessary, but dangerous, pathway. J.Biol.Chem. 2002; 277:25843-25846.
- [14] Yoo HS, Norred WP, Showker J, Riley RT. Elevated sphingoid bases and complex sphingolipid depletion as contributing factors in fumonisin-induced cytotoxicity. Toxicol.Appl.Pharmacol. 1996; 138:211-218.
- [15] Tsunoda M, Sharma RP, Riley RT. Early fumonisin B₁ toxicity in relation to disrupted sphingolipid metabolism in male BALB/c mice. J.Biochem.Mol.Toxicol. 1998; 12:281-289.
- [16] Schmelz EM, Dombrink-Kurtzman MA, Roberts PC, Kozutsumi Y, Kawasaki T, Merrill AH, Jr. Induction of apoptosis by fumonisin B₁ in HT29 cells is mediated by the accumulation of endogenous free sphingoid bases. Toxicol.Appl.Pharmacol. 1998; 148:252-260.

- [17] Yoo HS, Norred WP, Wang E, Merrill AH, Jr., Riley RT. Fumonisin inhibition of de novo sphingolipid biosynthesis and cytotoxicity are correlated in LLC-PK1 cells. *Toxicol.Appl.Pharmacol.* 1992; 114:9-15.
- [18] Ciacci-Zanella JR, Merrill AH, Jr., Wang E, Jones C. Characterization of cell-cycle arrest by fumonisin B₁ in CV-1 cells. *Food Chem.Toxicol.* 1998; 36:791-804.
- [19] Bose R, Verheij M, Haimovitz-Friedman A, Scotto K, Fuks Z, Kolesnick R. Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals. *Cell* 1995; 82:405-414.
- [20] Sharma N, He Q, Sharma RP. Sphingosine kinase activity confers resistance to apoptosis by fumonisin B₁ in human embryonic kidney (HEK-293) cells. *Chem.Biol.Interact.* 2004; 151:33-42.
- [21] Norred WP, Voss KA, Riley RT, Plattner RD. Fumonisin toxicity and metabolism studies at the USDA. *Fumonisin toxicity and metabolism. Adv.Exp.Med.Biol.* 1996; 392:225-236.
- [22] Wang W, Jones C, Ciacci-Zanella J, Holt T, Gilchrist DG, Dickman MB. Fumonisin and *Alternaria alternata* lycopersici toxins: sphinganine analog mycotoxins induce apoptosis in monkey kidney cells. *Proc.Natl.Acad.Sci.U.S.A* 1996; 93:3461-3465.
- [23] He Q, Kim J, Sharma RP. Fumonisin B₁ hepatotoxicity in mice is attenuated by depletion of Kupffer cells by gadolinium chloride. *Toxicology* 2005; 207:137-147.

- [24] Bhandari N, Brown CC, Sharma RP. Fumonisin B₁-induced localized activation of cytokine network in mouse liver. *Food Chem.Toxicol.* 2002; 40:1483-1491
- [25] Sharma RP, Bhandari N, Riley RT, Voss KA, Meredith FI. Tolerance to fumonisin toxicity in a mouse strain lacking the P75 tumor necrosis factor receptor. *Toxicology* 2000; 143:183-194.
- [26] Sharma RP, Bhandari N, He Q, Riley RT, Voss KA. Decreased fumonisin hepatotoxicity in mice with a targeted deletion of tumor necrosis factor receptor 1. *Toxicology* 2001; 159:69-79.
- [27] Sharma RP, He Q, Johnson VJ. Deletion of IFN-gamma reduces fumonisin-induced hepatotoxicity in mice via alterations in inflammatory cytokines and apoptotic factors. *J.Interferon Cytokine Res.* 2003; 23:13-23.
- [28] Pinelli E, Poux N, Garren L, Pipy B, Castegnaro M, Miller DJ, Pfohl-Leszkowicz A. Activation of mitogen-activated protein kinase by fumonisin B₁ stimulates cPLA(2) phosphorylation, the arachidonic acid cascade and cAMP production. *Carcinogenesis* 1999; 20:1683-1688.
- [29] Rentz SS, Showker JL, Meredith FI, Riley RT. Inhibition of sphingolipid biosynthesis decreases phosphorylated ERK2 in LLC-PK1 cells. *Food Chem.Toxicol.* 2005; 43:123-131.

- [30] Wattenberg EV, Badria FA, Shier WT. Activation of mitogen-activated protein kinase by the carcinogenic mycotoxin fumonisin B₁. *Biochem.Biophys.Res.Commun.* 1996; 227:622-627.
- [31] Howard RB, Pesch LA. Respiratory activity of intact, isolated parenchymal cells from rat liver. *J.Biol.Chem.* 1968; 243:3105-3109.
- [32] Johnson VJ, He Q, Kim SH, Kanti A, Sharma RP. Increased susceptibility of renal epithelial cells to TNFalpha-induced apoptosis following treatment with fumonisin B₁. *Chem.Biol.Interact.* 2003; 145:297-309.
- [33] Sharma N, He Q, Sharma RP. Augmented fumonisin B₁ toxicity in co-cultures: evidence for crosstalk between macrophages and non-parenchymatous liver epithelial cells involving proinflammatory cytokines. *Toxicology* 2004; 203:239-251.
- [34] Han Z, Boyle DL, Chang L, Bennett B, Karin M, Yang L, Manning AM, Firestein GS. c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. *J.Clin.Invest* 2001; 108:73-81.
- [35] Lim CW, Parker HM, Vesonder RF, Haschek WM. Intravenous fumonisin B₁ induces cell proliferation and apoptosis in the rat. *Nat.Toxins* 1996; 4:34-41.
- [32] Merrill AH, Jr., Sullards MC, Wang E, Voss KA, Riley RT. Sphingolipid metabolism: roles in signal transduction and disruption by fumonisins. *Environ.Health Perspect.* 2001; 109 (2):283-289.

- [37] Jones C, Ciacci-Zanella JR, Zhang Y, Henderson G, Dickman M. Analysis of fumonisin B1-induced apoptosis. *Environ. Health Perspect.* 2001; 109 Suppl 2:315-320.
- [38] Chang L, Karin M. Mammalian MAP kinase signalling cascades. *Nature* 2001; 410:37-40.
- [39] Liu ZG. Adding facets to TNF signaling. The JNK angle. *Mol. Cell* 2003; 12:795-796.
- [40] Liu H, Lo CR, Czaja MJ. NF-kappaB inhibition sensitizes hepatocytes to TNF-induced apoptosis through a sustained activation of JNK and c-Jun. *Hepatology* 2002; 35:772-778.
- [41] Schwabe RF, Uchinami H, Qian T, Bennett BL, Lemasters JJ, Brenner DA. Differential requirement for c-Jun NH2-terminal kinase in TNFalpha- and Fas-mediated apoptosis in hepatocytes. *FASEB J.* 2004; 18:720-722.
- [42] Deng Y, Ren X, Yang L, Lin Y, Wu X. A JNK-dependent pathway is required for TNFalpha-induced apoptosis. *Cell* 2003; 115:61-70.
- [43] Natoli G, Costanzo A, Ianni A, Templeton DJ, Woodgett JR, Balsano C, Levrero M. Activation of SAPK/JNK by TNF receptor 1 through a noncytotoxic TRAF2-dependent pathway. *Science* 1997; 275:200-203.
- [44] Liu H, Jones BE, Bradham C, Czaja MJ. Increased cytochrome P-450 2E1 expression sensitizes hepatocytes to c-Jun-mediated cell death from TNF-alpha. *Am. J. Physiol Gastrointest. Liver Physiol* 2002; 282:G257-G266.

- [45] Martinez-Larranaga MR, Anadon A, Diaz MJ, Fernandez R, Sevil B, Fernandez-Cruz ML, Fernandez MC, Martinez MA, Anton R. Induction of cytochrome P4501A1 and P4504A1 activities and peroxisomal proliferation by fumonisin B₁. *Toxicol. Appl. Pharmacol.* 1996; 141:185-194.
- [46] Kang YJ, Alexander JM. Alterations of the glutathione redox cycle status in fumonisin B₁-treated pig kidney cells. *J. Biochem. Toxicol.* 1996; 11:121-126.
- [47] Sahu SC, Eppley RM, Page SW, Gray GC, Barton CN, O'Donnell MW. Peroxidation of membrane lipids and oxidative DNA damage by fumonisin B₁ in isolated rat liver nuclei. *Cancer Lett.* 1998; 125:117-121.
- [48] Adler V, Yin Z, Fuchs SY, Benezra M, Rosario L, Tew KD, Pincus MR, Sardana M, Henderson CJ, Wolf CR, Davis RJ, Ronai Z. Regulation of JNK signaling by GSTp. *EMBO J.* 1999; 18:1321-1334.




Fig. 5.1 Fumonisin B₁ induced apoptosis in primary culture of liver cells. Treatment of isolated hepatocytes (a), nonparenchymal cells (b) and co-culture of hepatocytes and NPCs with 20 μM fumonisin B₁ for 48 h resulted in increased apoptosis compared to untreated cultures. For individual cultures, cells were plated in 96 well plates at 4×10^4 cells/well. For co-culture, cells were mixed in a ratio of 1 (NPCs) : 7 (hepatocytes) i.e. 5×10^3 NPCs and 35×10^3 hepatocytes. At the end of treatment, cells were incubated with Hoechst 33258 dye for 10 min and fluorescence intensity was recorded by microplate spectrofluorometer at 346/460 nm. Relative fluorescence units are arbitrarily defined based on fluorescence recorded at 346/460 nm. Similar findings were noted in 3 independent experiments. Results are expressed as mean \pm S.E. of 3 independent experiments. Asterisks on bars indicate significantly different value ($p < 0.05$) from the control.




Fig. 5.2 Primary hepatocyte cultures were treated with 20 μM fumonisin B₁ for 48 h and examined using annexin V dye under phase contrast or fluorescence microscope. Annexin V binds with exposed phosphatidyl serine on the surface of apoptotic cells and imparts on the cell surface a bright green staining. Hepatocyte culture treated with fumonisin B₁ had greater number of cells stained with Annexin V compared to control. Bar on lower left represents 10 μm .




Fig. 5.3 Culture of primary liver cells was stained by fluorescense-conjugated antibody against mice Thy 1.2 antigen on the surface of mature T cells. Green stained Thy 1.2 bearing cells in the right panel confirms the presence of mature T cells in the liver parenchymatous cell culture. Bar on lower left represents 10 μm .




Fig. 5.4 Concentrations of free sphinganine and sphingosine after exposure of hepatocytes to 20 μM fumonisin B₁ for 24 h (A and C) or 48 h (B and D). Mean ± SE (n= 3). Asterisks on bars indicate significantly different value ($p < 0.05$) from the concurrent control.




Fig. 5.5 Inhibition of fumonisin B₁ mediated apoptosis by JNK inhibitor (SP600125). Hepatocytes were pre-treated with 20 μM SP600125 for 30 min and then exposed to different concentrations of fumonisin B₁ for 48 h. The intensity of Hoechst 33258 fluorescence after fumonisin B₁ exposure was read by microplate spectrofluorometer. Relative arbitrarily fluorescence units are indicated at excitation/emission of 346/460 nm. Mean ± SE of 3 independent experiments. Asterisks on bars indicate a significant difference from the control ($p < 0.05$).




Fig. 5.6 Effect of fumonisin B₁ treatment on phosphorylation of JNK and expression of total JNK. Primary culture of hepatocytes were exposed to 20 μM fumonisin B₁ for 24 h. Cell lysates were analyzed by western blot to detect the p-JNK and total JNK (p54 and p46). Mean ± SE (n= 3). Asterisks on bars indicate a significant difference from the control $p < 0.05$.




Fig. 5.7 Effect of anti-TNF α and anti-IFN γ on fumonisin B₁ mediated apoptosis. Hepatocytes were treated with 20 μ M fumonisin B₁ in the presence of neutralizing antibodies for TNF α (1 μ g/ml) or/and IFN γ (1 μ g/ml) for 48 h. At the end of treatment, cells were incubated with Hoechst 33258 dye for 10 min and fluorescence intensity was recorded by fluorescent plate reader at 346/460 nm. Relative arbitrarily fluorescence units are indicated at excitation/emission of 346/460 nm. Mean \pm SE of 3 independent experiments. Asterisks on bars indicates significantly different value ($p < 0.05$) from the control. Letter “a” on bars indicates a significant decrease from the fumonisin B₁ treated group ($p < 0.05$).




Fig. 5.8 Effect of fumonisin B₁ treatment on phosphorylation of JNK and expression of total JNK in the presence of neutralizing antibodies for TNFα. Primary culture of hepatocytes were exposed to 20 μM fumonisin B₁ and TNFα (1 μg/ml) for 24 h. Cell lysates were analyzed by western blot to detect the p-JNK and total JNK (p54 and p46). Mean ± SE (n= 3). Asterisks on bars indicate a significant difference from the control $p < 0.05$.




Fig. 5.9 Effect of JNK inhibitor (JNKI) on fumonisin B₁ induced expression of TNF α . Cultures of primary hepatocytes were treated with 20 μ M fumonisin B₁ in the presence of 20 μ M SP600125 for 24 h. Expression of specific mRNA was quantified by RT-PCR and normalized to that of β -actin in the same sample. Mean \pm SE of 3 independent experiments. Asterisks on bars indicates significantly different value ($p < 0.05$) from the control.

CHAPTER 6

**AMELIORATION OF FUMONISIN B₁ HEPATOTOXICITY IN MICE BY
DEPLETION OF T CELLS WITH ANTI-THY1.2¹**

¹Sharma N., He Q., and Sharma R.P. 2005. Submitted to *Toxicological Sciences*

ABSTRACT

Fumonisin B₁ is a mycotoxin produced by *Fusarium verticillioides*, frequently associated with corn. It produces hepatic or renal damage in most animal species. Our previous studies indicated that fumonisin B₁ caused localized activation of cytokines in liver. In the current study, male athymic nude mice and their wild type counterparts (WT) with or without depletion of T cells were treated subcutaneously with fumonisin B₁ at 2.25 mg/kg/day for 5 days and sampled 24 h after the last injection. Depletion of T cells in WT was achieved by a single intravenous injection of 50 µg monoclonal antibody against Thy-1.2 surface antigen of mature peripheral T lymphocytes 24 h before the first fumonisin B₁ treatment. The fumonisin B₁-induced elevation in activities of circulating liver enzymes were not different between WT and nude mice, while depletion of T cells nearly abolished fumonisin B₁-mediated liver toxicity, indicated both by concentrations of circulating liver enzymes and enumeration of apoptotic hepatocytes. Since all the fumonisin B₁-treated groups had similar extent of hepatic sphinganine accumulation, the reduced toxicity of fumonisin B₁ in T cell-depleted mice was unrelated to its effect on sphinganine accumulation. Expression of fumonisin B₁-induced tumor necrosis factor α and interleukin-1 was observed in nude and WT mice but not in T cell-depleted mice. This study suggested that T cells and corresponding proinflammatory cytokines have a vital role in mediating fumonisin B₁-induced hepatic toxicity.

Key words: Fumonisin B₁; hepatotoxicity; CD90.2 T cells; tumor necrosis factor α ; interferon γ ; anti-Thy 1.2

INTRODUCTION

Fumonisin B₁ is a mycotoxin produced by *Fusarium verticillioides* and related species, commonly found in corn. The toxicity of fumonisin B₁ has been described in a number of farm and laboratory animals and depends on different factors such as animal species, gender, age, dose and route of administration (Diaz and Boermans, 1994). It has been established as a cause of equine leukoencephalomalacia and porcine pulmonary edema. Fumonisin B₁ has been shown to be hepatotoxic and nephrotoxic in mice and rats. The National Toxicology Program study reported renal carcinoma in male Fischer rats and hepatic cancer in female B6C3F mice (Howard *et al.*, 2001). In the Transkei region of South Africa where incidence of esophageal cancer is high, an association between fumonisin B₁ consumption and esophageal cancer was reported (Sydenham *et al.*, 1990). International Agency for Research on Cancer (1992) classified fumonisin B₁ as a Group 2B carcinogen, i.e., possibly carcinogenic to humans.

Fumonisin B₁ is structurally similar to sphingoid bases and causes inhibition of ceramide synthase (sphinganine or sphingosine *N*-acyltransferase) leading to accumulation of free sphingoid bases, sphingoid base metabolites, and depletion of more complex sphingolipids (Riley *et al.*, 1996). Studies in pig renal epithelial cells (LLC-PK₁) and human colonic cells (HT29) have shown that fumonisin B₁-induced apoptosis, necrosis, and inhibition of proliferation are sphinganine dependent (Merrill *et al.*, 2001). There is a close association between increased apoptosis in liver and kidney and the disruption of sphingolipid metabolism (Tsunoda *et al.*, 1998).

Fumonisin B₁ treatment caused an increased expression of tumor necrosis factor α (TNF α), interferon γ (IFN γ) and interleukin (IL)-12, in liver, where cells involved in TNF production were identified as Kupffer cells (Bhandari *et al.*, 2002). Increase of proinflammatory cytokines from immune cells has been implicated in fumonisin B₁-induced hepatotoxicity. Depletion of Kupffer cells by gadolinium chloride attenuated fumonisin B₁ induced hepatotoxicity (He *et al.*, 2005). Deletion of tumor necrosis factor receptors 1 and 2 and interferon γ genes reduced fumonisin B₁-induced hepatotoxicity in mice (Sharma *et al.*, 2001, 2003).

The role of inflammatory cytokines in the initiation and development of liver toxicity has been well documented. Liver associated immune cells such as lymphocytes, Kupffer cells and their cytokine products; especially TNF and IFN are involved in liver injury during alcoholic hepatitis (Batey and Wang, 2002). TNF α and IL-1 α are responsible for certain pathological manifestation of acetaminophen induced hepatotoxicity in mice (Blazka *et al.*, 1995). IFN γ and TNF α released from T lymphocytes and macrophages, respectively, are involved in concanavalin A (Con A)-induced hepatitis and in liver toxicity in response to repeated challenges of lipopolysaccharide (Wolf *et al.*, 2001).

Reports on the effects of fumonisin B₁ on the immune system are conflicting. Fumonisin- B₁ was found to be both immunosuppressive and immunostimulatory in BALB/c mice, depending on the dose administered and induced an antigenic response (Martinova and Merrill, 1995). Fumonisin B₁ was shown to alter the expression of the CD3 receptor, which is

integral to T lymphocyte activation. Gavage studies in mice indicated no changes in myeloid, erythroid or other cell types in bone marrow or total circulating immunoglobulin levels (Bondy *et al.*, 1997). Recently Taranu *et al.* (2005) reported that ingestion of fumonisin B₁ alters the Th1/Th2 balance leading to reduced vaccinal antibody response in pigs.

Despite many reports confirming the role of proinflammatory cytokines in fumonisin B₁ induced liver damage, little is known about the contribution of T cells in this regard. We hypothesized that fumonisin B₁ hepatotoxicity in mice will be compromised by depletion of T cells. Athymic nude mice are deficient in T cells; therefore in the current study we employed nude mice and their immunocompetent wild-type counterparts in this investigation. Depletion of T cells in wild-type mice was accomplished by injecting monoclonal antibodies directed against Thy-1.2 surface antigens; this approach has become an established method to investigate the T cell functions in mice (Opitz *et al.*, 1982). The objective of this study was to investigate the role of T cells in fumonisin B₁-induced hepatotoxicity in immunocompetent mice by depleting T cells and comparing it with immunodeficient athymic nude mice.

MATERIALS AND METHODS

Animals

Seven-week-old male athymic nude mice (Hsd:nu/nu, stock #6904M) and their wild-type (WT) counterparts (Hsd:nu/+, stock #7004M) were obtained from Harlan Laboratories

(Indianapolis, IN). The nu/+ mice are heterozygous between nude and normal mice and are fully immunocompetent; these were used as controls (henceforth referred to as WT) as our aim was to compare their response to fumonisin B₁ with corresponding immunodeficient nude mice. The mice were acclimated for 1 week before dosing under environmental conditions at 23°C and 65% relative humidity with a 12-h light/dark cycle. Animals had free access to fumonisin free feed and water at their own discretion. All experiments were conducted according to the Public Health Service Policy on Humane Care and Use of Laboratory Animals and protocols were approved by the Institutional Animal Care and Use Committee.

Treatments

Animals were randomly divided in four groups of WT mice and two groups of nude mice (5 mice per group). Two groups of WT mice received intravenous injections of 50 µg monoclonal anti-mouse Thy-1.2 (CD90.2) antibody (Southern Biotech, Birmingham, AL) per mouse 24 h before the first fumonisin B₁ treatment; these mice from now on are referred as T cell-depleted (TCD) mice. Dose of antibody to achieve depletion of T cells was selected based on previous studies and modified for the purity of the product and route of administration (Opitz *et al.*, 1982; Tiegs *et al.*, 1992). One group each of WT, TCD and nude mice were treated with five daily subcutaneous injections of either phosphate-buffered saline (PBS) or 2.25 mg/kg/day of fumonisin B₁ (> 98% purity, from Programme on Mycotoxins and Experimental Carcinogenesis, Tygerberg, South Africa) in PBS. The dose of fumonisin B₁ and duration of treatment was based on our previous studies in which it produced a consistent hepatotoxic damage in male mice (Sharma *et al.*, 2001, 2003).

Twenty four hours after the fifth and final injection, mice were euthanized by halothane and blood was drawn by heart puncture in heparinized tubes for hematological evaluation; plasma was isolated for determination of alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Activities of plasma ALT and AST were determined using a Hitachi 912 Automatic Analyzer (Roche Diagnostics, Indianapolis, IN).

Total white and red cells in blood were counted using an electronic counter (Coulter Electronics Inc., Hialeah, FL). Liver, kidney and spleen were removed, weighed, and aliquots of liver were fixed immediately in neutral 10% formalin or quickly frozen in liquid nitrogen and stored at -85°C until analysis.

Determination of apoptosis in liver

Liver sections (5 μm) were prepared from formalin-fixed paraffinized liver samples and subjected to terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end labeling (TUNEL) with a peroxidase-based *in situ* Cell Death Detection kit (Roche Diagnostics, Indianapolis, IN) as described previously (Sharma *et al.*, 2003). The stained apoptotic cells were normalized to the unit area.

Detection of Thy-1.2 bearing T cells in liver

Frozen sections (5 μM) were thawed in the presence of 10% normal horse serum in PBS and blocked for 1 h. Sections were incubated overnight with 1:100 dilution of anti-mouse Thy-1.2 antibody in a humidified chamber at 4°C , then washed with PBS and incubated with peroxidase-labeled anti-mouse immunoglobulin G for 1 h. After washing with PBS, the

sections were stained with 3,3-diaminobenzidine and counterstained with hematoxylin and eosin.

Analyses of sphingolipids

Levels of free sphinganine and sphingosine in hepatic tissues were determined after base treatment of lipid extracts by high performance liquid chromatography according to the methods reported previously (Tsunoda *et al.* 1998). The concentration of sphingoid bases, sphinganine and sphingosine, was quantified based on the recovery of the C₂₀-sphinganine (D-erythro-C₂₀-dihydro-sphingosine; Matreya, Pleasant Gap, PA) as the internal standard.

RNA isolation and ribonuclease protection assay (RPA)

Total RNA from liver tissue was isolated using TRI[®] reagent (Molecular Research Center, Cincinnati, OH) and used for RPA using RiboQuant TM RPA starter kit (BD Biosciences, San Diego, CA), as described earlier (Sharma *et al.*, 2003). High specific activity $\alpha^{32}\text{P}$ -UTP-labeled anti-sense RNA probes were synthesized using T7 RNA polymerase in vitro transcription kit according to the manufacturer's protocol (BD Biosciences, San Diego, CA). The synthesized probes were hybridized with 50 μg RNA overnight at 65°C and digested with RNase A and RNase T1, followed by treatment with protease K. The RNase-protected products were purified and resolved on gels containing 5% polyacrylamide/7 M urea. The $\alpha^{32}\text{P}$ labeled bands were exposed to an FX Imaging Screen K-HD[®] (Bio-Rad Laboratories, Hercules, CA) for 6–24 h and scanned by Bio-Rad Molecular Imager[®]FX. The relative gene expression was digitized using the Quantity one[®]software (Bio-Rad Laboratories)

Statistics

Data from these experiments were analyzed by two-way analysis of variance (ANOVA) followed by Duncan's multiple range test. Results are presented as mean \pm standard error (SE). All tests were performed using an SAS computer program (SAS Institute, Cary, NC). The level of $p \leq 0.05$ was considered statistically significant.

RESULTS

Depletion of T cells reduced FB₁-induced hepatotoxicity

After 5 days of treatment with fumonisin B₁, body and kidney weight were significantly reduced in WT mice and liver weight significantly increased in nude mice; in all other groups there were no significant differences in body, liver kidney or spleen weights related to fumonisin B₁ treatment (Table. 6.1). No differences were observed for food and water intake in any of the experimental groups (data not shown). Fumonisin B₁ treatment of WT mice caused a marked increase in plasma ALT and AST activities, 32-fold and 14-fold, respectively, compared to corresponding saline-treated WT group (Fig. 6.1). The fumonisin B₁-induced elevation of ALT and AST activity was not observed in TCD mice. Plasma ALT and AST activities increased in fumonisin B₁-treated nude mice to a similar extent as in WT mice, indicating that nude mice had no protection against fumonisin B₁ hepatotoxicity.

Depletion of T cells diminished fumonisin B₁-induced hepatocyte apoptosis

Histological observations were consistent with plasma ALT and AST findings, i.e., after treatment with fumonisin B₁ the WT mice had a number of TUNEL-positive cells in liver (Fig. 6.2). No apoptotic cells were seen in any of the saline-treated groups. The occurrence of TUNEL-positive cells was not observed in the TCD mice (pretreated with anti-Thy-1.2 antibody). The athymic nude mice were susceptible to hepatotoxic effects of fumonisin B₁ similar to WT mice, as evident by the presence of apoptotic cells after fumonisin B₁ treatment.

Injection of antibody against Thy1.2 antigen depleted T cells in WT mice

Treatment of WT mice with the monoclonal Thy-1.2 antibody resulted in reduction of peripheral leukocyte count to nearly half of the WT mice, measured 7 days after the intravenous injection of the antibody (Fig. 6.3a). Athymic nude mice also had a lower white blood count compared to WT mice. No effect of antibody injection or fumonisin B₁ treatment was observed on peripheral red blood cell counts in any group (data not presented). Since athymic nude mice were sensitive to fumonisin B₁ hepatotoxicity, we examined the presence of T cells in their livers by immunochemical staining of Thy-1.2 antigen bearing cells. Results indicated moderate staining of T cells in WT or nude mice but no staining in TCD mice, further confirming a nearly total depletion of T cells by anti-Thy-1.2 antibody, and suggesting the presence of residual Thy-1.2 antigen-bearing cells in livers of nude mice (Fig. 6.3b-d).

Fumonisin B₁-induced accumulation of free sphingoid bases is not affected by T cell depletion.

Concentrations of the free sphingoid bases, sphingosine and sphinganine, in liver with or without the fumonisin B₁ treatment of different groups are shown in Fig. 6.4. Fumonisin B₁

treatment increased the levels of free sphinganine and sphingosine to the same extent in livers of WT or TCD mice. The concentration of sphinganine in the liver of fumonisin B₁-treated nude mice was somewhat higher than that observed in fumonisin B₁-treated WT mice; however, the difference was not statistically significant (Fig. 6.4).

T cell depletion decreased the expression of proinflammatory cytokines after fumonisin B₁ treatment

It has been established that fumonisin B₁ causes localized activation of proinflammatory cytokines in mice liver produced by Kupffer cells, T cells, NK cells or epithelial cells. In the current study fumonisin B₁ induced the expression of cytokines produced by helper T (Th1) lymphocytes such as IL-2, IFN γ , lymphotoxin β (LT- β) in both WT and nude mice (Fig. 6.5). The cytokines produced by Kupffer cells or natural killer T cells, e.g., TNF α , IL-1 α , IL-1 β , IL-6 and interleukin-1 receptor antagonist (IL-1Ra), were also increased in these groups (Figs 6.5, 6.6). Such effect of fumonisin B₁-induced expression of cytokines produced by both T cells and Kupffer cells was not observed in TCD mice (Fig. 6.5 and 6.6).

DISCUSSION

Our results showed that in vivo depletion of T cells by antibodies directed against the Thy-1.2 surface antigen of T lymphocytes protected mice from fumonisin B₁-induced liver damage. Induction of an immune deficient state in experimental animals by anti-lymphocyte

antibodies has been intensively studied. Opitz *et al.* (1982) showed that within 8 h after administration of Thy-1.2 antibody helper function of T cells *in vivo* was decreased and reached to undetectable level within 24 h. No Thy-1.2 bearing cells could be detected in the peripheral lymphoid organs by fluorescein-labeled antibody 24 h later. Antibody-coated Thy 1.2 bearing cells are rapidly phagocytized by macrophages and eliminated from tissues and circulation. Despite the fact that the anti-Thy 1.2 antibody induced a transient and complete immune deficient state, the animals tolerated this treatment without any clinical signs of adverse effects.

Fumonisin B₁-induced hepatotoxicity was not altered in athymic nude mice. This can be explained by the observation that residual functional T cells were present in livers of nude mice and their livers showed induced expression of proinflammatory cytokines after fumonisin B₁ treatment. Immunochemical evaluation employing anti-Thy-1.2 antibody confirmed the presence of T cells in the liver of nude mice. Others have also demonstrated the presence of functional T lymphocytes in athymic nude mice (Ikehara *et al.* 1984; Shimamura *et al.* 1997).

Participation of T cell in liver cell destruction is a common mechanism as shown for Con A (Tiegs *et al.* 1992) and *Pseudomonas* exotoxin (Schumann *et al.* 1998). In these models activation of T lymphocytes followed by Kupffer cell activation and subsequent induction of cytokines are critical factors in the development of hepatotoxicity. Lymphocytes can damage hepatocytes either by releasing TNF-related apoptosis-inducing ligand (TRAIL), as well as Fas ligand or by inducing production of proinflammatory cytokines. The Fas ligand is expressed in activated T cells and induces apoptosis in Fas-bearing hepatocytes, as described for alcohol-induced hepatitis (Batey and Wang, 2002) and hepatitis caused by hepatitis B virus (Kondo *et*

al. 1997). Development of Con A-induced hepatitis was reduced significantly in IFN γ knockout mice, suggesting a central role for cytokines produced by activated T cells (Streetz *et al.* 2001b).

Consistent with our previous studies (Bhandari and Sharma, 2002) we observed that expression of various proinflammatory genes such as TNF , IFN γ , IL-1 β , IL-1 , IL-6, and LT- β , were higher in fumonisin B₁ treated WT or nude mice compared to saline-treated animals. There is considerable evidence that cytokine signaling pathways play an important role in fumonisin B₁-induced hepatotoxicity in vitro and in vivo. Fumonisin B₁ toxicity was reduced in mice lacking either TNF receptor (TNFR) 1 or TNFR 2 (Sharma *et al.*, 2001). Jones *et al.* (2001) reported that fumonisin B₁ toxicity was effectively prevented by inhibition of caspases, which are downstream of TNF cellular signaling. Interaction of different types of cells in liver may amplify the cytokine production in response to fumonisin B₁ as reported by Bhandari *et al.* (2002) after treatment of mice with fumonisin B₁, and also demonstrated by interactions of macrophages and nonparenchymal epithelial cells in vitro (Sharma *et al.* 2004). The ultimate extent of liver injury in fumonisin B₁ hepatotoxicity may therefore involve the hepatic cytokine network rather than a single cytokine.

Several studies have demonstrated that fumonisin B₁ alters immune function in vivo by altering the production of the pro-inflammatory mediators. Nitric oxide (NO) production by peritoneal macrophages from mice fed with fumonisin B₁ and challenged with *Trypanosoma cruzi* was significantly higher than by peritoneal macrophages from control mice (Dresden *et al.* 2002). Fumonisin B₁ stimulated not only the basal production of NO by rat splenic macrophages but significantly potentiated the Con A, IL-2 and anti-T cell receptor induced

proliferation of lymphocytes (Dombrink-Kurtzman *et al.*, 2000). The immunoregulatory cytokines IL-2, IFN γ , and TNF α constitute the type 1 (Th1) cytokine response, whereas the cytokines IL-4, IL-5, IL-6, IL-8, IL-10, and IL-13 constitute the type 2 (Th2) cytokine response (Abbas *et al.* 1996). Taranu *et al.* (2005) have shown that fumonisin B₁ can alter the Th1/Th2 balance in pigs towards activation of Th1 cytokines such as IFN and reduction of Th2 cytokines such as IL-4.

At microscopic level minimal or absent inflammatory response has been reported in fumonisin B₁-treated mice livers; however, it is possible that cytokines released by activated T cells in the liver sinusoid may reach Kupffer cells in the periportal area and surrounding hepatocytes by diffusion through fenestrae without involving the infiltration of immune cells. Liver sinusoidal endothelial cells pose a barrier for T cells and widespread T cell infiltration into the parenchyma is only observed in acute (viral) hepatitis. Streetz *et al.* (2001) showed that in Con A induced hepatitis TNF and IFN γ production does not contribute to influx of immune activated cells into the liver. It appears that activation of helper T cells is predominantly responsible for the induction of cytokine network as depletion of Kupffer cells by gadolinium chloride did not prevent fumonisin B₁-induced induction of various inflammatory cytokines (He *et al.*, 2005).

The role of cytokines in toxicant-induced hepatic injury has been established (Luster *et al.*, 2001). TNF α induced apoptosis primarily depends on the recruitment of a complex of adapter proteins, including TNF receptor-associated death domain (TRADD) and Fas-associated death domain (FADD) leading to the further activation of various caspases (Baud and Karin, 2001). Fas, TNF-related apoptosis-inducing ligand (TRAIL) and TNF receptors

(TNFR) can initiate cell death by two alternative pathways, one relying on caspase-8 and the other dependent on the kinase receptor interacting protein (RIP, Holler *et al.* 2000). IFN γ induced apoptosis is mediated by interferon regulatory factor-1 either directly or by inducing the transcription of IL-1 β converting enzyme (Streetz *et al.* 2001).

There is increasing evidence that sphingolipids play a key role in fumonisin B₁ toxicity by modulating numerous intracellular pathways controlling differentiation, growth, and apoptosis (Merrill *et al.* 2001). Fumonisin B₁ induced hepatotoxicity in several strains of mice or with different doses of fumonisin B₁ has been shown to correlate well with intracellular accumulation of sphinganine and sphingosine (Tsunoda *et al.* 1998). In our study, sphinganine and sphingosine accumulated to the similar extent in control and TCD mice, which seems to indicate that, their accumulation is not related to the observed protection from fumonisin B₁-induced hepatotoxicity in TCD mice. It is likely that accumulation of sphingolipids is responsible for activation of T cells leading to the production of various cytokines. Since T cells are only a minor part of the cellular components of liver, their depletion may not result in any significant change in the overall liver sphingolipid concentration.

Fumonisin B₁ increased the accumulation of intracellular sphingosine 1-phosphate (S1P) by phosphorylation of sphingosine by sphingosine kinase (Smith and Merrill, 1995). Higher concentrations of intracellularly produced S1P increase IFN γ and IL-2 secretion in peripheral blood lymphocytes (Payne *et al.* 2004). Physiological concentrations of extracellular S1P are required for optimal activity of T cells (Graeler and Goetzl, 2002) and increase the response of T cells to chemokines by binding to the S1P receptor on T cells (Wang *et al.* 2004). Liver-associated lymphocyte population is very diverse and includes heterogeneous population of

cells such as CD4⁺ T cells, CD8⁺ T cells, natural killer T cells and a thymus independent natural killer (NK) cells (Doherty *et al.* 1999). Unlike Con A induced hepatotoxicity, fumonisin B₁-induced hepatotoxicity does not depend on NK cells as deletion of NK cells by induced mutation did not influence the fumonisin B₁-induced hepatotoxicity (Unpublished data).

Results obtained in this study indicate that T cell activation followed by production of proinflammatory cytokines is an important mechanism for fumonisin B₁-induced hepatotoxicity in mice.

ACKNOWLEDGMENTS

Studies reported in this paper were supported in part by US Public Health Service grant No. ES09403 from the National Institute of Environmental Health Sciences and the Center for Academic Excellence in Toxicology at the University of Georgia.

REFERENCES

- Abbas, A. K., Murphy, K. M., and Sher, A. (1996). Functional diversity of helper T lymphocytes. *Nature* **383**, 787-793.
- Batey, R. G. and Wang, J. (2002). Molecular pathogenesis of T lymphocyte-induced liver injury in alcoholic hepatitis. *Front Biosci.* **7**, d1662-d1675.
- Baud, V. and Karin, M. (2001). Signal transduction by tumor necrosis factor and its relatives. *Trends Cell Biol.* **11**, 372-377.

- Bhandari, N., Brown, C. C., and Sharma, R. P. (2002). Fumonisin B₁-induced localized activation of cytokine network in mouse liver. *Food Chem. Toxicol.* **40**, 1483-1491.
- Bhandari, N. and Sharma, R. P. (2002). Fumonisin B₁-induced alterations in cytokine expression and apoptosis signaling genes in mouse liver and kidney after an acute exposure. *Toxicology* **172**, 81-92.
- Blazka, M. E., Wilmer, J. L., Holladay, S. D., Wilson, R. E., and Luster, M. I. (1995). Role of proinflammatory cytokines in acetaminophen hepatotoxicity. *Toxicol. Appl. Pharmacol.* **133**, 43-52.
- Bondy, G. S., Suzuki, C. A., Fernie, S. M., Armstrong, C. L., Hierlihy, S. L., Savard, M. E., and Barker, M. G. (1997). Toxicity of fumonisin B₁ to B6C3F1 mice: a 14-day gavage study. *Food Chem. Toxicol.* **35**, 981-989.
- Diaz, G. J. and Boermans, H. J. (1994). Fumonisin toxicosis in domestic animals: a review. *Vet. Hum. Toxicol.* **36**, 548-555.
- Doherty, D. G., Norris, S., Madrigal-Estebas, L., McEntee, G., Traynor, O., Hegarty, J. E., and O'Farrelly, C. (1999). The human liver contains multiple populations of NK cells, T cells, and CD3⁺ CD56⁺ natural T cells with distinct cytotoxic activities and Th1, Th2, and Th0 cytokine secretion patterns. *J. Immunol.* **163**, 2314-2321.
- Dombrink-Kurtzman, M. A., Gomez-Flores, R., and Weber, R. J. (2000). Activation of rat splenic macrophage and lymphocyte functions by fumonisin B₁. *Immunopharmacology* **49**, 401-409.
- Dresden, O. C., Pittman, N. G., Enongene, E. N., Bacon, C. W., Riley, R. T., and Voss, K. A. (2002). Host resistance to *Trypanosoma cruzi* infection is enhanced in mice fed

- Fusarium verticillioides* (= *F. moniliforme*) culture material containing fumonisins. *Food Chem. Toxicol.* **40**, 1789-1798.
- Graeler, M. and Goetzl, E. J. (2002). Activation-regulated expression and chemotactic function of sphingosine 1-phosphate receptors in mouse splenic T cells. *FASEB J.* **16**, 1874-1878.
- He, Q., Kim, J., and Sharma, R. P. (2005). Fumonisin B₁ hepatotoxicity in mice is attenuated by depletion of Kupffer cells by gadolinium chloride. *Toxicology* **207**, 137-147.
- Holler, N., Zaru, R., Micheau, O., Thome, M., Attinger, A., Valitutti, S., Bodmer, J. L., Schneider, P., Seed, B., and Tschopp, J. (2000). Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. *Nat. Immunol.* **1**, 489-495.
- Howard, P. C., Eppley, R. M., Stack, M. E., Warbritton, A., Voss, K. A., Lorentzen, R. J., Kovach, R. M., and Bucci, T. J. (2001). Fumonisin B₁ carcinogenicity in a two-year feeding study using F344 rats and B6C3F1 mice. *Environ. Health Perspect.* **109 Suppl 2**, 277-282.
- Ikehara, S., Pahwa, R. N., Fernandes, G., Hansen, C. T., and Good, R. A. (1984). Functional T cells in athymic nude mice. *Proc. Natl. Acad. Sci. U.S.A* **81**, 886-888.
- International Agency for research on Cancer (1992). Fumonicin B₁. IARC Monograph on the Evaluation of carcinogenic Risks to Humans. IARC 822: 301-366.
- Jones, C., Ciacci-Zanella, J. R., Zhang, Y., Henderson, G., and Dickman, M. (2001). Analysis of fumonisin B₁-induced apoptosis. *Environ. Health Perspect.* **109 Suppl 2**, 315-320.

- Kondo, T., Suda, T., Fukuyama, H., Adachi, M., and Nagata, S. (1997). Essential roles of the Fas ligand in the development of hepatitis. *Nat. Med.* **3**, 409-413.
- Luster, M. I., Simeonova, P. P., Gallucci, R. M., Bruccoleri, A., Blazka, M. E., and Yucesoy, B. (2001). Role of inflammation in chemical-induced hepatotoxicity. *Toxicol. Lett.* **120**, 317-321.
- Martinova, E. A. and Merrill, A. H., Jr. (1995). Fumonisin B₁ alters sphingolipid metabolism and immune function in BALB/c mice: immunological responses to fumonisin B₁. *Mycopathologia* **130**, 163-170.
- Merrill, A. H., Jr., Sullards, M. C., Wang, E., Voss, K. A., and Riley, R. T. (2001). Sphingolipid metabolism: roles in signal transduction and disruption by fumonisins. *Environ. Health Perspect.* **109 Suppl 2**, 283-289.
- Opitz, H. G., Opitz, U., Hewlett, G., and Schlumberger, H. D. (1982). A new model for investigations of T-cell functions in mice: differential immunosuppressive effects of two monoclonal anti-Thy-1.2 antibodies. *Immunobiology* **160**, 438-453.
- Payne, S. G., Milstien, S., Barbour, S. E., and Spiegel, S. (2004). Modulation of adaptive immune responses by sphingosine-1-phosphate. *Semin. Cell Dev. Biol.* **15**, 521-527.
- Riley, R. T., Wang, E., Schroeder, J. J., Smith, E. R., Plattner, R. D., Abbas, H., Yoo, H. S., and Merrill, A. H., Jr. (1996). Evidence for disruption of sphingolipid metabolism as a contributing factor in the toxicity and carcinogenicity of fumonisins. *Nat. Toxins* **4**, 3-15.

- Schumann, J., Angermuller, S., Bang, R., Lohoff, M., and Tiegs, G. (1998). Acute hepatotoxicity of *Pseudomonas aeruginosa* exotoxin A in mice depends on T cells and TNF. *J. Immunol.* **161**, 5745-5754.
- Sharma, N., He, Q., and Sharma, R. P. (2004). Augmented fumonisin B₁ toxicity in co-cultures: evidence for crosstalk between macrophages and non-parenchymatous liver epithelial cells involving proinflammatory cytokines. *Toxicology* **203**, 239-251.
- Sharma, R. P., Bhandari, N., He, Q., Riley, R. T., and Voss, K. A. (2001). Decreased fumonisin hepatotoxicity in mice with a targeted deletion of tumor necrosis factor receptor 1. *Toxicology* **159**, 69-79.
- Sharma, R. P., He, Q., and Johnson, V. J. (2003). Deletion of IFN- γ reduces fumonisin-induced hepatotoxicity in mice via alterations in inflammatory cytokines and apoptotic factors. *J. Interferon Cytokine Res.* **23**, 13-23.
- Shimamura, M., Ohteki, T., Launois, P., Garcia, A. M., and MacDonald, H. R. (1997). Thymus-independent generation of NK1⁺ T cells in vitro from fetal liver precursors. *J. Immunol.* **158**, 3682-3689.
- Smith, E. R. and Merrill, A. H., Jr. (1995). Differential roles of de novo sphingolipid biosynthesis and turnover in the "burst" of free sphingosine and sphinganine, and their 1-phosphates and N-acyl-derivatives, that occurs upon changing the medium of cells in culture. *J. Biol. Chem.* **270**, 18749-18758.
- Streetz, K., Fregien, B., Plumpe, J., Korber, K., Kubicka, S., Sass, G., Bischoff, S. C., Manns, M. P., Tiegs, G., and Trautwein, C. (2001). Dissection of the intracellular

pathways in hepatocytes suggests a role for Jun kinase and IFN regulatory factor-1 in Con A-induced liver failure. *J. Immunol.* **167**, 514-523.

Sydenham, E. W., Thiel, P. G., Marasas, W. F. O., Shephard, G. S., Vanschalkwyk, D. J., and Koch, K. R. (1990). Natural occurrence of some fusarium mycotoxins in corn from low and high esophageal cancer prevalence areas of the Transkei, Southern Africa. *J. Ag. Food Chem.* **38**, 1900-1903.

Taranu, I., Marin, D. E., Bouhet, S., Pascale, F., Bailly, J. D., Miller, J. D., Pinton, P., and Oswald, I. P. (2005). Mycotoxin fumonisin B₁ alters the cytokine profile and decreases the vaccinal antibody titer in pigs. *Toxicol. Sci.* **84**, 301-307.

Tiegs, G., Hentschel, J., and Wendel, A. (1992). A T cell-dependent experimental liver injury in mice inducible by concanavalin A. *J. Clin. Invest* **90**, 196-203.

Tsunoda, M., Sharma, R. P., and Riley, R. T. (1998). Early fumonisin B₁ toxicity in relation to disrupted sphingolipid metabolism in male BALB/c mice. *J. Biochem. Mol. Toxicol.* **12**, 281-289.

Wang, W., Graeler, M. H., and Goetzl, E. J. (2004). Physiological sphingosine 1-phosphate requirement for optimal activity of mouse CD4⁺ regulatory T Cells. *FASEB J.* **18**, 1043-1045.

Wolf, D., Hallmann, R., Sass, G., Sixt, M., Kusters, S., Fregien, B., Trautwein, C., and Tiegs, G. (2001). TNF- α -induced expression of adhesion molecules in the liver is under the control of TNFR1— relevance for concanavalin A-induced hepatitis. *J. Immunol.* **166**, 1300-1307.

Table 6.1. Changes in body and organ weights after fumonisin B₁ (FB₁) treatment in mice

Treatment	Body weights		Relative Liver weight (% of body weight)	Relative kidney weight (% of body weight)	Relative spleen weight (% of body weight)
	Before treatment	After treatment			
WT, saline-treated	31.2±0.9	32.9±0.9	4.31±0.25	1.52±0.05	0.29±0.01
WT, FB ₁ -treated	28.6±1.5	28.4±1.7*	4.66±0.21	1.33±0.05*	0.30±0.02
TCD, saline-treated	28.7±0.7	30.3±0.8	4.46±0.13	1.56±0.06	0.26±0.02
TCD, FB ₁ -treated	30.1±1.5	31.2±1.6	4.62±0.16	1.45±0.08	0.27±0.02
Nude, saline-treated	25.0±1.0	26.6±0.7	4.73±0.12	1.46±0.06	0.35±0.01
Nude, FB ₁ -treated	25.7±0.7	27.0±0.9	5.53±0.21*	1.35±0.04	0.31±0.02

*Significant difference at $p < 0.05$, compared to the respective control (saline treatment).




Fig. 6.1. Activities of circulating liver enzymes, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in plasma of WT, TCD and nude mice after treatment with fumonisin B₁. Results are expressed as mean ± standard error, (n= 5). Asterisks on bars indicate a significant difference from the corresponding saline treated group at $p < 0.05$. The letter “a” on bar indicates significant difference ($p < 0.05$) between the fumonisin B₁-treated WT and TCD groups.




Fig. 6.2. Enumeration of apoptotic cells in liver by TUNEL assay. (a) Liver from fumonisin B₁-WT mouse. (b) Liver from a fumonisin B₁-treated TCD mouse. (c) Liver from fumonisin B₁-treated nude mouse. Bar in the lower right in “c” equals 10 μ m. Arrows indicate TUNEL positive nuclei in apoptotic cells. (d) The number of TUNEL-positive cells in tissue sections (mean \pm standard error, $n=5$). The asterisk (*) indicates a significant difference from the corresponding saline-treated group ($p < 0.05$). The letter “a” on the bar indicates a significant difference ($p < 0.05$) between the fumonisin B₁-treated WT and TCD groups.




Fig. 6.3. (a) Peripheral white blood cell count in different groups of mice after 5 days of saline or fumonisin B₁ treatment; mean ± standard error (n= 3). The * indicates a significant difference from the similarly treated WT group ($p < 0.05$). (b) Immunohistochemical staining of frozen mouse liver section with anti Thy 1.2 antibody showing presence of Thy 1.2 antigen bearing T cells in the periportal regions of liver in WT. (c) No stained areas were observed in TCD mice. (d) Occurrence of T cells in nude mice (d). The bar in the lower right in "b" represents 25 μm.




Fig. 6.4. Free sphingosine and sphinganine levels in the liver of saline-treated or fumonisin B₁-treated mice. Results are expressed as mean \pm standard error, (n= 5). Asterisk on bars indicates a significant difference from the corresponding saline-treated group ($p < 0.05$).




Fig. 6.5. Fumonisin B₁ induced alteration in gene expression of selected inflammatory cytokines. The relative mRNA expression was normalized against *L-32*, a house-keeping gene. Mean \pm standard error, (n= 5). Asterisks on bars indicate a significant difference from the saline treated group of same strain $p < 0.05$. Letter “a” on bars indicates a significant decrease from the similarly treated WT ($p < 0.05$).




Fig. 6.6. Fumonisin B₁ induced alteration in gene expression of selected inflammatory cytokines. The relative mRNA expression was normalized against *L32*, a house-keeping gene. Mean \pm standard error, (n= 5). Asterisks on bar indicate a significant difference from the saline treated group of same strain ($p < 0.05$). Letter “a” on bars indicates a significant decrease from the similarly treated WT ($p < 0.05$).

CHAPTER 7

SUMMARY AND CONCLUSIONS

Fumonisin B₁ (FB₁), produced by *Fusarium verticillioides*, is a common mycotoxin found on corn and corn-based foods. It produces species, organ and gender-specific toxicity, including equine leukoencephalomalacia, porcine pulmonary edema renal damage in some animals and hepatic damage in all and is hepato and nephrocarcinogenic in rodents. Fumonisin B₁ perturbs sphingolipid metabolism by inhibiting ceramide synthase. Physiological consequences possible after ceramide synthase inhibition include apoptosis caused by accumulation of free sphingoid bases (sphinganine and sphingosine), increased proliferation caused by increased sphingosine-1-phosphate, or/and decreased ceramide and altered lipid raft function due to disruption of complex sphingolipids synthesis/transport. Fumonisin B₁ induces expression of tumor necrosis factor (TNF) α and other cytokines *in vivo* and *in vitro*. Fumonisin B₁ induces apoptosis in some cells whereas other cells are resistant to its apoptotic effects. Various sphingolipids and cytokines are important cell signaling factors, which may be important in rendering some cells resistant to fumonisin B₁ induced apoptosis.

The objectives of the present study were to (1) evaluate the role of sphingosine kinase, the enzyme that converts sphingoid bases to their respective phosphates, in rendering some cells resistant to fumonisin B₁-induced apoptosis, (2) Investigate the effect of interaction of macrophages (J774A.1) and nonparanchymatous liver epithelial cells (NMLi) in a co-culture on fumonisin B₁-induced apoptosis, (3) evaluate the role of TNF α and mitogen activated protein kinases in fumonisin B₁-induced apoptosis in murine primary hepatocytes, (4) examine the fumonisin B₁-induced hepatotoxicity in mice depleted of T cells.

In the first study, we demonstrated using specific inhibitor of sphingosine kinase, the enzyme that converts sphingoid bases to their respective phosphates that HEK-293 cells were resistant to apoptotic effects of fumonisin B₁ due to rapid conversion of accumulate sphinganine or sphingosine to their respective phosphates by sphingosine kinase. Higher activity of sphingosine kinase enhances cell survival by forming sphingosine-1-phosphate, which has anti-apoptotic and pro survival properties. Activity of sphingosine kinase enzyme may have substantial bearing on different responses of fumonisin B₁ in other cell types also. However, our findings are applicable to only HEK-293 cells and further investigations are required to determine whether or not this is a general mechanism for resistance to fumonisin B₁ in other cells *in vitro* and tissues *in vivo*.

The second study evaluated the effect of fumonisin B₁ on co-cultures of macrophages (J774A.1) and nonparanchymatous liver epithelial cells (NPECs). Co-cultures were more responsive to fumonisin B₁ induced cytotoxicity compared to individual cultures and interaction of the two cell types resulted in increased expression of proinflammatory cytokines in the co-cultures. Our results indicated that macrophage and NPECs interact in co-culture in response to fumonisin B₁ and potentiate expression of various cytokines, which may have implications in making hepatocytes more responsive to fumonisin B₁-induced cytotoxicity.

In the third study, we investigated the role of TNF α and downstream signaling events such as mitogen activated protein kinases (MAPKs) in fumonisin B₁ induced apoptosis in murine hepatocytes. Fumonisin B₁ induced apoptosis in hepatocytes by involving JNK activation, which could be prevented to some extent by JNK inhibitor and anti-TNF α . TNF α production is upstream of JNK signaling as JNK activation was inhibited by anti-TNF α ,

whereas inhibition of JNK had no effect on TNF α expression. This study provides evidence for tumor necrosis factor α -mediated activation of c-Jun NH₂-terminal kinase as a mechanism for fumonisin B₁-induced apoptosis in murine primary hepatocytes.

The final study determined the role of T cells in fumonisin B₁-induced apoptosis in mice liver. Athymic nude mice are deficient in T cells; therefore, we employed nude mice and their immunocompetent wild-type counterparts in this study. Depletion of T cells in wild-type mice was accomplished by injecting monoclonal antibodies directed against Thy-1.2 surface antigens; which is an established method to investigate the T cell functions in mice. Fumonisin B₁-induced elevation in activities of circulating liver enzymes were not different between WT and nude mice, while depletion of T cells nearly abolished fumonisin B₁-mediated liver toxicity, indicated both by concentrations of circulating liver enzymes and enumeration of apoptotic hepatocytes. Expression of fumonisin B₁-induced tumor necrosis factor α and other proinflammatory cytokines was observed in nude and wild type mice but not in T cell-depleted mice. Results obtained in this study indicated that T cell activation followed by production of proinflammatory cytokines is an important mechanism for fumonisin B₁-induced hepatotoxicity in mice.

All together, the data presented in this dissertation indicate that sphingolipid metabolism and lack of interaction of cytokines may be responsible for observed resistance to apoptotic effects of fumonisin B₁ in various cultured cells or *in vivo*.